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CHAPTER 1: SITUATION AND OBJECTIVES 
 
 
 
 
 
 
 
1.1 INTRODUCTION 
 
The mucosa has an important protective function by preventing entry of micro-
organisms and noxious substances from the environment into the body (Marieb, 1995). The 
ocular, nasal, oral, gastro-intestinal, vaginal and rectal mucosae can be exposed accidentally 
or intentionally to pharmaceuticals, personal care products, cosmetics, and chemicals. 
However, many compounds can irritate the mucosa. Mucosal irritation and damage might 
increase the susceptibility to pathogens (Stephenson, 2000; Fichorova et al., 2001; Van 
Damme et al., 2002) and decrease the patient compliance. Because pharmaceuticals may be 
applied frequently over a period of months or years, it is extremely important to evaluate the 
mucosal irritation potential or mucosal tolerance of pharmaceutical formulations. The 
mucosal tolerance is evaluated in the research and development of new drugs because of 
several additional reasons. Firstly, safety testing is a helpful tool in the selection of lead 
candidates in the drug discovery and development phase (Curren and Harbell, 2002). The 
results of the safety evaluation can guide the drug development process, because mucosal 
irritation can be decreased or eliminated by adapting the formulation or dosage form (Fara 
and Myrback, 1990). Elimination of toxic compounds early in drug development is also of 
economical concern, because this contributes to saving of money and time (Vanparys, 2002). 
Furthermore, regulatory authorities require that the local tolerance of potential new medicinal 
products is assessed before the products are administered to humans (EC, 1990).  
Pre-clinical studies to evaluate the ocular, nasal, oral, vaginal, and rectal tolerance of 
both the active agent and the clinical formulation are carried out in vertebrates in compliance 
with EU directives and guidelines (EC, 1965; EC, 1975a; EC, 1975b; EC, 1990). However, 
the use of vertebrates for safety studies is criticised based on ethical, scientific, economical 
and practical considerations (EC, 1986; CPMP, 1997). Directive 86/609/EEC stimulates 
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limitation of the use of laboratory animals without compromising human safety. This can be 
achieved by reduction, refinement or replacement of animal studies, known as the concept of 
the “Three Rs” (Balls et al., 1995; CPMP, 1997). Consequently, there is a great interest in 
developing alternative methods such as in vitro methods and the use of ‘lower’ organisms as 
test organisms (Balls et al., 1995). The development of a reliable and relevant alternative 
method for mucosal tolerance testing would be very useful for academic and pharmaceutical 
research centres to screen pharmaceuticals and ingredients. However, such a regulatory 
accepted alternative method is hitherto not available. 
Within this scope, an alternative mucosal irritation test using invertebrates was 
developed at the Laboratory of Pharmaceutical Technology (Ghent University, Belgium). The 
terrestrial slug Arion lusitanicus was selected as test organism. Because slugs exposed to 
irritating substances produce mucus to protect the body wall, the mucus production of the 
slugs was selected as end point to evaluate the irritation potential of a substance. Additionally, 
tissue damage can be estimated by the release of proteins and enzymes from the slug body 
wall (Adriaens and Remon, 1999; Adriaens, 2000). A five-day procedure of the Slug Mucosal 
Irritation test seems to be a promising method for mucosal tolerance testing of dilutions of 
absorption enhancers and drugs on the one hand and for mucosal tolerance testing of neat 
ocular and nasal bioadhesive powder formulations on the other hand (Adriaens and Remon, 
1999; Adriaens, 2000; Callens et al., 2001; Ceulemans et al., 2001).  
When an alternative method has been developed, the relevance and the reliability of 
the test should be investigated using reference standards (Balls et al., 1999). Because no list 
of reference standards intended for screening the mucosal tolerance is available, the relevance 
and reliability of the Slug Mucosal Irritation test were evaluated by means of eye irritation 
reference chemicals (Adriaens, 2000). A previous study showed that a two-day procedure 
enables to estimate the eye irritating and damaging properties of chemicals. The results were 
in agreement with the irritation data obtained after a single exposure of rabbit eyes to the 
chemicals (Adriaens and Remon, 2002). However, the test procedure needs to be further 
optimised and validated.   
 
1.2 OBJECTIVES 
 
On the one hand, this research aimed at the optimisation and validation of the test 
procedure and prediction model of the Slug Mucosal Irritation test for the evaluation of the 
eye irritation/damage potential of chemicals. The relevance and reliability of the developed 
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modified procedure and its prediction model were evaluated by using chemicals with known 
rabbit eye irritation data. The modified procedure was also used to evaluate the influence of 
the slug population and slug species on the end points of the test. 
Furthermore, the five-day procedure of the Slug Mucosal Irritation test was further 
optimised for local tolerance testing of solid, semi-solid and liquid formulations intended for 
repeated administration via the ocular, buccal, nasal, rectal or vaginal route. Because no list of 
reference formulations intended for screening the mucosal tolerance is available, formulations 
with known human, animal or in vitro irritation data were selected for this purpose.  
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CHAPTER 2: INTRODUCTION 
 
 
 
 
 
 
 
2.1 ANIMAL USE AND LOCAL TOLERANCE TESTING 
 
Before new chemicals, pharmaceuticals, and personal care products can be placed on 
the market, evaluation of their safety (such as ocular or mucosal tolerance) is required by 
regulatory authorities. Regulatory toxicology mainly aims at protecting public health against 
possible adverse effects posed by the use of pharmaceuticals and personal care products, 
ensuring the occupational safety of workers during the production process, and warning 
chemical users of potential health dangers. Regulatory authorities generally require that 
mucosal and ocular tolerance of products and chemicals is evaluated in vertebrates (EC, 1965; 
EC, 1967; EC, 1975a; EC, 1975b; EC, 1976; EC, 1990). Recent proposals for chemicals 
regulation in the EU will even lead to an increased use of vertebrates for the safety assessment 
of chemicals. The White Paper ‘Strategy for a future chemicals policy’ namely proposed to 
subject existing chemicals (marketed before 18 September 1981), for which less safety tests 
are required, and new chemicals (marketed after that date) to the same testing requirements. 
Adoption of the proposals in the White Paper would necessitate toxicity testing for around 
30000 existing chemicals that are currently marketed in volumes greater than one ton per year 
by 2012 (EC, 2001; IEH, 2001).  
Furthermore, the mucosal irritation and damage potential of chemicals or products is 
also assessed by academic researchers, pharmaceutical and chemical companies or research 
laboratories for fundamental research, product development purposes or in-house product 
safety evaluations. For example, the eye irritation potential is evaluated so that the workers’ 
eyes can be adequately protected and occupational health can be ensured. The assessment of 
the local tolerance can be helpful in the selection of lead candidates for drug development. 
For this purposes, animal testing is not required by regulatory authorities (Curren and Harbell, 
2002).  
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2.2 CONCEPT OF  THE “THREE RS” 
 
 Ethical, scientific, economical and practical considerations require that the use of 
laboratory animals is restricted as much as possible (EC, 1986; CPMP, 1997). Consequently, 
there is a great interest in developing reliable and relevant alternative methods which can be 
used to reduce, refine or replace the use of animal experiments. The three types of alternative 
procedures, i.e. reduction, refinement and replacement methods, are known as the “Three Rs”. 
 Russell and Burch (1959) defined reduction alternatives as methods which obtain 
comparable levels of information from the use of fewer animals, or more information from the 
same number of animals. Reduction of the number of animals can be achieved by the use of 
appropriate experimental design and statistics and by the international harmonisation of test 
protocols (Balls et al., 1995b). Refinement alternatives alleviate or minimise potential pain, 
suffering and distress of the experimental animals (Russell and Burch, 1959). The animal 
well-being can be improved by the proper use of anaesthetics, analgesics, and tranquilisers 
and by the provision of optimal environmental and caging conditions (Balls et al., 1995b). 
Replacement alternatives permit a given purpose to be achieved without using living 
vertebrate animals (Russell and Burch, 1959). Replacement alternatives encompass human 
studies, physicochemical techniques, mathematical and computer models, in vitro methods, 
assays based on foetal or embryonic forms of vertebrates, and methods that use ‘lower’ 
organisms – such as plants, micro-organisms and invertebrates – with limited sentience and/or 
not protected by laws regulating animal experiments (Balls et al., 1995b). 
It is interesting to note that a particular alternative test can serve both as partial 
replacement test and as reduction and refinement test. For example, an in vitro test can replace 
the use of the animal test for safety testing of certain classes of test substances on the one 
hand and contribute to a reduction or refinement of the animal use when it is used in a 
stepwise testing strategy on the other hand (Worth and Balls, 2004). 
The “Three Rs” are embedded in Directive 86/609/EEC, which regulates the use of 
animals for experimental and other scientific purposes in the EU. The latter directive defines 
an experimental animal as, unless otherwise qualified, any live non-human vertebrate, 
including free-living larval and/or reproducing larval forms, but excluding foetal or 
embryonic forms, used or to be used in experiments. Moreover, the directive states that an 
experiment using experimental animals may not be performed, if a scientifically satisfactory 
alternative method is available (EC, 1986).  
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2.3 VALIDATION OF ALTERNATIVE TESTS 
 
Before an alternative toxicity test is accepted by researchers and regulators, it has to be 
proved that the test provides a reliable level of protection which equals at least that provided 
by the conventional animal test (Balls et al., 1990; CPMP, 1997; Liebsch and Spielmann, 
2002). The validation of an alternative method has been defined as the process by which the 
reliability and relevance of an alternative method are established for a particular purpose 
(Balls et al., 1990).  
Archer et al. (1997) described that an alternative method for the (partial) replacement 
of an animal test consists of a test system on the one hand and a prediction model on the other 
hand. In case of a toxicity test, the test system generates safety related data for substances of 
interest, whereas the prediction model is a tool for the conversion of these data into in vivo 
toxicity predictions (Archer et al., 1997). By preference, prediction models are developed 
based on both in-house experience and statistical methods. However, they can also be 
formulated on the basis of either in-house experience or statistical analysis (Worth and Balls, 
2001). Classification prediction models make predictions on a categorical scale, whereas 
mathematical models make predictions on a continuous scale (Worth and Balls, 2001). 
Consequently, validation of a (partial) replacement test involves an independent 
evaluation of both the test system and its prediction model (Worth and Balls, 2001). 
Reliability has been defined by Balls et al. (1990, 1995a) as establishment of the 
reproducibility of test results both within and between laboratories and over time. Assessment 
of the relevance has been defined as establishing the scientific meaningfulness and usefulness 
of results from an alternative method for a particular purpose (Balls et al., 1990; Balls et al., 
1995a). In case of a replacement test method, the relevance of both the test system (scientific 
relevance) and its associated prediction model (predictive relevance) has to be demonstrated 
(Figure 2.1) (Worth and Balls, 2001). Evaluation of the predictive relevance involves the 
establishment of the accuracy of the predictions made by the prediction model (Worth and 
Balls, 2001). Evidence for the relevance of an alternative method is currently provided by 
demonstrating sufficient agreement between the data of the alternative method on the one 
hand and those obtained with the accepted in vivo test (Holzhütter et al., 1996; CPMP, 1997) 
or with in vitro validated assays (Hothorn, 2002) on the other hand.  
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Figure 2.1 A schematic representation of a replacement test and its performance properties (based 
on Worth and Balls, 2001) 
 
The relevance and the reliability of an alternative test should be investigated using 
reference standards, i.e. substances with a known degree of toxicity in vivo (Balls et al., 
1999). Substances are considered suitable reference standards, if they can be readily obtained 
in a chemically pure and stable form, they cover the entire range of in vivo toxicity, and they 
are associated with reproducible in vivo toxicity data of sufficient quality (Balls et al., 1999). 
Human data would be the ideal benchmark. However, human data are collected in studies 
which differ with respect to their purpose, exposure conditions, and means and time points of 
assessing safety outcomes. Consequently, it is not easy to compare the available human data 
and to develop a uniform reference database based on human data (Balls et al., 1990). 
Balls et al. (1995a) stated that the following five main stages have to be successfully 
passed through before an alternative test is accepted by regulators: test development, 
prevalidation, formal validation, independent assessment, and regulatory acceptance. A 
prevalidation study is an inter-laboratory study aimed at refining the protocol and prediction 
model of the alternative test method and at investigating the relevance and reliability of the 
test by using a small number of reference standards. The prevalidation process consists of 
three successive phases. Phase I (method refinement) involves the refinement of the protocol 
and prediction model of a test method and the evaluation of the reproducibility of the test 
results in a single laboratory. During phase II (method transfer), the transferability of the 
method to a second laboratory is assessed and any necessary refinements to the protocol and 
prediction model are made. If the results of phase II are acceptable, the method can proceed to 
phase III (method performance) which involves the assessment of the relevance and reliability 
of the test under blind conditions in three or more laboratories (Curren et al., 1995; Worth and 
Balls, 2002). In a formal validation study – also an inter-laboratory study – a larger number of 
Replacement test Test system Prediction model= +
Reliability 
 
Scientific relevance Predictive relevance 
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chemicals are tested under blind conditions in order to obtain a more definitive assessment of 
relevance and reliability (Worth and Balls, 2002). The validation of alternative methods is 
coordinated at EU level by the European Centre for the Validation of Alternative Methods 
(ECVAM) (EC, 1991). Once a method is successfully validated, the appropriate data can be 
submitted to an expert group for an independent assessment. If the expert group states that the 
criteria for test development and validation are satisfied, the validated alternative test is 
submitted to the EU authorities for consideration for regulatory acceptance (Worth and Balls, 
2002). It is important to note that adoption of an alternative test solely by the EC will not 
result in a reduction in overall animal use or suffering, because chemicals and formulations 
will still be tested outside the EU according to other regulatory requirements. In order to be 
effective all over the world, the alternative test needs therefore to be adopted at the level of 
the Organisation for Economic Cooperation and Development (OECD) or the International 
Conference on Harmonisation (ICH) (IEH, 2001; Liebsch and Spielmann, 2002). 
ECVAM proposed to make the validation process more flexible without 
compromising its high standards. For this purpose, the validation process is divided into seven 
independent modules (test definition, intra-laboratory variability, transferability, inter-
laboratory variability, predictive capacity, applicability domain, and performance standards). 
The information needed for completing each module is defined. This information can be 
provided via a prospective or retrospective approach or via a combination of both. Because 
the modules are considered to be separate aspects, they can be completed at different time 
points. Once all the modules are satisfactorily completed, the suitability of a test to enter the 
peer-review process is determined (Hartung et al., 2004). 
Hitherto, only a few formally validated in vitro tests have been accepted at the EU 
level and incorporated into the EU official test methods. Two in vitro tests replacing the in 
vivo skin corrosion test (rat skin transcutaneous electrical resistance test and human skin 
model tests) and an in vitro test for phototoxicity testing (3T3 neutral red uptake phototoxicity 
test) (EC, 2000) are accepted at the EU level and are also adopted in the OECD Test 
Guidelines. Consequently, the methods are recognised internationally (OECD, 2004).  
Several factors contribute to the fact that only a few alternative tests have been 
hitherto formally validated despite several years of intensive research and validation effort. 
Firstly, the conventional animal tests have not been formally validated (Balls et al., 1995b). 
Safety related end points in animals are mostly subjectively assessed, which results in variable 
data (Balls et al., 1999). The lack of availability of compounds with in vivo data of 
sufficiently high quality hampers the evaluation of the relevance of alternative tests (Balls et 
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al., 1995b). Furthermore, the use of the statistical approaches for the data analysis is often not 
appropriate. The development of protocols and prediction models of the alternative tests is 
also sometimes insufficient (Balls et al., 1999).  
It is interesting to note that a replacement alternative does not need to be formally 
validated in case the test is adopted for fundamental research, product development purposes 
or in-house product safety evaluations. The replacement test can be selected based on 
independent peer reviewed publications that report the test’s relevance and reliability for a 
particular purpose (Balls et al., 1995b; Balls and Fentem, 1999). For regulatory purposes, 
however, successful formal validation of alternative toxicity tests is required in order to 
ensure the protection of workers, patients, and consumers on the one hand, and the protection 
of the regulatory authorities themselves and of the companies involved in the production, 
transport and/or marketing of chemicals and products on the other hand. Furthermore, 
regulatory acceptance of an alternative test that afterwards points out to be not relevant and 
reliable would have disadvantageous consequences for further development of alternative 
tests (Balls and Fentem, 1999). 
 
2.4 ALTERNATIVE TESTS FOR LOCAL TOLERANCE TESTING 
 
2.4.1 In vitro tests 
 
Freshly harvested tissue slices, cryopreserved tissues, primary cell cultures, 
immortalised cell lines, and reconstructed three dimensional tissue models are used in vitro to 
evaluate the irritation potential of chemicals and pharmaceuticals. Besides the saving of 
animals, the increasing popularity of in vitro tests to evaluate the local tolerance of chemicals 
and pharmaceuticals can be explained by the following advantages. Firstly, in vitro models 
are generally faster and more standardised than in vivo models (Agu et al., 2002). 
Furthermore, only small amounts of the test substance are necessary in in vitro studies (Agu et 
al., 2002). The latter is important in view of the low availability of test compounds in the drug 
discovery and development phase. Moreover, the use of tissues or cells from human origin 
can reduce the problem of data extrapolation from animals to humans (Agu et al., 2002; 
Zucco et al., 2004). Consequently, the use of in vitro tests during the discovery phase can 
result in a better and earlier selection of lead candidates for drug development and can 
contribute to high throughput screening (Agu et al., 2002; Curren and Harbell, 2002; 
Vanparys, 2002). 
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However, complete replacement of in vivo methods by in vitro methods is not possible 
(Agu et al., 2002; Vanparys, 2002). At present, one of the main challenges is the in vitro 
reconstruction of the complex in vivo tissue composition and characteristics (Quadir et al., 
1999; Agu et al., 2002; Zucco et al., 2004). For example, the normal overlaying protective 
mucous layer is generally absent in in vitro mucosal models (Merkus et al., 1991; Furrer et 
al., 2002; Lebe et al., 2004). Furthermore, the isolated material and cell cultures generally 
have a restricted life span, so that repeated exposure to pharmaceutical compounds or 
formulations can not be investigated (Agu et al., 2002).  
An overview of the currently used in vitro tests for local tolerance testing of ocular, 
buccal, nasal, rectal and vaginal products is given in the beginning of the following chapters. 
 
2.4.2 Slug Mucosal Irritation test  
 
2.4.2.1 Background and principle 
 
 In order to decrease the number of vertebrates used for mucosal tolerance testing, an 
alternative mucosal irritation test was developed using invertebrates not protected by 
legislation controlling animal experiments. The terrestrial slug A. lusitanicus (phylum 
Mollusca, class Gastropoda, subclass Pulmonata, order Stylommatophora, suborder 
Sigmurethra, and family Arionidae) was selected as test organism, because the mucosal tissue 
of interest is located at the outside of the slug. Consequently, effects on the mucosal tissue 
caused by substances can be easily observed (Adriaens, 2000). Moreover, the slug mucosa 
histologically resembles the human mucosa (Adriaens, 2000). The soft, non-keratinised body 
wall of slugs namely comprises an outer single-layered epithelium consisting of ciliated and 
non-ciliated microvillous epithelial cells, mucus secreting cells, and mucous gland cells 
overlying connective tissue (Dyson, 1964; Lainé, 1971; Prior et al., 1994). Examination of the 
ventral foot epithelium of terrestrial slugs revealed three longitudinal bands. The medial band 
is composed of ciliated microvillous epithelial cells, mucus secreting cells, and mucous 
glands. This band is specialised for locomotion by generating waves of muscular contractions. 
The lateral absorptive bands consist of mucus secreting cells, mucous glands, and 
microvillous epithelial cells (Prior et al., 1994).  
The body wall of slugs is vulnerable to mechanical or chemical damage (South, 1992). 
Mucus secretions serve not only for the locomotion, the lubrication of the slug body wall and 
the prevention of dehydration of the slug, but also for the protection of the body wall against 
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damage (South, 1992; Deyrup-Olsen and Luchtel, 1998). The unique properties of mucus are 
mainly based on the presence of the complex glycoproteins or mucins. The slug mucins are 
packaged in the Golgi system of very large mucus secreting cells (up to 500 µm in length) 
into membrane-bound granules (up to 10 µm axis) (Deyrup-Olsen et al., 1983, 1992; Luchtel 
et al., 1991; Deyrup-Olsen and Luchtel, 1998). It seems probable that chemical and 
mechanical stimulation of the slug results in contractions of the smooth muscle cells (situated 
near by the mucus secreting cells in the slug body wall) which cause in turns apocrine 
secretion of the mucus granules by the mucus secreting cells (Deyrup-Olsen and Martin, 
1982; South, 1992; Deyrup-Olsen and Luchtel, 1998). Once the granules enter the 
extracellular environment and meet appropriate triggering conditions, the properties of the 
granule membrane change so that ions and water can flow across it. Consequently, the 
contained mucins hydrate and swell 100-fold or more within fractions of a second (Verdugo 
et al., 1987; Deyrup-Olsen and Luchtel, 1998).  
Several studies with the Slug Mucosal Irritation test identified the mucus production of 
the slugs as end point with high predictive power for the irritation potential of substances 
(Adriaens and Remon, 1999; Adriaens, 2000; Adriaens and Remon, 2002). Other authors also 
supported the mucus secretion as an indicator of irritation (Whitmore et al., 1979; Morris and 
Wallace, 1981; Morris and Harding, 1991). Furthermore, the tissue damaging potential of the 
substances was studied via microscopic examination of the slug body wall, evaluation of 
permeability of propidium iodide, and measurement of the release of several markers like 
proteins, enzymes (Adriaens, 2000), prostaglandins, and interleukins (data not published) 
from the slug body wall. The release of proteins and enzymes is also used in various other 
studies to evaluate tissue damage (Whitmore et al., 1979; Ichijima et al., 1992; Shao and 
Mitra, 1992; Shao et al., 1992; Krishnamoorthy et al., 1995; Marttin et al., 1995; 
Tengamnuay et al., 2000). Finally, proteins, lactate dehydrogenase and alkaline phosphatase 
released from the body wall of the slugs were selected as the most relevant markers to 
evaluate mucosal damage caused by substances (Figure 2.2) (Adriaens and Remon, 1999). 
Damage of the single-layered epithelium and the underlying connective tissue namely results 
in leakage of proteins and enzymes out of the cells and eventually in leakage of haemolymph 
(Adriaens, 2000). In case of cell damage, the release of the cytosolic enzyme lactate 
dehydrogenase occurs before the release of the membrane-bound enzyme alkaline 
phosphatase, because alkaline phosphatase is not present in the single-layered epithelium but 
in the underlying connective tissue (Adriaens, 2000).   
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Figure 2.2 A schematic representation of the Slug Mucosal Irritation test 
 
2.4.2.2 Test procedures 
 
 The Slug Mucosal Irritation test was developed for screening the irritation potential of 
absorption enhancers and drugs on mucosal surfaces. The slugs were put on 1% (w/v) 
dilutions of absorption enhancers, β-blocking agents or local anaesthetics for 15 minutes 
during five successive days (Adriaens and Remon, 1999; Adriaens, 2000). The effect on the 
mucosal tissue was determined from the mucus production and the reduction of the slug body 
weight during the contact period, and from the release of proteins and enzymes from the slug 
body wall after the treatment. The results of the Slug Mucosal Irritation test were in 
agreement with the data of various in vivo and in vitro models (Adriaens and Remon, 1999).  
This five-day test procedure of the Slug Mucosal Irritation test was utilised to evaluate 
the mucosal tolerance of bioadhesive powder formulations. The effect of the powders on the 
mucosal tissue was determined by placing the slugs on the neat powder for 15 minutes during 
five successive days (Adriaens, 2000). The mucus production and the release of proteins and 
enzymes induced by a repeated treatment with the powders were used to evaluate the mucosal 
tolerance. However, the Slug Mucosal Irritation test underestimated the irritation potential of 
the irritating powders with regard to nasal irritation data obtained in rabbits. Therefore, the 
duration of the contact period was prolonged to 30 minutes (Dhondt, 2001). Additional data 
obtained with the modified test procedure were in agreement with in vivo rabbit and human 
data. Therefore, it was concluded that the modified test procedure seems to be promising to 
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evaluate the mucosal tolerance of powder formulations early in the development process 
(Callens et al., 2001; Ceulemans et al., 2001).  
Because no list of reference standards for screening the mucosal tolerance is available, 
the relevance of the five-day Slug Mucosal Irritation test procedure was investigated using 15 
reference chemicals for eye irritation. The chemicals were tested as 1% (w/v) dilutions for 15 
minutes on five successive days. The study showed that the chemicals were accurately 
classified into two eye irritation categories (non-irritant and irritant) based on the mucus 
production during the first contact period. A concordance, sensitivity, and specificity of 87%, 
83% and 100% was obtained (Adriaens, 2000). In order to reduce the number of false 
negatives, the contact period was prolonged to 60 minutes (personal communication E. 
Adriaens, Ghent University, Belgium, 2001). The modified test procedure was evaluated by 
means of 12 of the previous tested chemicals and 16 additional chemicals (among which nine 
alcohols). The irritation potential of several eye reference chemicals was correctly estimated 
based on the amount of mucus produced during a 60-minute contact period with a 1% (w/v) 
dilution of the chemical. However, treatment of the slugs with some in vivo irritating 
chemicals (especially alcohols) did not result in an increased mucus production. This was 
probably due to the fact that the irritating alcohols altered the mucus production by 
anaesthetizing the slugs. However, the latter chemicals induced an increased protein release. 
For severely irritating chemicals, tissue damage could be detected immediately, but for 
moderately irritating chemicals the process was delayed and an additional 60-minute 
treatment with a 1% (w/v) dilution of the test substance was needed on the next day. Using 
this two-day test procedure, 89% of the 28 chemicals were correctly classified into two 
irritation categories with a sensitivity and specificity of 88% and 92%, respectively (Adriaens 
and Remon, 2002). 
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CHAPTER 3: EVALUATION OF THE EYE IRRITATION/ 
DAMAGE POTENTIAL OF CHEMICALS 
 
Based on Adriaens, E., Dhondt, M.M.M. and Remon, J.P. (2005). 
 
 
 
 
3.1 INTRODUCTION  
 
Accidental or intentional exposure of the eye to certain chemicals can cause severe eye 
irritation and damage and can even result in permanent blindness (Wilhelmus, 2001). Eye 
irritation has been defined as the production of changes in the eye following the application of 
a test substance to the anterior surface of the eye, which are fully reversible within 21 days of 
application. Serious eye damage or corrosion has been defined as the production of tissue 
damage in the eye or serious physical decay of vision, following the application of a test 
substance to the anterior surface of the eye, which is not fully reversible within 21 days of 
application (United Nations, 2003; EC, 2004).  
In order to protect the eyes of workers during the production of chemicals and to warn 
chemical users of potential dangers for the eye, evaluation of the eye irritation and damage 
potential of new chemicals is required by regulatory authorities before new chemicals can be 
introduced to the market (EC, 1967, EC, 2004; OECD, 2004). 
 
3.2 OCULAR TISSUES 
 
From ophthalmic and toxicological point of view, the cornea, conjunctiva, and iris are 
important and vulnerable ocular tissues. The cornea covers the iris and pupil at the anterior 
side of the eyeball. Because the cornea is normally transparent due to the absence of blood 
vessels, it allows light to pass into the eye. From anterior to posterior, the cornea is composed 
of the following five layers: the stratified squamous epithelium, the Bowman’s membrane, the 
stroma, the Descemet’s membrane, and the simple squamous endothelium. The epithelium 
and endothelium protect the intraocular contents and avoid the entrance of additional water 
into the cornea, which would cause swelling and opacity. In contrast with the endothelium, 
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the epithelium is extremely capable of regeneration and repair (Marieb, 1995; Curren and 
Harbell, 1998; Furrer et al., 2002; Beresford, 2005). 
The conjunctiva lines the inside of the eyelids and the visible part of the sclera 
(Marieb, 1995; Curren and Harbell, 1998). It consists of a non-keratinised stratified squamous 
mucous membrane containing mucus secreting cells (Marieb, 1995; Curren and Harbell, 
1998; York and Steiling, 1998; Beresford, 2005). Furthermore, the conjunctiva is highly 
vascularized (Curren and Harbell, 1998).  
The iris is located between the cornea and the lens. By varying the pupil size, the iris 
influences the amount of light that can enter the eye (Curren and Harbell, 1998).  
 
3.3 EVALUATION OF THE EYE IRRITATION/DAMAGE POTENTIAL OF CHEMICALS 
 
3.3.1 Draize rabbit eye test 
 
At present, the only regulatory accepted method for the evaluation of eye irritation/ 
damage of substances requires the application of the compound of interest to the eyes of 
albino rabbits, as described in the OECD test guideline 405 (OECD, 2004) and in the EU 
official test method B5 (EC, 2004). The rabbit eye irritation test is generally referred to as the 
Draize eye test. In the standard version, 0.1 ml or 0.1 g of the test substance is applied to the 
conjunctival sac of one of rabbit’ eyes, whereas the untreated eye serves as control. The test is 
usually performed without the use of anaesthetics. The extent of eye irritation/corrosion is 
evaluated by visual scoring the effects on cornea, conjunctiva, and iris at regular time points 
after treatment during maximum 21 days. For the cornea, the degree of opacity and corneal 
area involved are scored. The conjunctiva is evaluated for redness, chemosis, and discharge. 
The iris is examined for inflammation. The scores are then weighted and added up to give a 
maximum score of 110 (Draize et al., 1944). The modified maximum average score (MMAS) 
is obtained by averaging the individual animal weighted scores at 24 hours (or more) after 
application of the test substance and then selecting the maximum average score (ECETOC, 
1998). 
Based on these scores, different eye irritation classification systems have been 
developed. The EU eye irritation classification system assigns the risk phrase R41 to 
substances that result in severe reversible changes or irreversible changes of cornea, 
conjunctiva or iris; whereas chemicals that cause significant (non-severe) changes of cornea, 
conjunctiva or iris which are reversible within 21 days are labelled R36 (EC, 2001). Recently, 
___________________________________________________________________________ 
Chapter 3: Evaluation of the eye irritation/damage potential of chemicals 25 
the OECD, the United Nations, and other international regulatory authorities have developed 
a globally harmonised system (GHS) for classification and labelling of chemicals (United 
Nations, 2003). The GHS eye irritation classification system assigns category 1 to substances 
which cause lesions of the cornea, conjunctiva or iris which are not expected to reverse or are 
not fully reversible within an observation period of normally 21 days. Substances that have 
the potential to induce (non-severe) reversible eye irritation are classified as category 2. 
Reversible effects are further subclassified based on the duration of persistence as category 
2A (reverses within 21 days, irritating to eyes) or category 2B (reverses within 7 days, mildly 
irritating to eyes) (United Nations, 2003). Throughout this thesis, it is focused on the EU 
classification, because this classification is hitherto more frequently used throughout Europe. 
 
3.3.2 Alternative eye irritation tests 
 
 The rabbit eye irritation test is criticised because of ethical reasons for considerable 
time. Ocular testing of severe eye irritants is namely associated with pain and suffering of the 
test animals due to the fact that the eye is very sensitive. In order to reduce testing of severely 
eye irritating substances in rabbits and to decrease the number of animals used, a stepwise 
strategy for eye irritation testing and evaluation is recommended. The stepwise strategy 
combines evidence of eye and skin irritation/damage from existing human or animal studies 
and structure-activity relationship methods as well as physicochemical properties, pH data 
and the results of validated in vitro or ex vivo skin and eye irritation tests (United Nations, 
2003; EC, 2004; OECD, 2004). Four alternative methods (bovine corneal opacity and 
permeability test, hen’s egg test on chorio-allantoic membrane, isolated rabbit eye test and 
isolated chicken eye test) are accepted by a number of EU member states for the hazard 
identification of severe ocular irritants without animal testing (Worth and Balls, 2002). 
Chemicals with sufficient evidence of their eye irritation/damage potential are classified 
without the need to perform further tests in laboratory animals. Only for chemicals that are 
identified as non-irritant in all the preceding steps, the rabbit eye irritation test has to be 
conducted using at most three rabbits in order to confirm that the chemicals are not irritating 
to rabbits’ eyes (United Nations, 2003; EC, 2004; OECD, 2004). 
The rabbit eye irritation test is not only criticised based on ethical grounds, but also 
based on several scientific grounds. Firstly, the use of rabbits to evaluate eye irritation of 
substances may not be appropriate due to differences between rabbit and human eye anatomy 
and response (Wilhelmus, 2001; Curren and Harbell, 2002). Furthermore, the data obtained 
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with the rabbit eye irritation test are highly variable (Weil and Scala, 1971; Earl et al., 1997; 
Ohno et al., 1999) because of the subjective scoring of the tissue lesions, the spillage of test 
substance from the animal eyes, the inadequate number of the animals used, and the 
oversimplification of the overall irritation response by the use of the MMAS (York and 
Steiling, 1998). Moreover, the rabbit eye irritation test has not been formally validated 
(ICCVAM and NICEATM, 2005).  
Therefore, the search for alternative eye irritation tests has been the subject of 
considerable research for many years. Various methods based on isolated organs (Burton et 
al., 1981; Muir, 1984; Gautheron et al., 1992; Prinsen, 1994), organotypic models (Luepke, 
1985; Gilleron et al., 1997), cell based tests (Borenfreund and Puerner, 1985; Pape et al., 
1987), tissue based models (Kahn et al., 1993; Stern et al., 1998; Van Goethem et al., 2005), 
tests based on lower organisms (Kappler and Kristen, 1987; Silverman and Pennisi, 1987), 
and structure activity relationship models (Cronin et al., 1994; Abraham et al., 1998) have 
been developed. However, recently completed validation studies could not satisfactorily 
establish the scientific validity of one or more replacement tests for eye irritation (Balls et al., 
1995; Brantom et al., 1997; Balls et al., 1999). Several factors are responsible for the 
outcomes of these studies. The main reason is the high variability of the rabbit eye irritation 
test. Other possible contributing factors are the inability of in vitro tests to completely model 
the in vivo complexity of the eye, the use of the variable MMAS as in vivo end point to 
evaluate the validity of the alternative tests (Balls et al., 1999), and the factors described (in 
Chapter 2) to be responsible for the low number of formally validated alternative tests. 
Three alternative eye irritation tests to which the results of the Slug Mucosal Irritation 
test were compared in the discussion are specified below. 
 
3.3.2.1 Bovine corneal opacity and permeability test 
 
In the bovine corneal opacity and permeability (BCOP) test which is based on the 
method of Muir (1984, 1985), bovine corneas are used to assess objectively the eye irritation 
potential of substances (Gautheron et al., 1992). After fresh collection of bovine eyes from a 
local slaughterhouse, the corneas are dissected and placed in special holders, which consist of 
an anterior and a posterior chamber. Liquids and surfactants are applied for 10 minutes to the 
anterior chamber of the holder as 100% and 10% dilutions, respectively, whereas solids are 
tested for 4 hours as 20% dilutions. After treatment, the corneas are washed and two end 
points are investigated, namely corneal opacity and permeability. The opacity is determined 
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by using an opacitometer that measures the difference in light transmission passing through a 
treated cornea on the one hand and a control cornea on the other hand. Immediately after the 
opacity measurement, the permeability of the cornea is determined by exposure of the anterior 
corneal side to sodium fluorescein solution for 90 minutes followed by the assessment of the 
optical density of the medium in the posterior chamber. Based on the results of both corneal 
opacity and permeability, an in vitro score is calculated as follows: in vitro score = opacity + 
15 • optical density value (Vanparys et al., 1993; Gautheron et al., 1994; Gautheron, 1996). 
Substances with an in vitro score ≤ 25.0 are classified as non or mild irritant, substances with 
a score between 25.1 and 55.0 are classified as moderate irritants and substances with an in 
vitro score ≥ 55.1 are predicted as severe irritants (Gautheron et al., 1994).  
The regulatory authorities of France, Germany, United Kingdom, The Netherlands, 
Belgium, and Ireland accept the BCOP test for identifying severely eye irritants (i.e. 
substances labelled with risk phrase R41) (Worth and Balls, 2002). Recently, an expert panel 
confirmed that the BCOP assay is an accurate and reliable method for identification of ocular 
corrosive and severely irritating substances other than alcohols, ketones, and solids when used 
in a stepwise testing scheme (ICCVAM and NICEATM, 2005). The discrepancies with the in 
vivo results may be due to the fact that the BCOP assay can not predict effects on the 
conjunctiva (Gilleron et al., 1996).  
 
3.3.2.2 Hen’s egg test on chorio-allantoic membrane 
 
In the hen’s egg test on chorio-allantoic membrane (HET-CAM) which is originally 
developed by Luepke (1985), test substances are placed on the vascularized non-innervated 
chorio-allantoic membrane of fertilized hen’s eggs in order to assess their eye irritating 
properties. It is namely reported that the chorio-allantoic membrane can be used to predict the 
effects of chemical exposure on the conjunctiva (Weterings and Van Erp, 1987). To perform 
the test the egg shell and the inner membrane of 10-day old chicken eggs are removed, so that 
the chorio-allantoic membrane that separates the embryo from the air chamber becomes 
visible. After application of the test substance directly onto the chorio-allantoic membrane, 
the presence of coagulation, haemorrhage, and lysis of the membrane and its blood vessel 
network is examined microscopically (Gilleron et al., 1997). Several HET-CAM protocols are 
available to enable evaluation of substances with different physicochemical properties 
(Spielmann, 1997). In the most frequently used reaction time method, the presence of 
coagulation, lysis, and haemorrhage is scored for five minutes after the application of 
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generally undiluted test substance (Spielmann, 1992; Gilleron et al., 1997). The reaction times 
for each end point are combined in an in vitro eye irritation score, ranging from 0 to 21 
(Kalweit et al., 1990). Substances with an in vitro score < 5 are classified as non-irritants or 
mild irritants, whereas those with a score ≥ 5 are classified as moderate, severe or extreme eye 
irritants (Spielmann et al., 1991). 
The HET-CAM assay has been accepted by the British, French, Dutch and German 
authorities for the classification of severe eye irritants (Worth and Balls, 2002). An expert 
panel concluded that the HET-CAM has been shown to be useful for identification of severe 
or corrosive ocular irritants in a stepwise testing strategy.  However, the panel stated that the 
generation of a high number of false positive results is a limiting factor (ICCVAM and 
NICEATM, 2005).  
 
3.3.2.3 Reconstituted human corneal epithelial model  
 
The reconstituted human corneal epithelial (HCE) model (SkinEthic Laboratories, 
Nice, France) is a three-dimensional model and consists of immortalized human corneal 
epithelial cells. The construct histologically resembles the stratified epithelium of the normal 
human corneal epithelium. Chemicals are applied directly onto the surface of the epithelial 
culture for 10 minutes. After treatment, the cell viability is measured using the MTT assay. 
Furthermore, histological sections are prepared and the release of enzymes and cytokines is 
determined. The classification prediction model can discriminate between eye irritants and 
non-irritants and is defined based on a viability cut-off value of 60%. When the viability after 
10 minutes exposure is < 60%, the test chemical is considered irritant. A recent study showed 
that the interlaboratory reproducibility of the HCE model is good (Van Goethem et al., 2005).  
 
3.4 OBJECTIVES 
 
Previous research demonstrated that the two-day procedure of the Slug Mucosal 
Irritation test can be used as an alternative for screening the eye irritation and damage 
potential of chemicals (e.g. in a stepwise scheme for eye irritation testing). The chemicals 
were first classified based on the amount of mucus produced during a 60-minute contact 
period with a 1% (w/v) dilution of the chemical. Chemicals that induced a mucus production 
higher than 6.3% of the body weight were classified as R41, whereas chemicals that induced 
2.2% to 6.3% mucus production were classified as R36. Test substances that induced less than 
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2.2% mucus were additionally tested at a 1% (w/v) concentration on the next day and were 
then classified into the EU eye irritation categories based on the protein release (Adriaens and 
Remon, 2002). The fact that the described method needs two days for completion can be a 
limiting factor for high throughput screening. Therefore, the objective of this study was to 
reduce the test procedure to one day and to determine whether the modified assay is a relevant 
and reliable method to screen the eye irritation potential of test substances. 
Because several in vivo irritating chemicals were identified based on the amount of 
mucus produced during a 60-minute contact period with a 1% (w/v) concentration, this step of 
the test procedure was maintained. Indeed, a lot of data related to the mucus production and 
protein and enzyme release induced by 1% (w/v) dilutions of chemicals are available. In a 
first phase, it was investigated if increasing the concentration of the in vivo irritants that were 
underestimated based on the mucus production, induced a faster onset on the tissue damage. 
To evaluate the influence of an increasing concentration on the specificity of the test, the 
concentration response effect of six in vivo non-irritating chemicals was also investigated. 
Once the test concentration for the second contact period was selected, the modified 
test procedure was evaluated with a set of 28 reference chemicals that had already been tested 
in a previous study (Adriaens and Remon, 2002). Phosphate buffered saline (PBS) and 
benzalkonium chloride were respectively used as negative and positive control like in 
previous studies. Indeed, incubation of freshly excised pig corneas in PBS did not change the 
corneal cell structure and tissue integrity (Berdy et al., 1992; Baydoun et al., 2004). 
Furthermore, treatment of the slugs with PBS caused neither irritation nor tissue damage as 
was demonstrated by the low mucus production and protein release (Adriaens and Remon, 
1999; Adriaens, 2000; Adriaens et al., 2001; Adriaens and Remon, 2002). Benzalkonium 
chloride was selected as a positive control, because the toxicity of benzalkonium chloride to 
the eye is demonstrated in in vivo and in vitro eye irritation tests (Vanparys et al., 1993; 
Gilleron et al., 1997; ECETOC, 1998; Van Goethem et al., 2005). Benzalkonium chloride is 
also used as positive control in other alternative eye irritation tests such as the HET-CAM 
(Gilleron et al., 1997). Moreover, treatment of the slugs with this chemical resulted in severe 
irritation and damage of the slug mucosa as was demonstrated by an increased mucus 
production and the release of proteins and enzymes from the slug body wall (Adriaens and 
Remon, 1999; Adriaens, 2000; Adriaens et al., 2001; Adriaens and Remon, 2002).  
Based on the end points of the Slug Mucosal Irritation test on the one hand and on the 
eye irritation categories derived from the rabbit eye irritation data on the other hand, a 
classification prediction model was developed to classify the chemicals into the EU eye 
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irritation categories. It was not opted to develop a mathematical prediction model to predict 
the MMAS score of the chemicals, because the MMAS scores do not take into account the 
irreversibility of the effects in individual eye tissues. Furthermore, the MMAS values are 
variable, especially in the middle part of the irritation scale (Prinsen, 1999). 
Next, the reliability and the relevance of the modified test procedure and prediction 
model were assessed. For this purpose, the chemicals were tested on five separate occasions. 
Both the intra-laboratory reproducibility of the test results and the intra-laboratory 
reproducibility of the EU classifications obtained with the Slug Mucosal Irritation test were 
determined. The results obtained with the Slug Mucosal Irritation test were compared with the 
EU classification obtained with the rabbit eye irritation test and the concordance, specificity, 
sensitivity, positive and negative predictive values were determined. 
Additionally, the relevance of the modified assay was evaluated by means of 12 
reference chemicals that were not used for the development of the prediction model. Only 
those chemicals were selected with sufficient and as much as possible unambiguous data from 
animal and in vitro models. Furthermore, the selected test chemicals were distributed 
uniformly across the EU eye irritation categories. 
 
3.5 MATERIALS AND METHODS 
 
3.5.1 Chemicals 
 
The 28 reference chemicals used for the optimisation and evaluation of the test 
procedure and prediction model and the 12 reference chemicals used for the evaluation of the 
relevance of the modified assay are presented in Tables 3.1 and 3.2, respectively. The 
chemicals belong to various chemical classes. They cover the entire irritancy range and were 
selected from the eye irritation reference chemicals data bank. This data bank contains the 
individual rabbit eye irritation scores generated according to OECD Test Guideline 405 as 
well as the MMAS (ECETOC, 1998).  
The individual rabbit eye irritation data (ECETOC, 1998) were used to classify the 
chemicals into the EU eye irritation classes (Prinsen, 1999; EC, 2001) and the GHS eye 
irritation classes (United Nations, 2003). Chemicals which could not be classified as irritant 
or corrosive to the eye were classified as non-irritant (NI). All of the chemicals classified as 
R41 were also classified as category 1. With the exception of one chemical, all of the 
chemicals classified as R36 were also classified as category 2. Sodium lauryl sulphate was 
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classified as R36 on the basis of the EU criteria, whereas it was classified as category 1 on the 
basis of the GHS criteria. Furthermore, 2-methyl-1-pentanol and ethanol were classified as NI 
on the basis of the EU criteria, but as category 2B on the basis of the GHS criteria.  
 
Table 3.1 Eye reference chemicals selected for the optimisation and evaluation of the test 
procedure and prediction model 
Test substance Chemical information Draize eye test 
 CASRN Supplier Purity  
(%) 
Conc  
(%) 
MMAS EU  
class 
GHS 
class 
n
PBS   Sigma       
3,3-Dimethylpentane 562-49-2 Aldrich 99 100 0.0 NI NI 3
PEG 400 25322-68-3 α Pharma - 100 0.0 NI NI 6
3-Methoxy-1,2-propanediol 623-39-2 Aldrich 98 100 0.0 NI NI 3
Propylene glycol 57-55-6 Fraver - 100 1.3 NI NI 6
Glycerol 56-81-5 Sigma 99 100 1.7 NI NI 6
PEG 600 25322-68-3 Merck - 100 2.0 NI NI 6
Methylcyclopentane 96-37-7 Aldrich 98 100 3.7 NI NI 6
Tween 20 9005-64-5 α Pharma - 100 4.0 NI NI 4
Methyl isobutyl ketone 108-10-1 Aldrich > 99 100 4.8 NI NI 4
Toluene 108-88-3 Vel 99 100 9.0 NI NI 4
2-Methyl-1-pentanol 105-30-6 Aldrich 99 100 13.0 NI Cat 2B 3
Ethanol 64-17-5 Merck 99.2 100 24.0 NI Cat 2B 3
Ammonium nitrate 6484-52-2 Sigma > 99.5 100 18.3 R36 Cat 2B 3
1-Octanol 111-87-5 Aldrich 99 100 41.0 R36 Cat 2B 3
4-Carboxybenzaldehyde 619-66-9 Aldrich > 97 100 50.3 R36 Cat 2A 3
2-Ethyl-1-hexanol 104-76-7 Aldrich > 99 100 51.3 R36 Cat 2B 4
Sodium lauryl sulphate 151-21-3 Sigma 99 15 59.2 R36 Cat 1 6
1-Hexanol 111-27-3 Fluka ≥ 99 100 64.8 R36 Cat 2A 4
Acetone 67-64-1 Vel 99 100 65.8 R36 Cat 2A 4
Triton X-100 9002-93-1 Sigma > 99 10 68.7 R36 Cat 2A 6
p-Fluoroaniline 371-40-4 Aldrich 99 100 69.8 R36 Cat 2 6
Lauric acid 143-07-7 Merck > 99 100 38.0 R41 Cat 1 3
Imidazole 288-32-4 Sigma 99 100 59.3 R41 Cat 1 3
Sodium oxalate 62-76-0 Fluka ≥ 99 100 61.3 R41 Cat 1 3
Cyclohexanol 108-93-0 Aldrich 99 100 79.8 R41 Cat 1 4
Cetylpyridinium bromide 140-72-7 Sigma > 99 10 89.7 R41 Cat 1 6
Sodium hydroxide 1310-73-2 Vel ≥ 98 10 108.0 R41 Cat 1 1
Benzalkonium chloride 8001-54-5 Sigma > 98 10 108.0 R41 Cat 1 3
CASRN, Chemical Abstract Service Registry Number; Cat 1, irreversible effects on eyes; Cat 2, reversible 
effects on eyes; Cat 2A, irritating to eyes; Cat 2B, mildly irritating to eyes; MMAS, Modified Maximum 
Average Score (ECETOC, 1998); NI, non-irritant; R36, irritating to eyes; R41, risk of serious damage to eyes. 
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Table 3.2 Additional eye reference chemicals selected for the evaluation of the relevance of the 
modified assay 
Test substance Chemical information Draize eye test 
 CASRN Supplier Purity 
(%) 
Conc  
(%) 
MMAS EU  
class 
GHS  
class 
n
Potassium tetrafluoroborate 14075-53-7 Aldrich > 99.99 100 0.0 NI NI 3
Tetra-aminopyrimidine sulphate 5392-28-9 Aldrich 97 100 10.3 NI NI 3
Methyl amyl ketone 110-43-0 Aldrich 99 100 10.5 NI NI 4
Ethyl acetate 141-78-6 Aldrich > 99.5 100 15.0 NI NI 4
Methyl acetate 79-20-9 Aldrich 99 100 39.5 R36 Cat 2B 4
Isopropanol 67-63-0 Aldrich > 99.5 100 30.5 R36 Cat 2B 4
γ-Butyrolactone 96-48-0 Fluka ≥ 99 100 43.0 R36 Cat 2B 3
1-Butanol 71-36-3 Merck ≥ 99 100 60.8 R36 Cat 2B 4
Pyridine 110-86-1 Fluka ≥ 99.8 100 48.0 R41 Cat 1 3
Promethazine hydrochloride 58-33-3 Sigma 98 100 71.7 R41 Cat 1 3
Chlorhexidine 55-56-1 Aldrich 98 100 82.3 R41 Cat 1 3
Trichloroacetic acid 76-03-9 Sigma 99 30 106 R41 Cat 1 1
CASRN, Chemical Abstract Service Registry Number; Cat 1, irreversible effects on eyes; Cat 2B, mildly 
irritating to eyes; Conc, concentration; MMAS, Modified Maximum Average Score (ECETOC, 1998); NI, non-
irritant; R36, irritating to eyes; R41, risk of serious damage to eyes. 
 
The dilutions of the chemicals were prepared in phosphate buffered saline (PBS, pH 
7.4; Sigma, St. Louis, MO, USA). PBS and benzalkonium chloride were respectively used as 
negative and positive control.  
 
3.5.2 Eye irritation/damage test procedure of the Slug Mucosal Irritation test 
 
The parenteral slugs of A. lusitanicus were collected in local gardens along Varsenare 
and Aalter (Belgium). The slugs were bred in plastic containers in the laboratory at 18-22°C 
and fed with lettuce, cucumber, carrots, and commercial dog food. The slugs were carefully 
examined and those presenting defects, such as a damaged body wall, were discarded. Slugs 
weighing between 3 g and 6 g were isolated two days before the start of an experiment and 
placed in a plastic box lined with a paper towel (moistened with PBS) at 18-22°C.  
The concentration response effect of 13 reference chemicals on the mucosal tissue of 
the slugs was investigated. Dilutions ranging from 1% to 10% (w/v) prepared in PBS were 
tested. The slugs on the one hand and the Petri dishes containing a membrane filter (cellulose 
acetate 0.45 µm, 90 mm; Sartorius AG, Goettingen, Germany) moistened with 2 ml of the test 
medium on the other hand were weighed at the beginning of the experiment. Subsequently, 
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the slugs were placed individually during 60 minutes in a Petri dish on the test medium. For 
each concentration, five slugs were used. After this contact period, the amount of mucus 
produced was measured by reweighing the Petri dishes containing the test medium (without 
the slugs). The mucus production was expressed as percentage (w/w) of the body weight. 
Next, the slugs were transferred to a fresh Petri dish and 1 ml PBS was added. One hour later, 
the PBS samples were collected with a micropipette. The samples were analysed immediately 
for the presence of proteins, lactate dehydrogenase (LDH), and alkaline phosphatase (ALP) 
released from the slug body wall.  
In the next steps, 28 reference chemicals and 12 additional reference chemicals were 
tested using the modified test procedure. Each experiment contained five negative control 
slugs (PBS), five positive control slugs (benzalkonium chloride), and six series of five slugs 
each treated with the test chemicals. At the beginning of the experiment, the slugs on the one 
hand and the Petri dishes containing a membrane filter moistened with 2 ml of a 1% (w/v) 
dilution of the test chemical on the other hand were weighed. Subsequently, the slugs were 
placed individually during 60 minutes in a Petri dish on the test medium. After this first 
contact period, the mucus production was measured, the slugs were transferred to a fresh Petri 
dish and 1 ml PBS was added. One hour later, the PBS samples were collected with a 
micropipette. Two hours after the end of the first contact period, the slugs were placed during 
60 minutes in a Petri dish on a membrane filter moistened with 2 ml of the more concentrated 
dilution of the chemical. After this second contact period, the mucus production was 
measured, the slugs were transferred to a fresh Petri dish and 1 ml PBS was added. The PBS 
samples were collected after 60 minutes. The samples were analysed immediately for the 
presence of proteins, LDH, and ALP released from the body wall of the slugs.  
 
3.5.3 Analytical procedures 
 
3.5.3.1 Protein determination 
 
The protein concentration in the samples was determined with a NanoOrange® protein 
quantitation kit (Molecular Probes, Leiden, The Netherlands). The NanoOrange® reagent 
allows accurate detection of proteins in solution at concentrations between 10 ng/ml and 10 
µg/ml. The NanoOrange® working solution was prepared by diluting 500-fold the 
NanoOrange® protein quantitation reagent (component A) in NanoOrange® diluent. The 
NanoOrange® diluent was made by diluting NanoOrange® component B 10-fold in distilled 
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water. The protein concentration in each sample was determined by adding 3 µl sample to 247 
µl working solution in a 96-well plate (polystyrene, OptiPlate-96F, PerkinElmer, Zaventem, 
Belgium). In order to convert fluorescence to µg/ml protein and to control for day-to-day 
variation in the performance of the fluorometer, also ten standards covering the full assay 
range (0-10 µg/ml) were prepared. The standards were prepared in a 96-well plate using 
bovine serum albumin (NanoOrange® component C, 2 mg/ml) and working solution. 
Immediately after preparation, the 96-well plates with samples and standards were covered 
with aluminium foil and heated to 90-96°C for 10 minutes. After cooling down the standards 
and samples to room temperature, fluorescence measurements were carried out on a 
fluorometer (Wallac 1420 multilabel counter Victor 2, PerkinElmer, Turku, Finland) using 
excitation/emission wavelengths of 485/590 nm. The protein release of the slugs was 
expressed as µg/ml per gram body weight. 
 
3.5.3.2 Lactate dehydrogenase determination 
 
The lactate dehydrogenase activity (LDH, EC 1.1.1.27) was measured using 
commercial kits (DG 1340-UV, Sigma Diagnostics, St. Louis, MO, USA and LDH/HBDH 
2.8, ABX Diagnostics, Montpellier, France). LDH catalyzes the interconversion of pyruvate 
and lactate. During reduction of pyruvate, an equimolar amount of NADH is oxidized to 
NAD+. The oxidation of NADH results in a decrease in the absorbance at 340 nm. The rate of 
decrease in absorbance at 340 nm is directionally proportional to LDH activity in the sample. 
The LDH reagents measure the enzyme activity using an optimised method based on the 
standard method recommended by the German Society for Clinical Chemistry (DGKC, 1972). 
One international unit (IU) of LDH activity is defined as the amount of enzyme that catalyzes 
the formation of 1 µmol/l of NAD+ per minute under the conditions of the assay. The LDH 
activity measurements were conducted at 37°C on a Cobas Plus analyser (ABX, Brussels, 
Belgium) of which the performance was daily checked with standard solutions (Accutrol 
Normal, Sigma Diagnostics, St. Louis, MO, USA and N-Control, ABX Diagnostics, 
Montpellier, France). The detection limit of the method was 4 IU/l. The LDH release of the 
slugs was expressed as IU/l per gram body weight. 
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3.5.3.3 Alkaline phosphatase determination 
 
The alkaline phosphatase activity (ALP, EC 3.1.3.1) was measured using commercial 
kits (DG 1245-UV, Sigma Diagnostics, St. Louis, MO, USA and ALP 6, ABX Diagnostics, 
Montpellier, France). ALP hydrolyzes p-nitrophenyl phosphate to p-nitrophenol and inorganic 
phosphate. The hydrolysis occurs at alkaline pH and the p-nitrophenol formed shows an 
absorbance maximum at 405 nm. The rate of increase in absorbance at 405 nm is directly 
proportional to ALP activity in the sample. The ALP reagents of Sigma Diagnostics measure 
the enzyme activity using an optimised method based on the standard method recommended 
by the German Society for Clinical Chemistry (DGKC, 1972), whereas the ALP reagents of 
ABX Diagnostics measure the enzyme activity using an optimised method based on the 
method recommended by the French Clinical Biology Society (Mathieu et al., 1982). One 
international unit (IU) of ALP activity is defined as the amount of enzyme that catalyzes the 
formation of 1 µmol/l of p-nitrophenol per minute under the conditions of the assay. The ALP 
activity measurements were conducted at 37°C on a Cobas Plus analyser (ABX, Brussels, 
Belgium) of which the performance was daily checked with standard solutions (Accutrol 
Normal, Sigma Diagnostics, St. Louis, MO, USA and N-Control, ABX Diagnostics, 
Montpellier, France).  The detection limit of the method was 4 IU/l. The ALP release of the 
slugs was expressed as IU/l per gram body weight. 
 
3.5.4 Data analysis 
 
For each slug, the mucus production during each contact period and the protein, LDH, 
and ALP release after each contact period were calculated. These data were used for the 
statistical analyses (SPSS version 12.0; SPSS, Chicago, IL, USA). A probability value (p) < 
0.05 was considered statistically significant. 
Pearson correlations between the end points of the Slug Mucosal Irritation test and the 
MMAS of the Draize eye test were determined in order to select the most predictive end 
points. Based on these end points, a classification prediction model for the determination of 
the EU eye irritation category of chemicals was developed. For this purpose, the data of the 
Slug Mucosal Irritation test on the one hand and the EU eye irritation categories based on the 
rabbit eye irritation data on the other hand were analysed using linear discriminant analysis 
and cut-off values for the classification of the chemicals were calculated. Various random 
subsets of the Slug Mucosal Irritation test data were used to calculate cut-off values. On the 
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basis of these results and in-house experience, cut-off values were established and the 
chemicals were classified into one of the corresponding EU categories. 
The repeatability of the test results and the classifications obtained in the five runs was 
evaluated using various statistical methods as suggested by Balls et al. (1995), Bruner et al. 
(1996), Holzhütter et al. (1996), and Fentem et al. (2001). Firstly, the coefficients of variation 
were calculated. Ideally, the overall mean coefficient of variation should be < 30% (Fentem et 
al., 2001). Furthermore, statistically significant differences between the test results obtained 
in the repeated experiments were determined for each chemical using a one-way ANOVA. 
The data were tested for normal distribution with a Kolmogorov-Smirnov test. The 
homogeneity of variances was tested with the Levene’s test. If the variances were found not to 
be equal, the data were transformed to their logarithm. To compare further the effects of the 
repeated experiments, a multiple comparison among pairs of means was performed with a 
Scheffé test. The repeatability of the test results was also assessed using the Pearson 
correlation coefficient and the slope of the linear regression line. The agreement between the 
predicted categories of the repeated experiments was evaluated using the κ-statistics. A κ-
value of 0.75 or higher suggests strong agreement above chance (Fleiss, 1981).  
The relevance of the assay was evaluated using several statistical methods as proposed 
by Balls et al. (1990), Holzhütter et al. (1996), and Hothorn (2002). The extent of agreement 
between the eye irritation categories predicted by the alternative test and the categories 
assigned on the basis of the Draize eye test was assessed by constructing contingency tables. 
For this purpose, the overall predicted category for each chemical was used. If there was any 
discrepancy between the categories obtained in the different runs, then the category obtained 
in three or four runs was used. Concordance, sensitivity, and specificity were calculated as 
defined by Cooper et al. (1979). Concordance is the number of compounds correctly 
classified by the alternative test, divided by the total number of compounds tested. Sensitivity 
(evaluation of false negatives) is the total number of irritants correctly classified by the 
alternative test, divided by the total number of in vivo irritants tested. Specificity (evaluation 
of false positives) is the total number of non-irritants correctly predicted by the alternative 
test, divided by the total number of in vivo non-irritants tested. Fentem et al. (2001) stated that 
the sensitivity and specificity should be > 60%. Furthermore, the positive predictive value 
(likelihood that a positive outcome in the alternative test correctly identifies an irritant) and 
the negative predictive value (likelihood that a negative outcome in the alternative test 
correctly identifies a non-irritant) were calculated. The positive predictive value is the total 
number of irritants correctly classified by the alternative test, divided by the total number of 
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irritants identified by the alternative test. The negative predictive value is the total number of 
non-irritants correctly classified by the alternative test, divided by the total number of non-
irritants identified by the alternative test. To determine the sensitivity, specificity, positive and 
negative predictive value of the alternative test, the chemicals were divided into two classes: 
non-irritant (NI) and irritant (R36 and R41).  
In order to provide criteria for test validity, acceptance criteria for the negative and 
positive control were calculated as defined by Hahn and Meeker (1991). 
 
3.6 RESULTS 
 
3.6.1 Modification of the test procedure using concentration response experiments 
 
Historical data from the negative control (45 experiments) showed that when slugs are 
placed during 60 minutes on PBS, the amount of mucus is typically less than 2% of the body 
weight. Furthermore, negative control slugs showed low protein levels after the contact period 
(less than 50 µg/ml.g) and no LDH release was detected. Therefore, chemicals that induce a 
response that is comparable to the negative control slugs are considered to be non-irritant. 
Taking this into account, the concentration response effect of several in vivo irritants that were 
underestimated by the mucus production and of some in vivo non-irritating chemicals was 
investigated. 1%, 2.5%, 5% and 10% (w/v) dilutions of each chemical were tested. Because 
an increasing concentration of the chemicals influenced especially the mucus production and 
protein release, these data are presented in Table 3.3 and Table 3.4, respectively. The data of 
the ALP release are not mentioned, because ALP release was only induced after treatment 
with 5% or 10% (w/v) dilutions of a few chemicals. 
PEG 400 and lauric acid induced no concentration response effect, the mucus 
production and protein release were low at all tested concentrations and no LDH release was 
detected. Increasing concentrations of glycerol and propylene glycol resulted in an increased 
mucus production (> 4% of the body weight) which is an indication of irritation, this effect 
started at a 5% and a 10% (w/v) concentration, respectively. However, the protein levels were 
low and no LDH release was detected indicating that these chemicals induced no tissue 
damage at the tested concentrations. Tween 20® had no effect on the mucus production and 
the LDH release was below the detection limit, while a concentration response effect was 
present for the protein release (low to moderate release). A 10% (w/v) dilution of ethanol 
induced severe irritation (increased mucus production, protein and LDH release), whereas 
___________________________________________________________________________ 
Chapter 3: Evaluation of the eye irritation/damage potential of chemicals 38 
concentrations of 5% (w/v) and lower had no effect. No concentration response effect was 
found on the mucus production for 2-ethyl-1-hexanol, 1-hexanol, and cyclohexanol, while 1-
octanol induced an increased mucus production from a 2.5% (w/v) concentration on. A 2.5% 
(w/v) dilution of acetone and a 10% (w/v) dilution of toluene resulted in an increased mucus 
production (> 6% of the body weight), whereas other concentrations had no effect on this end 
point. All those chemicals induced a concentration dependent tissue damage. Acetone and 
cyclohexanol resulted in tissue damage at concentrations of 5% (w/v) and higher, whereas 
toluene, 1-octanol, 2-ethyl-1-hexanol, and 1-hexanol resulted in tissue damage starting at a 
2.5% (w/v) concentration. For benzalkonium chloride, maximum mucus production, protein 
and LDH release data were obtained at a 2.5% (w/v) concentration. 
From the results of the concentration response experiments, it is clear that all in vivo 
irritating chemicals, except lauric acid, can be identified based on the protein and LDH 
release when they are tested as a 5% (w/v) dilution. Therefore, it was decided to select a 5% 
(w/v) concentration for the second contact period. However, preliminary experiments showed 
that the specificity of the test decreased. Consequently, the test concentration of the second 
contact period was reduced to 3.5% (w/v). 
 
Table 3.3 Concentration response effect of the reference chemicals on the mucus production as 
assessed with the Slug Mucosal Irritation test 
Test substance Draize eye test  Slug Mucosal Irritation test Mucus production (%) a 
 
EU 
class 
MMAS 
 
 
1.0%  2.5% 5.0% 10.0% 
PEG 400 NI 0.0  -1.3 ± 1.3 -1.2 ± 0.8 -1.1 ± 0.5 1.2 ± 3.0 
Propylene glycol NI 1.3  1.4 ± 2.3 1.9 ± 1.7 1.1 ± 1.8 4.3 ± 3.2 
Glycerol NI 1.7  2.3 ± 2.4 2.9 ± 4.8 5.4 ± 2.1 6.7 ± 5.5 
Tween 20 NI 4.0  0.1 ± 1.2 1.0 ± 2.0 -1.4 ± 0.7 -0.9 ± 0.5 
Toluene NI 9.0  -0.5 ± 1.2 2.4 ± 5.0 2.2 ± 2.3 10.6 ± 12.6 
Ethanol NI 24.0  -0.5 ± 1.1 -1.1 ± 0.8 -0.7 ± 1.6 9.4 ± 3.4 
1-Octanol R36 41.0  -1.2 ± 1.4 3.7 ± 3.5 13.5 ± 6.5 6.5 ± 6.3 
2-Ethyl-1-hexanol R36 51.3  -0.6 ± 0.7 1.0 ± 1.3 0.6 ± 0.6 1.3 ± 0.7 
1-Hexanol R36 64.8  0.5 ± 1.0 1.0 ± 2.0 1.0 ± 0.5 2.0 ± 2.0 
Acetone R36 65.8  0.4 ± 2.6 6.5 ± 2.0 2.0 ± 0.8 1.5 ± 2.4 
Lauric acid R41 38.0  -1.9 ± 1.9 -1.3 ± 2.1 -1.1 ± 0.8 0.1 ± 1.7 
Cyclohexanol R41 79.8  0.6 ± 0.6 0.6 ± 0.8 -0.3 ± 0.9 0.6 ± 1.4 
Benzalkonium chloride R41 108.0  20.3 ± 9.5 30.4 ± 5.1 32.3 ± 6.6 31.1 ± 4.1 
MMAS, modified maximum average score (ECETOC, 1998); NI, non-irritant; R36, irritating to eyes, R41, risk 
of serious damage to eyes. 
a Values are the mean ± standard deviation of 5 slugs. 
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Table 3.4 Concentration response effect of the reference chemicals on the protein release as 
assessed with the Slug Mucosal Irritation test 
Test substance Draize eye test Slug Mucosal Irritation test Protein release (µg/ml.g) a 
 
EU 
class 
MMAS  
 1.0%  2.5% 5.0% 10.0% 
PEG 400 NI 0.0 9 ± 12 12 ± 15 7 ± 2 1 ± 1 
Propylene glycol NI 1.3 13 ± 13 15 ± 10 46 ± 71 12 ± 11 
Glycerol NI 1.7 21 ± 23 8 ± 4 9 ± 5 35 ± 45 
Tween 20 NI 4.0 37 ± 29 65 ± 47 67 ± 36 83 ± 33 
Toluene NI 9.0 8 ± 8 141 ± 104 149 ± 97 135 ± 108 
Ethanol NI 24.0 3 ± 3 14 ± 21 7 ± 3 210 ± 203 
1-Octanol R36 41.0 50 ± 72 255 ± 102 420 ± 113 295 ± 49 
2-Ethyl-1-hexanol R36 51.3 58 ± 25 76 ± 11 75 ± 37 136 ± 30 
1-Hexanol R36 64.8 4 ± 4 92 ± 69 99 ± 48 167 ± 142 
Acetone R36 65.8 18 ± 18 18 ± 20 482 ± 206 488 ± 65 
Lauric acid R41 38.0 19 ± 19 13 ± 6 17 ± 20 12 ± 7 
Cyclohexanol R41 79.8 14 ± 6 17 ± 22 67 ± 60 166 ± 29 
Benzalkonium chloride R41 108.0 323 ± 207 490 ± 134 628 ± 183 522 ± 52 
MMAS, modified maximum average score (ECETOC, 1998); NI, non-irritant; R36, irritating to eyes, R41, risk 
of serious damage to eyes. 
a Values are the mean ± standard deviation of 5 slugs. 
                
3.6.2 Validation of the modified test procedure 
 
3.6.2.1 Evaluation of the modified test procedure 
 
Table 3.5 summarizes the data obtained for the 28 reference chemicals and the 
negative control. The ALP release data are not mentioned, because ALP release was only 
induced after the first contact period for one out of the 28 reference chemicals (imidazole) and 
after the second contact period for seven out of the 28 reference chemicals. 
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Table 3.5 Irritation potential of the reference chemicals as assessed with the Draize eye test and 
the Slug Mucosal Irritation test 
Test substance Draize eye test Slug Mucosal Irritation test 
 EU MMAS 1st 60-min. contact period a 2nd 60-min. contact period b n 
 
class  Mucus 
(%) 
Protein 
(µg/ml.g)
LDH 
(IU/l.g)
Mucus 
(%) 
Protein 
(µg/ml.g) 
LDH 
(IU/l.g)  
PBS    -1.3 19 - -1.9 18 - 25 
3,3-Dimethylpentane NI 0.0 -2.6 13 - 0.8 24 - 5 
PEG 400 NI 0.0 -0.1 8 - -0.9 11 - 5 
3-Methoxy-1,2-propanediol NI 0.0 -0.5 24 - -0.1 10 - 5 
Propylene glycol NI 1.3 -1.4 11 - -0.4 17 - 5 
Glycerol NI 1.7 0.8 13 - 0.3 11 - 5 
PEG 600 NI 2.0 -2.4 31 - -1.7 12 - 5 
Methylcyclopentane NI 3.7 -0.4 21 - -1.7 18 - 5 
Tween 20 NI 4.0 -2.6 24 - -1.3 56 - 5 
Methyl isobutyl ketone NI 4.8 3.1 313 - 6.2 47 0.4 5 
Toluene NI 9.0 -1.9 20 - -0.7 208 - 5 
2-Methyl-1-pentanol NI 13.0 0.5 5 - -1.2 194 9.0 5 
Ethanol NI 24.0 -0.1 27 - -4.0 10 - 5 
Ammonium nitrate R36 18.3 4.3 29 - 15.4 277 2.8 5 
1-Octanol R36 41.0 5.6 172 1.1 3.6 259 13.2 5 
4-Carboxybenzaldehyde R36 50.3 2.8 45 - 4.6 38 2.6 5 
2-Ethyl-1-hexanol R36 51.3 -0.1 78 1.5 -3.4 238 5.8 5 
Sodium lauryl sulphate R36 59.2 19.0 67 - 12.2 437 11.9 5 
1-Hexanol R36 64.8 -2.6 14 - -2.4 230 8.7 5 
Acetone R36 65.8 0.0 97 - -1.3 122 - 5 
Triton X-100 R36 68.7 13.0 44 - 15.0 251 8.3 5 
p-Fluoroaniline R36 69.8 2.0 29 - -4.0 53 3.1 5 
Lauric acid  R41 38.0 -1.8 15 - -3.8 30 - 5 
Imidazole R41 59.3 6.1 270 - 22.8 415 3.9 5 
Sodium oxalate R41 61.3 12.5 178 6.6 20.4 255 21.9 5 
Cyclohexanol R41 79.8 0.7 103 - -3.4 63 1.5 5 
Cetylpyridinium bromide R41 89.7 13.8 177 0.9 5.7 370 9.6 5 
Sodium hydroxide R41 108.0 15.8 80 - 6.4 88 0.9 5 
Benzalkonium chloride R41 108.0 20.2 282 8.2 8.2 496 66.5 25 
MMAS, modified maximum average score (ECETOC, 1998); NI, non-irritant; R36, irritating to eyes; R41, risk 
of serious damage to eyes; -, below the detection limit. 
a Treatment with a 1% (w/v) dilution of the chemical.  
b Treatment with a 3.5% (w/v) dilution of the chemical.  
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The results of the Slug Mucosal Irritation test were compared to the EU categories. 
Because nine out of the 16 in vivo irritants induced an increased mucus production (> 4%) 
during the first contact period with a 1% (w/v) dilution of the test substance, this end point 
can be used as a first step to discriminate between irritants and non-irritants. However, seven 
in vivo irritating chemicals resulted in a mucus production that was comparable to the 
negative controls. Three of those chemicals resulted in some tissue damage after the first 
contact period and by increasing the test concentration during the second contact period to 
3.5% (w/v), six out of the seven in vivo irritants that were underestimated by the mucus 
production were detected based on the protein and LDH release. Only the in vivo irritating 
lauric acid induced neither mucus production nor increased release of proteins or enzymes. 
The amount of mucus secreted during the second contact period did not give any additional 
information. However, the modified assay also affected the false positive results. Eleven of 12 
in vivo non-irritants resulted in a mucus production that was comparable to the negative 
control slugs and nine in vivo non-irritants did not result in tissue damage and can therefore be 
considered non-irritant. One in vivo non-irritant (methyl isobutyl ketone) induced a slight 
increase of the mucus production as well as an increased protein release after the first contact 
period. Two other in vivo non-irritants (toluene and 2-methyl-1-pentanol) induced tissue 
damage after the second contact period. 
 
3.6.2.2 Development of prediction model 
 
The results obtained with the Slug Mucosal Irritation test were compared with the 
MMAS values and with the EU categories based on the rabbit eye irritation data (ECETOC, 
1998; EC, 2001). Based on statistical analyses and in-house experience, it was decided to 
work out a prediction model that classifies the chemicals first based on the amount of mucus 
produced during the first contact period with a 1% (w/v) dilution of the chemical. Chemicals 
that induced ≤ 3% mucus production are tested during a second contact period with a 3.5% 
(w/v) dilution of the chemical. Those compounds are then classified based on the tissue 
damage which is expressed as a score. The score for tissue damage takes into account the 
protein release after the first contact period (P1), and the protein and LDH release after the 
second contact period (P2, LDH2) and is calculated as follows: P1 + P2 + 30 • LDH2. The 
classification prediction model is presented in Figure 3.1. 
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Figure 3.1  Classification prediction model of the Slug Mucosal Irritation test for the 
determination of the EU eye irritation category of chemicals using A. lusitanicus as 
test organism (P1 and P2, protein release after 1st and 2nd contact period; LDH2, LDH 
release after 2nd contact period; NI, non-irritant; R36, irritating to eyes; R41, risk of 
serious damage to eyes). 
 
3.6.2.3 Reliability of the modified test procedure and prediction model 
 
In order to investigate the repeatability of the modified procedure, all chemicals were 
tested independently on five separate occasions. Tables 3.6 and 3.7 show for each of the 28 
reference chemicals the mucus productions (of the first contact period) and the scores for 
tissue damage obtained in the repeated experiments and the mean of the five runs. Because 
several compounds induced a mucus production that was close to zero, the coefficients of 
variation for the end point mucus production were large and misleading. Consequently, it was 
decided to not present the coefficients of variation. For each chemical, a one-way ANOVA 
test was performed to detect statistically significant differences between the test results 
obtained in the five runs. For 16 out of the 28 test substances, significantly different mucus 
productions were detected in the five runs (p < 0.05). However, only for four out the latter 16 
substances, the average mucus production of the five runs was more than 1%. For seven out 
of the 28 test substances, significantly different scores were detected in the five runs (p < 
0.05). 
 
NI 
 
R41 
 
 
R36 
> 6 ≤  3 > 3 & ≤  6 
> 500 ≤ 100 > 100 & 
≤ 500 
MUCUS PRODUCTION (%) 
1st contact period  
SCORE FOR TISSUE DAMAGE 
= P1 + P2 + 30 • LDH2 
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Table 3.6 Intra- and inter-experiment variability for the mucus production (%) 
 
Test substance Run 1 Run 2 Run 3 Run 4 Run 5 Average
3,3-Dimethylpentane -2.6 ± 1.5 a -1.5 ± 1.2 a, b -0.1 ± 0.6 b -0.1 ± 0.6 b 0.0± 1.3 b -0.8± 1.2
PEG 400* -0.1 ± 1.1 0.5 ± 0.9 1.4 ± 1.7 0.7 ± 0.9 1.3± 0.7 0.8± 0.7
3-Methoxy-1,2-propanediol -0.5 ± 1.0 a, b 0.2 ± 0.9 a, b -0.9 ± 1.7 a 2.5 ± 0.6 c 1.6± 0.7 b, c 0.6± 1.4
Propylene glycol -1.4 ± 1.0 a -0.2 ± 0.9 a, b, c -0.8 ± 1.5 a, b 1.3 ± 1.0 b, c 1.6± 0.5 c 0.1± 1.3
Glycerol* 0.8 ± 2.1 1.4 ± 1.0 -0.4 ± 2.0 1.9 ± 0.5 1.4± 0.7 1.0± 0.9
PEG 600 -2.4 ± 1.9 a -0.6 ± 0.8 a, b -0.1 ± 0.5 a, b 0.4 ± 0.7 b 0.7± 1.5 b -0.4± 1.2
Methylcyclopentane -0.4 ± 0.6 a, b 0.2 ± 0.5 a, b -1.7 ± 0.8 a 0.8 ± 1.4 b 0.7± 1.0 b -0.1± 1.0
Tween 20 -2.6 ± 1.4 a -0.4 ± 1.9 a, b -0.8 ± 0.8 a, b 1.5 ± 1.1 b -0.3± 1.2 a, b -0.5± 1.4
Methyl isobutyl ketone* 3.1 ± 1.7 4.4 ± 4.4 1.9 ± 2.7 5.0 ± 5.2 1.0± 0.9 3.1± 1.7
Toluene -1.9 ± 1.0 a 0.0 ± 0.3 a, b -1.1 ± 1.1 a 1.3 ± 0.9 b, c 2.5± 1.3 c 0.2± 1.8
2-Methyl-1-pentanol 0.5 ± 2.0 a 0.0 ± 0.6 a -1.6 ± 1.0 a, b -2.9 ± 0.9 b 1.0± 0.8 a -0.6± 1.6
Ethanol -0.1 ± 1.2 a, b -0.1 ± 0.5 a, b -1.1 ± 0.5 a 0.9 ± 0.4 b 0.9± 0.9 b 0.1± 0.9
Ammonium nitrate* 4.3 ± 3.4 6.0 ± 1.1 4.9 ± 0.6 4.3 ± 0.5 5.0± 1.7 4.9± 0.7
1-Octanol 5.6 ± 2.5 a 0.6 ± 1.0 b 1.1 ± 1.2 b 2.5 ± 1.0 b 2.3± 0.9 b 2.4± 2.0
4-Carboxybenzaldehyde 2.8 ± 2.6 a 3.6 ± 3.0 a 6.1 ± 2.5 a, b 9.4 ± 3.1 b 5.4± 1.8 a, b 5.5± 2.6
2-Ethyl-1-hexanol -0.1 ± 1.7 a, b 0.8 ± 1.0 a, b 0.4 ± 1.3 a, b -1.1 ± 0.6 a 2.2± 1.0 b 0.4± 1.2
Sodium lauryl sulphate* 19.0 ± 4.4 18.4 ± 7.2 23.6 ± 5.6 18.0 ± 3.8 16.9± 3.7 19.2± 2.6
1-Hexanol -2.6 ± 1.3 a 0.0 ± 0.6 b, c -0.9 ± 1.3 a, b -2.6 ± 0.9 a 1.6± 0.9 c -0.9± 1.8
Acetone* 0.0 ± 2.0 1.1 ± 1.0 -0.4 ± 1.1 -0.9 ± 1.4 1.4± 0.3 0.2± 1.0
Triton X-100 13.0 ± 2.6 a 8.1 ± 3.9 a, b 6.6 ± 3.1 b 11.6 ± 1.6 a, b 9.2± 2.5 a, b 9.7± 2.6
p-Fluoroaniline 2.0 ± 1.8 a, b, c 3.0 ± 0.6 b, c 0.3 ± 1.4 a, b 0.1 ± 1.5 a 4.1± 1.1 c 1.9± 1.7
Lauric acid  -1.8 ± 1.2 a -0.5 ± 0.5 a, b -1.0 ± 0.7 a, b 0.1 ± 1.4 a, b 1.1± 0.8 b -0.4± 1.1
Imidazole* 6.1 ± 3.4 7.2 ± 0.4 11.2 ± 14.7 5.5 ± 1.0 5.6± 2.2 7.1± 2.4
Sodium oxalate* 12.5 ± 4.1 9.4 ± 1.4 10.1 ± 2.7 12.9 ± 2.2 12.0± 2.6 11.4± 1.5
Cyclohexanol* 0.7 ± 1.3 0.4 ± 0.8 0.5 ± 0.8 1.7 ± 0.8 1.8± 0.6 1.0± 0.7
Cetylpyridinium bromide* 13.8 ± 6.5 6.4 ± 2.0 7.9 ± 3.9 10.1 ± 6.7 8.4± 0.7 9.3± 2.9
Sodium hydroxide* 15.8 ± 7.9 6.4 ± 2.5 11.7 ± 4.0 11.8 ± 4.8 14.9± 3.5 12.1± 3.7
Benzalkonium chloride* 14.0 ± 10.4 25.0 ± 8.6 16.7 ± 6.4 18.9 ± 4.0 24.8± 2.8 19.9± 4.9
Values are the mean data ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 
5 runs.  
* For this test substance, there are no significant differences between the mucus productions of the 5 runs (p > 
0.05, One-way ANOVA). 
a, b, c Mucus productions of the slugs treated with this test substance marked with the same superscript are not 
significantly different from each other (p > 0.05, Scheffé test). 
 
 
 
 
 
 
 
 
___________________________________________________________________________ 
Chapter 3: Evaluation of the eye irritation/damage potential of chemicals 44 
Table 3.7 Intra- and inter-experiment variability for the score for tissue damage 
 
Test substance Run 1 Run 2 Run 3 Run 4 Run 5 Average 
3,3-Dimethylpentane* 37 ± 25 57 ± 53 62 ± 112 77 ± 56 15 ± 13 50±24 
PEG 400* 19 ± 12 13 ± 9 36 ± 33 25 ± 5 25 ± 21 24±9 
3-Methoxy-1,2-propanediol 34 ± 24 b, c 8 ± 4 a 53 ± 42 c 84 ± 52 c 11 ± 3 a, b 38±32 
Propylene glycol 28 ± 12 a 10 ± 4 a, b 9 ± 9 b 24 ± 11 a, b 9 ± 5 a, b 16±9 
Glycerol* 24 ± 28 15 ± 21 4 ± 3 22 ± 10 23 ± 23 18±8 
PEG 600* 43 ± 63 30 ± 18 39 ± 72 29 ± 10 18 ± 7 32±9 
Methylcyclopentane 39 ± 13 b 13 ± 4 a, b 9 ± 9 a 19 ± 7 a, b 28 ± 17 a, b 21±12 
Tween 20* 81 ± 20 118 ± 66 93 ± 40 71 ± 28 78 ± 14 88±18 
Methyl isobutyl ketone* 373 ± 109 333 ± 141 490 ± 211 445 ± 212 493 ± 365 427±71 
Toluene* 228 ± 87 173 ± 118 144 ± 68 249 ± 80 115 ± 86 182±56 
2-Methyl-1-pentanol* 471 ± 225 190 ± 135 1002 ± 950 595 ± 368 312 ± 195 514±313 
Ethanol* 37 ± 35 18 ± 8 18 ± 13 19 ± 8 20 ± 10 22±8 
Ammonium nitrate* 389 ± 209 254 ± 83 117 ± 76 231 ± 89 218 ± 108 242±97 
1-Octanol* 828 ± 633 447 ± 256 549 ± 444 334 ± 176 409 ± 166 513±192 
4-Carboxybenzaldehyde* 163 ± 76 207 ± 196 162 ± 81 215 ± 158 35 ± 33 156±72 
2-Ethyl-1-hexanol* 491 ± 171 217 ± 66 569 ± 362 213 ± 90 408 ± 285 380±161 
Sodium lauryl sulphate* 860 ± 730 364 ± 135 607 ± 323 387 ± 217 310 ± 220 506±228 
1-Hexanol 506 ± 190 a, b 197 ± 130 a 906 ± 850 b 1755 ± 581 b 185 ± 123 a 710±654 
Acetone* 219 ± 219 63 ± 29 250 ± 309 135 ± 152 102 ± 117 154±79 
Triton X-100 545 ± 448 a 427 ± 252 a 1719 ± 713 b 846 ± 351 a, b 451 ± 369 a 798±541 
p-Fluoroaniline* 174 ± 80 244 ± 114 305 ± 232 94 ± 49 103 ± 33 184±91 
Lauric acid* 45 ± 20 48 ± 47 26 ± 24 42 ± 40 34 ± 22 39±9 
Imidazole* 803 ± 369 574 ± 202 1198 ± 789 667 ± 331 848 ± 254 818±239 
Sodium oxalate* 1088 ± 465 683 ± 154 887 ± 807 502 ± 50 446 ± 134 721±268 
Cyclohexanol* 209 ± 85 139 ± 171 145 ± 75 106 ± 181 43 ± 35 128±61 
Cetylpyridinium bromide 836 ± 625 b 283 ± 83 a, b 659 ± 151 b 886 ± 643 b 188 ± 214 a 570±319 
Sodium hydroxide* 195 ± 104 136 ± 81 147 ± 83 270 ± 134 342 ± 317 218±87 
Benzalkonium chloride 2489 ± 1512 a, b 1889 ± 687 a, b 3446 ± 738 b 1851 ± 631 a, b 1310 ± 360 a 2197±813 
Values are the mean data ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 
5 runs.  
* For this test substance, there are no significant differences between the scores of the 5 runs (p > 0.05, One-way 
ANOVA). 
a, b, c Scores of the slugs treated with this test substance marked with the same superscript are not significantly 
different from each other (p > 0.05, Scheffé test). 
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The repeatability of the test results was also evaluated using the Pearson correlation 
coefficient and the slope of the regression line. Generally, the data are highly correlated 
between the different trials for both end points (Tables 3.8 and 3.9). For the mucus 
production, the slope of the regression line is close to one suggesting that the data are of the 
same magnitude, whereas for the score for tissue damage the magnitude of the data varies 
between the different trials.  
 
Table 3.8 Repeatability of the mucus production data (of the first 60-minute contact period) 
 
 Run 1 Run 2 Run 3 Run 4 Run 5 
Run 1 - 0.83 0.90 0.91 0.88 
Run 2 0.89 (0.30) - 0.91 0.90 0.95 
Run 3 0.92 (0.41) 0.87 (0.66) - 0.92 0.90 
Run 4 1.00 (-0.62) 0.91 (-0.21) 0.98 (-0.70) - 0.92 
Run 5 0.95 (-0.91) 0.95 (-0.83) 0.95 (-1.06) 0.91 (-0.09) - 
Values above the dashes are the Pearson correlation coefficients. Values below the dashes are the slopes of the 
linear regression lines while the values between the brackets are the intercepts (n = 28). The correlation and 
regression coefficients are significant (p < 0.001). 
 
Table 3.9 Repeatability of the score for tissue damage data 
 
 Run 1 Run 2 Run 3 Run 4 Run 5 
Run 1 - 0.96 0.91 0.78 0.89 
Run 2 1.35 (56) - 0.92 0.72 0.91 
Run 3 0.65 (87) 0.47 (28) - 0.84 0.90 
Run 4 0.84 (96) 0.56 (53) 1.17 (4) - 0.70 
Run 5 1.56 (35) 1.13 (-11) 2.20 (-29) 1.13 (98) - 
Values above the dashes are the Pearson correlation coefficients. Values below the dashes are the slopes of the 
linear regression lines while the values between the brackets are the intercepts (n = 28). The correlation and 
regression coefficients are significant (p < 0.001). 
 
The reference chemicals can be classified into one of the EU eye irritation categories 
using the classification prediction model described in Figure 3.1. The agreement between the 
classifications of the repeated experiments was assessed using the κ-statistics. The 
classification prediction model shows a high reproducibility with κ-values ranging from 0.63 
to 0.84 (Table 3.10). Eighteen chemicals were classified the same during the five different 
trials. For six compounds, the classification differed between the R36 and R41 and for another 
four compounds, there was a switch between the R36 and NI category.  
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Table 3.10 Repeatability of the classification prediction model of the Slug Mucosal Irritation test 
 
Test substance Predicted EU category a 
 Run 1 Run 2 Run 3 Run 4 Run 5 
3,3-Dimethylpentane NI NI NI NI NI 
PEG 400 NI NI NI NI NI 
3-Methoxy-1,2-propanediol NI NI NI NI NI 
Propylene glycol NI NI NI NI NI 
Glycerol NI NI NI NI NI 
PEG 600 NI NI NI NI NI 
Methylcyclopentane NI NI NI NI NI 
Tween 20 NI R36 NI NI NI 
Methyl isobutyl ketone R36 R36 R36 R36 R36 
Toluene R36 R36 R36 R36 R36 
2-Methyl-1-pentanol R36 R36 R41 R41 R36 
Ethanol NI NI NI NI NI 
Ammonium nitrate R36 R36 R36 R36 R36 
1-Octanol R36 R36 R41 R36 R36 
4-Carboxybenzaldehyde R36 R36 R41 R41 R36 
2-Ethyl-1-hexanol R36 R36 R41 R36 R36 
Sodium lauryl sulphate R41 R41 R41 R41 R41 
1-Hexanol R41 R36 R41 R41 R36 
Acetone R36 NI R36 R36 R36 
Triton X-100 R41 R41 R41 R41 R41 
p-Fluoroaniline R36 R36 R36 NI R36 
Lauric acid    NI NI NI NI NI 
Imidazole R41 R41 R41 R36 R36 
Sodium oxalate R41 R41 R41 R41 R41 
Cyclohexanol R36 R36 R36 R36 NI 
Cetylpyridinium bromide R41 R41 R41 R41 R41 
Sodium hydroxide R41 R41 R41 R41 R41 
Benzalkonium chloride R41 R41 R41 R41 R41 
Agreement between the runs κ-value 
Run 1 -     
Run 2 0.84 ± 0.09 -    
Run 3 0.79 ± 0.09 0.63 ± 0.11 -   
Run 4 0.79 ± 0.10 0.63 ± 0.12 0.78 ± 0.10 -  
Run 5 0.84 ± 0.09 0.78 ± 0.10 0.63 ± 0.11 0.73 ± 0.11 - 
NI, non-irritant; R36, irritating to eyes; R41, risk of serious damage to eyes.  
a EU eye irritation categories were assigned using the classification prediction model described in Figure 3.1 and 
the data presented in Tables 3.6 and 3.7. 
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3.6.2.4 Relevance of the modified assay based on 28 chemicals  
 
 Next, the EU eye irritation categories predicted by the Slug Mucosal Irritation test 
were compared with the EU categories based on the rabbit eye irritation data (ECETOC, 
1998; EC, 2001). Acetone, p-fluoroaniline, and cyclohexanol were falsely predicted non-
irritant in one of the five trials, while they were predicted R36 in the other cases. For Tween 
20®, a false positive result was obtained in the second trial, whereas it was predicted correctly 
in the other trials. Sodium lauryl sulphate and Triton X-100® were overestimated in the five 
trials, while cyclohexanol was underestimated in the five trials in comparison with the EU 
label. To evaluate the concordance, sensitivity, and specificity of the Slug Mucosal Irritation 
test, the overall obtained classification was compared with the EU risk phrase of the reference 
chemicals (Figure 3.2 and Table 3.11). Only one chemical (lauric acid) was predicted non-
irritant in the five different trials resulting in a sensitivity of 94%. Methyl isobutyl ketone, 
toluene, and 2-methyl-1-pentanol were overestimated (false positives) in the five trials 
resulting in a specificity of 75%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2  Left-graph shows the agreement between the mucus production and the EU eye 
irritation category based on the Draize eye test for substances that induced > 3% 
mucus production. Right-graph shows the agreement between the score for tissue 
damage and the Draize EU eye irritation category for substances that induced ≤ 3% 
mucus production. Data points are presented as the mean values of the 5 runs. 
Correctly classified (●), false positive (●), false negative (●), overestimated (●), and 
underestimated (●) test substances are indicated. 
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Table 3.11 Agreement of the EU classification of the chemicals obtained with the Slug Mucosal 
Irritation test and the Draize rabbit eye test 
Slug Mucosal Irritation test Draize test EU category 
Predicted EU category R41 R36 NI 
R41 5 3 0 
R36 1 6 3 
NI 1 0 9 
71% of the chemicals are correctly classified into three classes with a sensitivity of 94%, a specificity of 75%, a 
positive predictive value of 83% and a negative predictive value of 90% (irritants versus non-irritants). 
 
3.6.2.5 Relevance of the modified assay based on 12 additional chemicals 
 
 Additionally, the relevance of the modified assay was assessed by means of 12 
reference chemicals that were not used for the development of the prediction model. Table 
3.12 summarizes the mucus production, score for tissue damage, and EU eye irritation 
category based on both the Slug Mucosal Irritation test and the Draize eye irritation test for 
each of the chemicals.  
 
Table 3.12  Irritation potential of additional reference chemicals as assessed with the Draize eye 
test and the Slug Mucosal Irritation test 
Test substance Draize eye test  Slug Mucosal Irritation test  
 EU 
class 
MMAS  Mucus a 
(%) 
Score a 
 
Predicted 
EU class b
Potassium tetrafluoroborate NI 0.0  2.8 ± 0.8 18 ± 4 NI 
Tetra-aminopyrimidine sulphate NI 10.3  2.6 ± 1.1 22 ± 18 NI 
Methyl amyl ketone NI 10.5  8.3 ± 7.3 187 ± 133 R41 
Ethyl acetate NI 15.0  -0.8 ± 0.7 22 ± 14 NI 
Methyl acetate R36 39.5  -0.6 ± 0.5 29 ± 39 NI 
Isopropanol R36 30.5  0.0 ± 0.6 84 ± 53 NI 
γ-Butyrolactone R36 43.0  0.3 ± 0.8 98 ± 118 NI 
1-Butanol R36 60.8  0.0 ± 1.1 35 ± 12 NI 
Pyridine R41 48.0  6.5 ± 2.3 245 ± 100 R41 
Promethazine hydrochloride R41 71.7  22.2 ± 6.8 2812 ± 656 R41 
Chlorhexidine R41 82.3  16.5 ± 4.5 998 ± 575 R41 
Trichloroacetic acid R41 106  7.0 ± 5.5 230 ± 157 R41 
MMAS, modified maximum average score (ECETOC, 1998); NI, non-irritant; R36, irritating to eyes; R41, risk 
of serious damage to eyes.  
a Values are the mean ± standard deviation of 5 slugs. 
b EU eye irritation categories were assigned using the classification prediction model described in Figure 3.1. 
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 Using the prediction model presented in Figure 3.1, methyl amyl ketone, pyridine, 
promethazine hydrochloride, chlorhexidine, and trichloroacetic acid were classified as R41 
based on the mucus production of the slugs. Potassium tetrafluoroborate, tetra-
aminopyrimidine sulphate, ethyl acetate, methyl acetate, isopropanol, γ-butyrolactone, and 1-
butanol were classified as NI based on the score for tissue damage. However, it has to be 
noted that the scores obtained for isopropanol and especially γ-butyrolactone were close to the 
NI-R36 score cut-off value.  
When the EU categories predicted by the Slug Mucosal Irritation test were compared 
with the EU categories assigned on the basis of the rabbit eye irritation test, a concordance, 
sensitivity and specificity of 58%, 50% and 75% was obtained. Methyl acetate, isopropanol, 
γ-butyrolactone, and 1-butanol were falsely predicted non-irritant by the Slug Mucosal 
Irritation test. Methyl amyl ketone was falsely predicted R41. 
 
3.6.2.6 Test validity  
 
The validity of a test can be evaluated by means of negative and positive controls. A 
positive control has been defined by Balls et al. (1999) as a substance which is known to give 
a positive response in a particular assay and which is used to confirm the correct conduct of 
the assay. The data of 30 repeated experiments (150 negative and 150 positive control slugs), 
presented in Table 3.13, were analysed for this purpose. Figure 3.3 shows the average mucus 
production of slugs treated during 60 minutes with the negative control (PBS) or the positive 
control (1% (w/v) benzalkonium chloride). The average mucus productions of the negative 
control slugs varied from -2.1 to 1.5%, whereas those of the positive control slugs varied from 
14.0 to 29.7%. Figure 3.4 presents the average score for tissue damage of both controls. The 
average scores of the negative control slugs varied from 3 to 89, whereas those of the positive 
control slugs varied from 1055 to 5967.  
For the negative control, ANOVA testing revealed no significant difference in mucus 
production and score for tissue damage between the repeated experiments (p > 0.05). In each 
of the 30 repeated experiments, PBS was classified as NI. For the positive control, no 
significant differences in mucus productions on the one hand and scores on the other hand 
were detected between the repeated experiments (p > 0.05). Moreover, benzalkonium chloride 
was classified as R41 in each of the repeated experiments. 
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Table 3.13 Intra- and inter-experiment variability for the mucus production and score for tissue 
damage of the negative and positive control slugs  
Experiment Negative control  Positive control 
 Mucus (%) * Score * Mucus (%) *  Score * 
1 -0.5 ± 1.4  89 ± 101   17.4 ± 7.3   2879 ± 1286  
2 -2.0 ± 1.4  40 ± 36   14.0 ± 10.4  2489 ± 1512  
3 -2.1 ± 1.0  25 ± 18   18.3 ± 4.4   2474 ± 250  
4 -1.1 ± 0.5  24 ± 17   21.5 ± 13.9   3048 ± 1650  
5 -0.7 ± 0.6  10 ± 6   29.7 ± 6.2   2970 ± 729  
6 -0.2 ± 0.6   77 ± 87   15.4 ± 3.6   3389 ± 1296  
7 -0.1 ± 0.5   13 ± 8   15.8 ± 3.6   1159 ± 396  
8 0.7 ± 0.6   29 ± 17   17.8 ± 4.3   1356 ± 79  
9 -0.3 ± 0.6   16 ± 5   16.4 ± 4.9   1833 ± 495  
10 0.8 ± 1.2   14 ± 14   16.0 ± 4.9   1818 ± 357  
11 -1.4 ± 0.3   17 ± 11   25.0 ± 8.6   1889 ± 687  
12 -1.3 ± 0.4   40 ± 30   16.6 ± 6.2   1522 ± 684  
13 -1.0 ± 0.7   23 ± 25   21.2 ± 6.0   3296 ± 1722  
14 -1.1 ± 0.8   25 ± 16   18.1 ± 6.3   5967 ± 1121  
15 -1.9 ± 0.8   3 ± 3   27.1 ± 9.9   4422 ± 2132  
16 -1.4 ± 0.6   4 ± 4   25.6 ± 8.5   2636 ± 507  
17 -1.8 ± 0.5   34 ± 13   16.7 ± 6.4   3446 ± 738  
18 1.5 ± 1.1   27 ± 37   18.2 ± 6.2   1410 ± 632  
19 1.2 ± 0.8   40 ± 43   20.7 ± 6.0   1872 ± 303  
20 0.9 ± 2.4   21 ± 12   24.3 ± 3.8   1294 ± 704  
21 1.1 ± 0.8   50 ± 24   14.6 ± 5.1   1432 ± 317  
22 0.1 ± 0.8   44 ± 46   17.6 ± 3.8   2208 ± 1103  
23 0.2 ± 1.2   41 ± 61   18.9 ± 4.0   1851 ± 631  
24 0.5 ± 0.8   30 ± 44   22.3 ± 1.8    1577 ± 404 
25 0.7 ± 1.1   11 ± 2   24.9 ± 6.5   1535 ± 863  
26 0.3 ± 1.0   30 ± 20   24.8 ± 2.8   1310 ± 360  
27 0.4 ± 2.5   12 ± 11   27.0 ± 5.0   1597 ± 285  
28 0.5 ± 1.6   8 ± 4   18.7 ± 1.3   1055 ± 257  
29 0.5 ± 0.7   18 ± 33   19.5 ± 2.7   1330 ± 388  
30 0.4 ± 0.5   19 ± 6   18.6 ± 3.5   1443 ± 814  
Inter-experiment mean -0.3 ± 1.0  28 ± 19  20.1 ± 4.2  2217 ± 1098 
Values are the mean ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 30 
experiments. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
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Figure 3.3  Mucus production of slugs treated during 60 minutes with the negative control PBS 
(●) or the positive control 1% (w/v) benzalkonium chloride (▲). Data points are 
presented as the mean values (n = 5) and standard deviation bars are indicated. Solid 
lines represent the mean mucus production of 150 slugs, whereas blue and red dashed 
lines respectively represent the acceptance criteria for the mean mucus production of 5 
negative and positive control slugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Score for tissue damage of slugs treated with PBS (●) or benzalkonium chloride (▲). 
Data points are presented as the mean values (n = 5) and standard deviation bars are 
indicated. Solid lines represent the mean score of 150 slugs, whereas blue and red 
dashed lines respectively represent the acceptance criteria for the mean score of 5 
negative and positive control slugs. 
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Based on the data of 30 repeated experiments, acceptance criteria were established to 
provide criteria for test validity. The acceptance criteria were calculated as described by Hahn 
and Meeker (1991). Acceptance criteria were established based on the 95% prediction 
intervals to contain a future observation. The results of the tested reference chemicals were 
only accepted if the following conditions were satisfied. For the negative control slugs, the 
mean mucus production (n = 5) during the first contact period and the mean score for tissue 
damage (n = 5) should be less than 2.0% and 100, respectively. For the positive control slugs, 
both values should be more than 11.0% and 850, respectively.  
 
3.7 DISCUSSION 
 
Mucosal tissue and certain tissues of the eye resemble histologically. The conjunctiva 
is namely a mucous membrane that lines the inside of the eyelids and the visible part of the 
sclera (Marieb, 1995; Curren and Harbell, 1998). The HET-CAM is used as an alternative test 
for predicting the eye irritation potential of chemicals and cosmetics (Gilleron et al., 1996; 
Gilleron et al., 1997; Steiling et al., 1999) as well as for predicting the irritation potential of 
dental products (Schendel et al., 1994; Dahl, 1999). Previous research showed that the Slug 
Mucosal Irritation test can be used as an alternative for screening the eye irritation potential of 
chemicals (Adriaens and Remon, 2002). The proposed test protocol was a two-day test 
procedure and this can be a limiting factor for high throughput screening. Therefore, the 
objective of this study was to reduce the eye irritation/damage test procedure of the Slug 
Mucosal Irritation test to one day. Because several in vivo irritants can be detected based on 
the amount of mucus produced during a 60-minute contact period with a 1% (w/v) dilution of 
the chemical, this step of the test procedure was maintained. To select an appropriate 
concentration for the second contact period, the concentration response effect of several in 
vivo irritants that were underestimated by the mucus production, and a few in vivo non-
irritants was investigated.  
PEG 400, propylene glycol, glycerol, Tween 20®, toluene, and ethanol resulted in no 
adverse effects when applied undiluted to rabbit eyes (ECETOC, 1998). PEG 400 
concentrations up to 10% (w/v) did not affect the end points of the Slug Mucosal Irritation 
test. Increasing concentrations of propylene glycol, glycerol, and Tween 20® affected the 
mucus production or protein release slightly indicating that they induced only mild irritation 
when tested at concentrations up to 10% (w/v). The response detected with the Slug Mucosal 
Irritation test was in agreement with clinical data reported for propylene glycol and glycerol. 
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Upon instillation, those chemicals may cause a stinging and burning sensation, but no obvious 
eye injury was noted (Grant, 1986). Rinsing of human eyes with aqueous solutions of PEG 
400 (1/1) caused only a slight burning sensation without causing injury (Grant, 1974). 
Although toluene and ethanol were non-irritant in the Draize eye test, these chemicals induced 
severe tissue damage of the body wall of slugs when tested at a 2.5% and a 10% (w/v) 
concentration, respectively. A splash of ethanol on human eyes caused immediate burning and 
stinging discomfort and toluene vapours may cause irritation to the eye (Grant, 1986). 1-
Octanol, 2-ethyl-1-hexanol, 1-hexanol, acetone, lauric acid, and cyclohexanol resulted all in 
irritation of the rabbit eye (ECETOC, 1998). When those chemicals were tested at a 1% (w/v) 
concentration, they did not affect the end points of the Slug Mucosal Irritation test. Lauric 
acid concentrations up to 10% (w/v) did not induce a positive response, while 2.5% (w/v) or 
higher concentrations of 1-octanol, 2-ethyl-1-hexanol, 1-hexanol, acetone, and cyclohexanol 
resulted in tissue damage. The results of the concentration response experiments showed that 
increasing the test concentration resulted in a faster onset of tissue damage. Consequently, 
chemicals that were underestimated when tested at a 1% (w/v) concentration can be predicted 
correctly when tested at a higher concentration. Therefore, the concentration of the second 
contact period was set at 3.5% (w/v).  
The repeatability and relevance of the modified test procedure were evaluated using 28 
eye reference chemicals (ECETOC, 1998). A single 60-minute exposure to especially 
irritating surfactants and inorganic chemicals induced a highly increased mucus production 
and tissue damage; those chemicals were consequently correctly predicted based on the 
mucus produced during the first contact period. It is known from several in vitro assays that 
surfactants have a fast onset of tissue damage and the mechanism is thought to involve 
membrane disruption (Harbell et al., 1997). For chemicals that did not affect the mucus 
secretion, an additional contact period with a 3.5% (w/v) concentration was introduced. The 
protein and LDH release from the slug body wall after both contact periods was combined 
into a score for tissue damage. Based on the results, a classification prediction model was 
developed. The prediction model classifies the test substances into the EU eye irritation 
categories (EC, 2001) based on both end points (mucus production and score for tissue 
damage). A classification prediction model simplifies the interpretation of the data, but has 
also some disadvantages. A classification prediction model namely reduces the information 
about the severity of the irritation or tissue damage (Curren and Harbell, 1998). So especially 
for substances with a borderline irritation/damage potential, a careful analysis of the data is 
still recommended. 
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In order to investigate the repeatability of the modified test procedure and prediction 
model, all chemicals were tested independently on five separate occasions. For 16 out of the 
28 chemicals, significantly different mucus productions were detected in the five runs. It was 
striking that seven of these 16 chemicals were alcohols. However, only for three out of these 
16 chemicals, the differences in mucus production were not only statistically significant, but 
resulted also in different eye irritation categories. Furthermore, significantly different scores 
were detected in the five runs for seven out of the 28 chemicals. Three of these seven 
chemicals were alcohols. Only for three out of these seven chemicals, the statistically 
different scores obtained in the different runs resulted in different eye irritation categories. 
Furthermore, analysis of the repeatability of the data obtained for the end points revealed that 
the mucus production was the more reproducible end point. This is in agreement with the 
study of Adriaens and Remon (2002). The score for tissue damage was calculated using 
protein and LDH values after each contact period, which resulted probably in a higher 
variation. The mean κ-value for the agreement between the predicted irritation categories of 
the repeated trials was 0.74, indicating substantial reproducibility. For ten out of the 28 
chemicals, different predicted EU categories were obtained throughout at least one of the five 
runs. Of interest is the fact that five of these ten chemicals belonged to the chemical class of 
the alcohols. It is important to note that four of these ten chemicals (1-octanol, 2-ethyl-1-
hexanol, 1-hexanol, and cyclohexanol) were also underestimated or overestimated by at least 
one of the rabbits in the rabbit eye irritation test (ECETOC, 1998; EC, 2001) and by some 
experiments with the BCOP test (ICCVAM and NICEATM, 2004). Especially for the R36 
labelled chemicals, differences between the EU eye irritation categories predicted by the Slug 
Mucosal Irritation test were observed. High variability in the rabbit eye irritation test data was 
also observed for mildly or moderately irritating chemicals, whereas a good reproducibility 
was reported for non-irritating and severely irritating chemicals (Balls et al., 1995).  
Next, the EU eye irritation categories predicted by the Slug Mucosal Irritation test 
were compared with the irritation categories assigned on the basis of the rabbit eye irritation 
data (Table 3.14). 75% of the 12 rabbit non-irritants were correctly predicted by the Slug 
Mucosal Irritation test. Three false positive results were obtained. Methyl isobutyl ketone, 
toluene, and 2-methyl-1-pentanol induced tissue damage, while they were classified as non-
irritant in the rabbit eye irritation test. However, several references cited in the Hazard 
Substances Data bank mentioned the eye irritating potential of these chemicals (TOXNET®, 
2005). Exposure to methyl isobutyl ketone irritated the conjunctiva and mucous membranes 
of the nose and throat of men (Hjelm et al., 1990). The HET-CAM (Gilleron et al., 1997) and 
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the HCE model (Van Goethem et al., 2005) scored methyl isobutyl ketone as irritant. Methyl 
isobutyl ketone was also labelled R36 in the material safety data sheet provided by the 
chemical supplier. Furthermore, toluene was classified as moderate irritant by means of the 
BCOP test (Vanparys et al., 1993) and as irritant by the HET-CAM (Gilleron et al., 1997) and 
the HCE model (Van Goethem et al., 2005). Additionally, 2-methyl-1-pentanol was rated 8 
when tested on rabbit eye, whereas the most severe injuries were rated 10 (Grant, 1986). 2-
Methyl-1-pentanol is also classified as eye irritant by the human corneal epithelial model 
(Van Goethem et al., 2005) and as severe irritant by the BCOP test (personal communication 
F. Van Goethem and Ph. Vanparys, J & J, Beerse, Belgium, 2004). 2-Methyl-1-pentanol was 
classified as mild irritant (category 2B) on the basis of the GHS criteria (ECETOC, 1998; 
United Nations, 2003). These data indicate that the EU classification based on rabbit eye 
irritation data probably underestimated the eye irritation potential of those chemicals.  
67% of the nine chemicals labelled R36 were correctly predicted by the Slug Mucosal 
Irritation test. The irritation potential of sodium lauryl sulphate, 1-hexanol, and Triton X-100® 
was overestimated. The discrepancy between the slug and rabbit classifications of sodium 
lauryl sulphate and Triton X-100® may be due to the fact that they were the only R36 labelled 
chemicals that were diluted before application to the rabbit eye, whereas the other R36 
labelled chemicals were applied undiluted to the rabbit eyes. Sodium lauryl sulphate, 1-
hexanol, and Triton X-100® were predicted as (severe) irritants with the HET-CAM test 
(Gilleron et al., 1997; Steiling et al., 1999) and the authors suggested that the test predicted 
the irritation potential of surfactants in a much more realistic way than the in vivo data 
(Steiling et al., 1999). Treatment of bovine cornea’s with sodium lauryl sulphate induced 
destruction of the corneal epithelium (Gautheron et al., 1992). This chemical was also 
classified as category 1 (irreversible effects on eyes) on the basis of the GHS criteria 
(ECETOC, 1998; United Nations, 2003). Furthermore, 1-hexanol and Triton X-100® were 
classified as severe irritants with the BCOP test (Vanparys et al., 1993). Moreover, Triton X-
100® is labelled R41 in the material safety data sheet of the supplier. 
71% of the seven chemicals classified as R41 based on the rabbit eye irritation data 
were correctly classified by the Slug Mucosal Irritation test. Cyclohexanol was 
underestimated one irritation category. For lauric acid, a false negative result was obtained. 
Lauric acid is a solid compound and in the Draize eye test solids are placed in the 
conjunctival sac of the rabbit eye where they can remain for up to 24 h (York and Steiling, 
1998; Balls et al., 1999). Such a high and prolonged exposure does not occur in case of 
accidental human exposure and can not be predicted by many alternatives (Balls et al., 1999). 
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Furthermore, exposure of the rabbit eye to insoluble solids may provoke blinking (York and 
Steiling, 1998) and mechanical injury (Balls et al., 1999). However, mechanical injury can 
not be measured in the Slug Mucosal Irritation test. Furthermore, it is worth noting that lauric 
acid is labelled R36 in the material safety data sheet of the supplier. 
The overall performance of the assay was found satisfactory, 71% of the 28 chemicals 
were correctly classified into three EU categories. It is interesting to note that about half of 
the 29% incorrectly classified chemicals belonged to the chemical class of the alcohols. 
Several references cited in the Hazard Substances Data bank mentioned anaesthetizing 
properties of these under- or overestimated alcohols (TOXNET®, 2005). Anaesthesia of the 
slugs is probably responsible for an alteration of the mucus production (Adriaens and Remon, 
2002), whereas tissue fixation by the alcohols can probably explain the modified protein and 
enzyme release. When the 28 chemicals were divided into non-irritants or irritants, a 
sensitivity and specificity of 94% and 75% were respectively obtained.  
In the current study, the sensitivity of the test was increased in comparison with the 
two-day test procedure (Adriaens and Remon, 2002). Only one false negative was obtained, 
whereas lauric acid and acetone were predicted non-irritant with the two-day test procedure. 
The predictive ability of the middle category (R36) was also improved. 67% of the R36 
labelled chemicals were correctly predicted with the one-day procedure, against 44% with the 
two-day procedure. However, the specificity of the test was decreased. In the previous study, 
only one false positive was obtained (methyl isobutyl ketone), whereas the one-day procedure 
resulted in three false positives (methyl isobutyl ketone, toluene, and 2-methyl-1-pentanol). 
Because several data from the literature mentioned the irritation potential of those chemicals, 
we suppose that the modified test procedure and prediction model of the Slug Mucosal 
Irritation test predicted the irritation potential more accurately.  
The concordance obtained in the current study was comparable to that obtained in a 
post hoc data analysis of the results of 59 ECETOC reference chemicals tested in the 
international EC/HO validation study. 72.5% of the chemicals were namely correctly 
classified into three classes using a prediction model based on the end points of the neutral red 
uptake test (lgNRU) and the BCOP test (lgBCOPo5) (Moldenhauer, 2003). Twenty-two of 
those chemicals were also evaluated with the Slug Mucosal Irritation test and 16 out of the 22 
substances were predicted the same.  
The results of the Slug Mucosal Irritation test were also compared with available data 
of three other alternative eye irritation tests, namely BCOP test, HET-CAM, and HCE model 
(Table 3.14).  
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Table 3.14  Comparison of the irritation potential of the chemicals as assessed with the Draize eye 
test, Slug Mucosal Irritation (SMI) test, BCOP test, HET-CAM, and HCE model 
Test substance Draize test SMI 
test 
BCOP test a HET-CAM b HCE model c
 EU 
class 
GHS 
class 
EU 
class
Class Conc 
(%) 
Source Class Conc 
(%) 
Class Conc 
(%) 
3,3-Dimethylpentane NI NI NI NI 100 PC    NI 100 
PEG 400 NI NI NI NI 100 PC I 100  NI 100 
3-Methoxy-1,2-propanediol NI NI NI NI 100 PC    NI 100 
Propylene glycol NI NI NI NI 100 V      
Glycerol NI NI NI NI 100 PC I 100  NI 100 
PEG 600 NI NI NI NI 100 C      
Methylcyclopentane NI NI NI NI 100 PC I 100  I 100 
Tween 20 NI NI NI NI 100 V I 100  NI 100 
Methyl isobutyl ketone NI NI R36 NI 100 G I 100  I 100 
Toluene NI NI R36 I (Mod) 100 V I 100  I 100 
2-Methyl-1-pentanol NI Cat 2B R36 I (Sev) 100 PC    I 100 
Ethanol NI Cat 2B NI I (Sev) 100 V I 100  I 100 
Ammonium nitrate R36 Cat 2B R36 NI 20 PC I 100    
1-Octanol R36 Cat 2B R36 I (Mod) 100 G I 100  I 100 
4-Carboxybenzaldehyde R36 Cat 2A R36 I (Mod) 20 PC NI 100    
2-Ethyl-1-hexanol R36 Cat 2B R36 I (Mod) 100 PC I 100  I 100 
Sodium lauryl sulphate R36 Cat 1 R41 I (Mod) 15 PC I 15    
1-Hexanol R36 Cat 2A R41 I (Sev) 100 V I 100  I 100 
Acetone R36 Cat 2A R36 I (Sev) 100 V I 100  I 100 
Triton X-100 R36 Cat 2A R41 I (Sev) 100 V I 10  I 5 
p-Fluoroaniline R36 Cat 2 R36 I (Mod) 100 PC I 100    
Lauric acid R41 Cat 1 NI         
Imidazole R41 Cat 1 R41 I (Sev) 20 G I 100    
Sodium oxalate R41 Cat 1 R41 NI 20 G I 100    
Cyclohexanol R41 Cat 1 R36 I (Sev) 100 V I 100  I 100 
Cetylpyridinium bromide R41 Cat 1 R41 I (Mod) 6 PC I 10  I 6 
Sodium hydroxide R41 Cat 1 R41 I (Sev) 1 PC I 10  I 1 
Benzalkonium chloride  R41 Cat 1 R41 I (Sev) 20 V I 10  I 10 
Cat 1, irreversible effects on eyes; Cat 2, reversible effects on eyes; Cat 2A, irritating to eyes; Cat 2B, mildly 
irritating to eyes; Conc, concentration; I, irritant; Mod, moderate; NI, non-irritant; R36, irritating to eyes; R41, 
risk of serious damage to eyes; Sev, severe.  
a BCOP in vitro scores and classifications were taken from different sources in the literature: (C) Casterton et al., 
1996, (G) Gautheron et al., 1994, (PC) personal communication with F. Van Goethem and Ph. Vanparys, J & J, 
Beerse, Belgium, 2004 and (V) Vanparys et al., 1993. 
b HET-CAM classifications were taken from Gilleron et al., 1997. 
c HCE classifications were taken from Van Goethem et al., 2005.  
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SMI test Draize test  BCOP test Draize test 
 I NI   I NI 
I 15 3  I 13 3 
NI 1 9  NI 2 9 
Concordance  Concordance 
Sensitivity  Sensitivity 
Specificity 
86% 
94% 
75%  Specificity 
81% 
87% 
75% 
       
HET-CAM Draize test  HCE model Draize test 
 I NI   I NI 
I 14 7  I 9 5 
NI 1 0  NI 0 5 
Concordance  Concordance 
Sensitivity  Sensitivity 
Specificity 
64% 
93% 
0%  Specificity 
74% 
100% 
50% 
 
Figure 3.5 Agreement of the eye irritation classification obtained with the Draize eye test on the 
one hand and the Slug Mucosal Irritation (SMI) test, BCOP test, HET-CAM, and HCE 
model on the other hand (based on the data presented in Table 3.14) 
 
When considering two irritation classes (irritants and non-irritants), 23 out of the 27 
substances tested both with the BCOP test and the Slug Mucosal Irritation test were classified 
the same in both tests. Figure 3.5 shows that for the tested compounds the concordance, 
sensitivity, and specificity of the Slug Mucosal Irritation test (86%, 94% and 75%, 
respectively) were comparable to those of the BCOP test (81%, 87% and 75%, respectively). 
The concordance, sensitivity, and specificity of the BCOP test are in agreement with 
published data. When 52 compounds were classified as irritant or non-irritant based on an 
inter-laboratory study of the BCOP test, a concordance, sensitivity, and specificity of 73%, 
93% and 66% was obtained with the EU classification based on the Draize eye test data, 
respectively (Gautheron et al., 1994). 
Only 16 out of the 22 chemicals tested with both the HET-CAM and the Slug Mucosal 
Irritation test were classified into the same category (namely irritant) by means of both tests. 
For the chemicals tested in this study, the concordance and specificity of the Slug Mucosal 
Irritation test were higher than those of the HET-CAM (concordance and specificity of 64% 
and 0%, respectively); only the sensitivities of both alternative tests were comparable. 
Gilleron et al. (1997) also reported the low specificity of the HET-CAM. An evaluation of the 
HET-CAM with 60 chemicals resulted in a concordance, sensitivity, and specificity of 80%, 
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96% and 23%, respectively. Especially liquids and surfactants were overestimated; when only 
those compounds were considered the specificity was reduced to 0%. For the solids on the 
other hand, the specificity was 100% (Gilleron et al., 1997). The non-irritants tested in the 
current study were all liquids or surfactants. 
Comparison of the Slug Mucosal Irritation test results with the data of the HCE model 
showed that 17 out of the 19 substances evaluated with both tests were classified the same. 
For the chemicals tested in this study, the concordance and specificity of the Slug Mucosal 
Irritation test were higher than those of the HCE model (concordance and specificity of 74% 
and 50%, respectively); only the sensitivities of both alternative tests were comparable. 
Comparison of the HCE classification of 20 test substances in a multi-center prevalidation 
with the NI/I classification based on the Draize eye test data resulted in a concordance, 
sensitivity, and specificity of 70%, 100% and 45%, respectively (Van Goethem et al., 2005).  
Finally, the relevance of the modified assay was evaluated by using 12 chemicals that 
were not used for the development of the prediction model (Table 3.15). 75% of the four 
rabbit non-irritants were correctly predicted by the Slug Mucosal Irritation test. The correctly 
classified non-irritants (potassium tetrafluoroborate, tetra-aminopyrimidine sulphate, and 
ethyl acetate) were an inorganic chemical, a heterocyclic hydrocarbon or an ester. The overall 
classification of inorganic chemicals and hydrocarbons tested in the repeatability study was 
also in agreement with the classification based on the rabbit eye irritation test and/or 
alternative eye irritation tests (Table 3.14). Only methyl amyl ketone induced an increased 
mucus production and tissue damage and was consequently falsely predicted as irritant, while 
it was classified as non-irritant in the Draize eye test. Methyl amyl ketone was also classified 
as moderate eye irritant by means of the BCOP test (personal communication F. Van 
Goethem and Ph. Vanparys, J & J, Beerse, Belgium, 2004) and as irritant by means of the 
HCE model (Van Goethem et al., 2005). Moreover, methyl amyl ketone is labelled “irritating 
to eyes” in the material safety data sheet of the supplier. It is striking that methyl amyl ketone 
and methyl isobutyl ketone – the two tested ketones labelled as non-irritant based on the 
rabbit eye irritation test – were not only overestimated in the experiments with the Slug 
Mucosal Irritation test, but also by the HCE model and the BCOP test or HET-CAM (Tables 
3.14 and 3.15). Although anaesthetizing properties of these ketones are reported in the Hazard 
Substances Data bank (TOXNET®, 2005), the experiments showed that exposure of the slugs 
to these ketones induced a slower onset of anaesthesia than exposure of the slugs to the tested 
alcohols.  
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Table 3.15  Comparison of the irritation potential of the chemicals as assessed with the Draize eye 
test, Slug Mucosal Irritation (SMI) test, BCOP test, HET-CAM, and HCE model 
Test substance Draize test SMI 
test 
BCOP test a HET-CAM b HCE model c
 EU 
class 
GHS 
class 
EU 
class
Class Conc 
(%) 
Source Class Conc 
(%) 
Class Conc 
(%) 
Potassium tetrafluoroborate NI NI NI       NI 100 
Tetra-aminopyrimidine sulph. NI NI NI NI 20 G NI 100  I 100 
Methyl amyl ketone NI NI R41 I (Mod) 100 PC    I 100 
Ethyl acetate NI NI NI I (Mod) 100 B I 100    
Methyl acetate R36 Cat 2B NI I (Mod) 100 C I 100    
Isopropanol R36 Cat 2B NI I (Sev) 100 V I 100    
γ-Butyrolactone R36 Cat 2B NI I (Mod) 100 G I 100    
1-Butanol R36 Cat 2B NI I (Sev) 100 V      
Pyridine R41 Cat 1 R41 I (Sev) 100 G I 100    
Promethazine hydrochloride R41 Cat 1 R41 I (Sev) 20 G I 100    
Chlorhexidine R41 Cat 1 R41 I (Sev) 20 B I 100    
Trichloroacetic acid R41 Cat 1 R41 I (Sev) 30 C I 30    
Cat 1, irreversible effects on eyes; Cat 2B, mildly irritating to eyes; Conc, concentration; I, irritant; Mod, 
moderate; NI, non-irritant; R36, irritating to eyes; R41, risk of serious damage to eyes; Sev, severe.  
a BCOP in vitro scores and classifications were taken from different sources in the literature: (B) Balls et al., 
1995, (C) Casterton et al., 1996, (G) Gautheron et al., 1994, (PC) personal communication with F. Van Goethem 
and Ph. Vanparys, J & J, Beerse, Belgium, 2004 and (V) Vanparys et al., 1993. 
b HET-CAM classifications were taken from Gilleron et al., 1997. 
c HCE classifications of potassium tetrafluoroborate and tetra-aminopyrimide sulphate were obtained via 
personal communication with F. Van Goethem, J & J, Beerse, Belgium, 2004, whereas HCE classification of 
methyl amyl ketone was taken from Van Goethem et al., 2005.  
 
None of the four chemicals labelled as R36 on the basis of the rabbit eye irritation data 
were correctly predicted by the Slug Mucosal Irritation test. Methyl acetate, isopropanol, γ-
butyrolactone, and 1-butanol were falsely predicted non-irritant based on the score for tissue 
damage. However, it has to be noted that the scores obtained for isopropanol and especially γ-
butyrolactone were close to the NI-R36 score cut-off value. Of interest is the fact that not only 
the alcohols isopropanol and 1-butanol, but also the esters methyl acetate and γ-butyrolactone 
have anaesthetizing properties (ACGIH, 1991; Gill et al., 1995; Kapp et al., 1996; 
TOXNET®, 2005). Balls et al. (1999) stated that developers of an alternative test intended as a 
screening test in a stepwise strategy have to worry less about the generation of false negatives 
than about the generation of false positives, because chemicals falsely predicted as non-
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irritant will normally be detected by the rabbit eye irritation test which is performed as last 
step of the stepwise testing strategy. 
The four severe irritants (R41) were correctly predicted by the Slug Mucosal Irritation 
test. Two of these severe irritants (pyridine and promethazine hydrochloride) were 
heterocyclic hydrocarbons. As mentioned above, the overall classification of hydrocarbons 
tested in the repeatability study was also in agreement with the classification based on the 
rabbit eye irritation test and/or alternative eye irritation tests. 
The results of this study demonstrate that by increasing the test concentration of the 
second contact period to 3.5% (w/v), the Slug Mucosal Irritation test procedure for the 
evaluation of the eye irritating and damaging properties of chemicals can be reduced to one 
day. The end points – mucus production and score for tissue damage – are measured 
objectively and both are complementary for a better prediction. The one-day test procedure 
seems to be a reliable method that can accurately classify chemicals other than alcohols and 
other than substances with anaesthetizing properties into three eye irritation categories 
corresponding with the EU label.  
Because the results of the study are sufficiently promising, the transferability of the 
test and the inter-laboratory reproducibility will be assessed. Several benchmark chemicals 
will be tested by the participating laboratories using standard operation procedures. Any 
necessary refinements to the test protocol and the prediction model will be made in order to 
maximise the inter- and intra-laboratory reproducibility. Hartung et al. (2004) reported that 
this step contributes to the evaluation of the practicability of the test, the assessment of the 
extent of training needed to properly transfer the test to another laboratory, and the evaluation 
of the intra-laboratory and inter-laboratory variability of the test. 
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CHAPTER 4: SLUG SPECIES- AND POPULATION-
SPECIFIC EFFECTS ON THE TEST END POINTS 
 
Based on Dhondt, M.M.M., Adriaens, E., Pinceel, J., Jordaens, K., Backeljau, T. and Remon, 
J.P. (accepted September 2005). 
 
 
 
4.1 INTRODUCTION 
 
In previous studies, the terrestrial slug A. lusitanicus collected in Belgium was always 
used as test organism. In order to evaluate the robustness of the Slug Mucosal Irritation test, it 
is important to investigate the possible effects of the used slug population and species on the 
end points of the test. Information about the robustness of the test is useful in case research 
laboratories or companies located outside Belgium appeal to the Slug Mucosal Irritation test 
or in case of problems with the availability of Belgian A. lusitanicus. Therefore, the present 
study investigated the effects of one Belgian and two Swiss A. lusitanicus populations and the 
effects of Limax species on both the end points of the Slug Mucosal Irritation test and the 
predicted eye irritation classification. It was opted to compare the Belgian A. lusitanicus with 
two conspecific populations from Switzerland in order to make sure that both geographical 
distance and ecological differentiation were as large as possible, without risking that different 
species were sampled. Furthermore, it was opted to compare A. lusitanicus with a slug species 
which is at least as big as A. lusitanicus, because the use of small slugs is not recommended 
from a practical viewpoint. Additionally, it was preferred that the selected species is widely 
distributed throughout the world. Based on these criteria, the medium-sized and widespread 
slug species L. flavus and L. maximus were selected. Furthermore, life spans of several years 
are recorded for Limax species, whereas Arion species have a life span of one year (South, 
1992). It was opted to choose two species belonging to the same family to investigate if they 
affect the end points of the Slug Mucosal Irritation test and the eye irritation classification 
differently or not. 
Because 28 eye reference chemicals were extensively tested in previous studies with 
the Slug Mucosal Irritation test (Adriaens and Remon, 2002; Adriaens et al., 2005), the 
effects of the slug population and slug species on the test end points and on the eye irritation 
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classification were assessed using the same eye reference chemicals and the eye 
irritation/damage test procedure. The mucus productions and the scores for tissue damage of 
Swiss A. lusitanicus and Belgian L. flavus and L. maximus slugs were compared with those of 
Belgian A. lusitanicus slugs. Furthermore, the effects of the slug population and species on 
the predicted EU eye irritation classifications were investigated.  
 
4.2 MATERIALS AND METHODS 
 
4.2.1. Chemicals 
 
1% and 3.5% (w/v) dilutions of the chemicals presented in Table 3.1 were prepared in 
PBS (pH 7.4). The negative control was PBS, whereas benzalkonium chloride was used as a 
positive control.  
 
4.2.2 Eye irritation/damage test procedure of the Slug Mucosal Irritation test 
 
Belgian A. lusitanicus and L. flavus were collected in local gardens along Varsenare 
and Aalter, whereas Belgian L. maximus slugs were collected in gardens along Aalter and 
Nazareth. The Swiss A. lusitanicus slugs were collected in Nuglar and Court (located 60 km 
from each other). The housing and feeding conditions were identical to the ones described in 
Chapter 3.  
 Each experiment contained five negative control slugs (PBS), five positive control 
slugs (benzalkonium chloride), and six series of five slugs each treated with the test 
chemicals. At the beginning of the experiment, the slugs on the one hand and the Petri dishes 
containing a membrane filter (cellulose acetate 0.45 µm, 90 mm; Sartorius AG, Goettingen, 
Germany) moistened with 2 ml of a 1% (w/v) dilution of the chemical on the other hand were 
weighed. Subsequently, the slugs were placed individually during 60 minutes in a Petri dish 
on the test medium. After this first contact period, the amount of mucus produced was 
measured by reweighing the Petri dishes containing the test medium (without the slugs). The 
mucus production was expressed as percentage (w/w) of the body weight. Next, the slugs 
were transferred to a fresh Petri dish and 1 ml PBS was added. One hour later, the PBS 
samples were collected with a micropipette. Two hours after the end of the first contact 
period, the slugs were placed for 60 minutes in a Petri dish on a membrane filter moistened 
with 2 ml of a 3.5% (w/v) dilution of the chemical. After this second contact period, the slugs 
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were transferred to a fresh Petri dish and 1 ml PBS was added. The PBS samples were 
collected after 60 minutes. The samples were analysed immediately for the presence of 
proteins and LDH released from the slug body wall.  
 
4.2.3 Analytical procedures 
 
 The protein and LDH determinations were performed according to the analytical 
procedures described in Chapter 3. 
 
4.2.4 Data analysis 
 
For each slug, the mucus production during the first contact period and the score for 
tissue damage were calculated. The score for tissue damage combines the protein release after 
the first and second contact period (P1 and P2) and the LDH release after the second contact 
period (LDH2) and was calculated as follows: P1 + P2 + 30 • LDH2. These values were used 
for the statistical analyses using the computer program SPSS (version 12.0; SPSS, Chicago, 
IL, USA). A p value < 0.05 was considered statistically significant.  
A two-way ANOVA was performed to investigate the population effect and species 
effect on the mucus production and the score for tissue damage. The data were tested for 
normal distribution with a Kolmogorov-Smirnov test. The homogeneity of variances was 
tested with the Levene’s test. If variances were unequal, the data were log-transformed. If no 
significant interaction was present, the main effects were interpreted separately from the 
interaction and a multiple comparison among pairs of means was performed using a Scheffé 
post hoc test. If a significant interaction between both factors was present, for each test 
substance the population or species effects were investigated with a Bonferroni post hoc test.  
For both L. flavus and L. maximus, a classification prediction model for the 
determination of the EU eye irritation category of chemicals was developed using linear 
discriminant analysis. Various random subsets of the Slug Mucosal Irritation test data were 
used to calculate cut-off values to discriminate between the eye irritation categories. On the 
basis of these results and in-house experience, cut-off values were established and the 
chemicals were classified into one of the corresponding EU categories. 
The agreement between the EU categories obtained with the different slug species was 
evaluated using the κ-statistics. A κ-value of 0.75 or higher suggests strong agreement above 
chance (Fleiss, 1981). The relevance of the assay using different slug populations and species 
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was evaluated by assessing the agreement between the eye irritation categories predicted by 
the Slug Mucosal Irritation test and the categories assigned on the basis of the Draize eye test. 
Concordance, sensitivity, and specificity were calculated as defined by Cooper et al. (1979). 
The chemicals were divided into three eye irritation categories for the determination of the 
concordance of the test, whereas they were divided into two classes, non-irritant (NI) and 
irritant (R36 and R41), for the determination of the sensitivity and specificity. 
 
4.3 RESULTS 
 
4.3.1 Slug population-specific effects on the test end points 
 
The effect of the A. lusitanicus population on the test end points and on the eye 
irritation classification was investigated by comparing the data of two Swiss slug populations 
with the data of the Belgian slug population. For this purpose, the negative control and seven 
chemicals (including the positive control) covering the whole irritancy range were used.  
The Belgian and the Swiss populations were put on 1% (w/v) dilutions of the 
chemicals during one hour and the mucus production was measured (Table 4.1). For the 
mucus production, two-way ANOVA testing revealed no significant interaction between the 
population and the chemical (p = 0.346). The chemical had a statistically significant effect on 
the mucus production (p < 0.001). The population had no statistically significant effect on the 
mucus production (p = 0.750). The average mucus productions of the Belgian population (4.2 
± 6.4%), the Swiss population from Nuglar (4.5 ± 7.8%), and the Swiss population from 
Court (5.5 ± 9.5%) were consequently not significantly different. Therefore, the Swiss 
populations can be used as test organism without modifying the mucus production cut-off 
values determined in Chapter 3 for Belgian A. lusitanicus. 
Furthermore, all chemicals were tested with each of the three slug populations during a 
second contact period. The protein and LDH values after the two contact periods were used to 
calculate the scores for tissue damage (Table 4.2). The high score for tissue damage of Swiss 
A. lusitanicus from Court treated with 2-ethyl-1-hexanol was mainly due to the high release of 
LDH by these slugs after the second contact period (33 U/l.g which was six times higher than 
in both other populations). For the Swiss slugs from Nuglar treated with benzalkonium 
chloride, the LDH release after the second contact period (81 U/l.g) was twofold higher than 
the LDH release of the other slug populations. This resulted also in a high score for tissue 
damage.  
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Table 4.1  Effects of A. lusitanicus population and test substance on the mucus production 
Test substance Mucus production (%) 
 Belgian population Swiss population  
from Nuglar 
Swiss population  
from Court 
PBS 0.2 ± 1.2 0.7 ± 0.7 0.0 ± 0.5 
PEG 600 0.5 ± 0.7 0.2 ± 0.6 1.4 ± 1.1 
Tween 20 -0.3 ± 1.2 -0.5 ± 0.2 -0.1 ± 0.7 
Acetone 1.4 ± 0.3 1.4 ± 0.5 -0.1 ± 1.6 
2-Ethyl-1-hexanol 2.2 ± 1.0 1.5 ± 1.3 2.5 ± 2.4 
4-Carboxybenzaldehyde 6.1 ± 3.6 4.2 ± 0.6 5.5 ± 2.7 
Imidazole 5.6 ± 2.2 6.4 ± 3.4 8.5 ± 3.6 
Benzalkonium chloride 18.1 ± 7.0 22.5 ± 8.8 26.1 ± 12.8 
Average * 4.2 ± 6.4  4.5 ± 7.8  5.5 ± 9.5  
Values are the mean ± standard deviation of 5 slugs; bold values are the mean ± standard deviation of 40 slugs. 
Two-way ANOVA testing revealed no significant interaction and no significant population effect (p > 0.05), but 
a significant chemical effect (p < 0.001). 
* There are no significant differences between the mucus productions of the three populations (p > 0.05, Two-
way ANOVA).  
 
Table 4.2  Effects of A. lusitanicus population and test substance on the score for tissue damage 
Test substance Score for tissue damage 
 Belgian slug 
population 
Swiss slug population  
from Nuglar 
Swiss slug population 
from Court 
PBS* 41 ± 61 42 ± 52 58 ± 77 
PEG 600* 10 ± 6  16 ± 11  38 ± 26  
Tween 20* 78 ± 14 67 ± 38 67 ± 25 
Acetone* 102 ± 117 143 ± 123 145 ± 119 
2-Ethyl-1-hexanol 407 ± 286 a 335 ± 244 a 1327 ± 768 b 
4-Carboxybenzaldehyde* 80 ± 82 137 ± 91 179 ± 65 
Imidazole* 848 ± 254 790 ± 186 616 ± 170 
Benzalkonium chloride 1758 ± 1259 a 3159 ± 996 b 1912 ± 883 a 
Average 416 ± 718 586 ± 1068 543 ± 771 
Values are the mean ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 40 
slugs. 
Two-way ANOVA testing revealed a significant interaction and a significant chemical effect (p < 0.05), but no 
significant population effect (p > 0.05). 
* For this test substance, there are no significant differences between the scores of the three populations (p > 
0.05, Bonferroni test).  
a, b Scores of the slugs treated with this test substance marked with the same superscript are not significantly 
different from each other (p > 0.05, Bonferroni test).  
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For the score for tissue damage, two-way ANOVA testing revealed a significant 
interaction between the population and the test substance (p < 0.001). The chemical had a 
statistically significant effect on the score (p < 0.001), whereas the population had no 
statistically significant effect on the score (p = 0.178). Only for 2-ethyl-1-hexanol and 
benzalkonium chloride, the score for tissue damage of one of the Swiss populations was 
significantly higher than the score of the Belgian population (p < 0.05, Bonferroni test). 
Consequently, the Swiss A. lusitanicus populations can be used as test organism without 
changing the score cut-off values determined in Chapter 3. 
By means of the prediction model presented in Figure 3.1, the chemicals were 
classified into the EU eye irritation categories (Table 4.3). PBS and four of the seven 
chemicals (PEG 600, Tween 20, acetone, and benzalkonium chloride) were classified into 
the same category by using each of the three slug populations. Comparison of the assigned 
categories predicted by the Swiss populations with those predicted by the Belgian population 
showed that 2-ethyl-1-hexanol, 4-carboxybenzaldehyde, and imidazole were classified in 
different categories by at least one population. For 4-carboxybenzaldehyde and imidazole, 
differences in EU classification were based on differences in mucus production. 2-Ethyl-1-
hexanol was classified in different categories because of differences in the scores for tissue 
damage.  
 
Table 4.3  Effects of A. lusitanicus population on the eye irritation classification 
Test substance Slug Mucosal Irritation test a  Draize eye test 
 Belgian slug 
population 
Swiss slug 
population  
from Nuglar 
Swiss slug 
population  
from Court 
 Rabbit 
PBS NI NI NI   
PEG 600 NI NI NI  NI 
Tween 20 NI NI NI  NI 
Acetone R36 R36 R36  R36 
2-Ethyl-1-hexanol R36 R36 R41  R36 
4-Carboxybenzaldehyde R41 R36 R36  R36 
Imidazole R36 R41 R41  R41 
Benzalkonium chloride  R41 R41 R41  R41 
a EU eye irritation categories (NI, non-irritant; R36, irritating to eyes; R41, risk of serious damage to eyes) were 
assigned using the data presented in Table 4.1 and Table 4.2 and the prediction model presented in Figure 3.1.  
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4.3.2 Slug species-specific effects on the test end points 
 
The effects of the slug species on the end points of the Slug Mucosal Irritation test and 
on the eye irritation classification were investigated by comparing data of Belgian L. flavus 
and L. maximus with data of Belgian A. lusitanicus. For this purpose, the negative control and 
28 eye reference chemicals (including the positive control) covering the entire irritancy range 
were used.  
A. lusitanicus, L. flavus, and L. maximus were put on 1% (w/v) dilutions of the 
chemicals during one hour and the mucus production was measured (Table 4.4). For the 
mucus production, a two-way ANOVA revealed a statistically significant interaction between 
the chemical and the slug species (p < 0.001). Moreover, both the chemical and the species 
had a significant effect on the mucus production (p < 0.001). The mucus productions of L. 
flavus treated with PBS and 20 out of the 28 chemicals were higher than those of A. 
lusitanicus treated with the same substances. However, only for glycerol, PEG 600, Tween 
20, methyl isobutyl ketone, 2-methyl-1-pentanol, 1-hexanol, imidazole, cyclohexanol, and 
cetylpyridinium bromide, the mucus production of L. flavus was significantly higher than that 
of A. lusitanicus (p < 0.05, Bonferroni test). The mucus production of L. flavus was on 
average 1.4 ± 2.8% higher than that of A. lusitanicus. Based on linear discriminant analyses 
and on the fact that L. flavus treated with NI and R36 chemicals respectively produced 1.5 ± 
1.6% and 0.9 ± 2.2% more mucus than A. lusitanicus treated with the same chemicals, the NI-
R36 mucus production cut-off value was elevated to 4% for L. flavus. Treatment of L. flavus 
with R41 chemicals resulted in mucus productions that were on average 1.9 ± 5.0% higher in 
comparison with A. lusitanicus. Based on this observation and on linear discriminant 
analyses, the R36-R41 mucus production cut-off value was elevated to 8% for L. flavus. 
The mucus productions of L. maximus treated with PBS and 23 out of the 28 
chemicals were higher than those of A. lusitanicus treated with the same substances. For PBS, 
3,3-dimethylpentane, Tween 20, methyl isobutyl ketone, 2-methyl-1-pentanol, 1-octanol, 2-
ethyl-1-hexanol, sodium lauryl sulphate, 1-hexanol, acetone, Triton X-100, imidazole, 
cyclohexanol, and cetylpyridinium bromide, the mucus production of L. maximus was 
significantly higher than that of A. lusitanicus (p < 0.05, Bonferroni test). L. maximus 
produced significantly less mucus than A. lusitanicus slugs, when they were put on a 1% 
(w/v) dilution of 4-carboxybenzaldehyde (p < 0.05, Bonferroni test). The mucus production of 
L. maximus was on average 3.9 ± 5.6% higher than that of A. lusitanicus. L. maximus treated 
with NI and R36 chemicals respectively produced 1.7 ± 2.2% and 4.6 ± 6.7% more mucus 
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than A. lusitanicus treated with the same chemicals. Based on linear discriminant analyses, the 
NI-R36 mucus production cut-off value was elevated to 5% for L. maximus. Treatment of L. 
maximus with R41 chemicals resulted in mucus productions that were on average 7.3 ± 7.4% 
higher in comparison with A. lusitanicus. Based on linear discriminant analyses, the R36-R41 
mucus production cut-off value was elevated to 10% for L. maximus. 
All chemicals were also tested with each of the three slug species during a second 
contact period. Table 4.5 shows the scores for tissue damage. The high scores for tissue 
damage of L. flavus treated with Triton X-100 and benzalkonium chloride were due to high 
release of LDH after the second contact period (> 29 U/l.g), which was four times higher than 
the LDH release of A. lusitanicus. For A. lusitanicus treated with imidazole, the release of 
proteins after the second contact period (584 µg/ml.g) was twofold higher than the protein 
release of L. flavus and resulted in a high score for tissue damage. The higher score of L. 
flavus treated with cyclohexanol was due to high protein release after the second contact 
period (141 µg/l.g for L. flavus versus 23 µg/l.g for A. lusitanicus). The high scores for tissue 
damage of L. maximus treated with 2-methyl-1-pentanol, 1-octanol, sodium lauryl sulphate, 1-
hexanol, Triton X-100, cetylpyridinium bromide, and benzalkonium chloride were related to 
high release of LDH after the second contact period (> 8 U/l.g), which was at least three times 
higher than the LDH release of A. lusitanicus.  
For the score for tissue damage, a two-way ANOVA revealed a statistically significant 
interaction between the chemical and the slug species (p < 0.001). The chemical and the 
species had a statistically significant effect on the score (p < 0.001). For Triton X-100 and 
benzalkonium chloride, the score of L. flavus was significantly higher than the score of A. 
lusitanicus (p < 0.05, Bonferroni test). For both chemicals, significantly different scores were 
also obtained throughout the five runs of the repeatability study with Belgian A. lusitanicus 
(Chapter 3). Therefore, the score cut-off values determined for A. lusitanicus were not 
modified for L. flavus.  
For 2-methyl-1-pentanol, sodium lauryl sulphate, 1-hexanol, Triton X-100, 
cetylpyridinium bromide, and benzalkonium chloride, the score of L. maximus was 
significantly higher than the score of A. lusitanicus (p < 0.05, Bonferroni test). For four out of 
these six chemicals (1-hexanol, Triton X-100, cetylpyridinium bromide, and benzalkonium 
chloride), the scores for tissue damage obtained with A. lusitanicus during the repeatability 
study were also significantly different (Chapter 3). Consequently, the score cut-off values 
determined for A. lusitanicus were not modified for L. maximus.  
 
___________________________________________________________________________ 
Chapter 4: Slug species- and population-specific effects on the test end points 77 
Table 4.4  Effects of slug species and test substance on the mucus production 
Test substance Mucus production (%) 
 A. lusitanicus L. flavus L. maximus 
PBS 0.3 ± 1.0 a 1.4 ± 0.8 a, b 2.4 ± 1.2 b 
3,3-Dimethylpentane 0.0 ± 1.3 a 0.9 ± 0.9 a, b 1.9 ± 1.1 b 
PEG 400* 1.3 ± 0.7 2.3 ± 0.7 1.5 ± 0.9 
3-Methoxy-1,2-propanediol* 1.6 ± 0.7 2.1 ± 1.2 2.0 ± 0.8 
Propylene glycol* 1.6 ± 0.5  1.9 ± 0.6  0.2 ± 0.6  
Glycerol 1.4 ± 0.7 a 3.7 ± 1.7 b 2.4 ± 2.2 a, b 
PEG 600 0.7 ± 1.5 a 3.2 ± 1.1 b 1.7 ± 1.9 a, b 
Methylcyclopentane 0.7 ± 1.0 a, b 0.2 ± 0.9 a 2.2 ± 1.1 b 
Tween 20 -0.3 ± 1.2 a 2.4 ± 1.6 b 1.6 ± 1.1 b 
Methyl isobutyl ketone 1.0 ± 0.9 a 5.9 ± 1.8 b 7.8 ± 2.4 b 
Toluene* 2.5 ± 1.3 3.8 ± 1.3 4.1 ± 1.0 
2-Methyl-1-pentanol 1.0 ± 0.8 a 3.8 ± 1.3 b 6.1 ± 2.4 b 
Ethanol* 0.9 ± 0.9 0.7 ± 0.3 1.0 ± 0.8 
Ammonium nitrate* 5.0 ± 1.7 5.0 ± 1.2 7.5 ± 1.5 
1-Octanol 2.3 ± 0.9 a 4.4 ± 1.2 a, b 6.0 ± 2.3 b 
4-Carboxybenzaldehyde 5.4 ± 1.8 a 3.7 ± 1.2 a, b 2.1 ± 0.5 b 
2-Ethyl-1-hexanol 2.2 ± 1.0 a 2.6 ± 1.3 a, b 4.9 ± 1.3 b 
Sodium lauryl sulphate 16.9 ± 3.7 a 17.6 ± 7.8 a 34.2 ± 3.5 b 
1-Hexanol 1.6 ± 0.9 a 7.6 ± 1.9 b 12.3 ± 4.9 c 
Acetone 1.4 ± 0.3 a 1.9 ± 0.8 a 5.1 ± 2.1 b 
Triton X-100 9.2 ± 2.5 a 11.7 ± 3.4 a 18.7 ± 3.0 b 
p-Fluoroaniline* 4.1 ± 1.1 4.6 ± 2.3 3.6 ± 2.6 
Lauric acid* 1.1 ± 0.8 0.9 ± 1.3 1.7 ± 0.6 
Imidazole 5.6 ± 2.2 a 11.4 ± 2.4 b 13.4 ± 6.1 b 
Sodium oxalate* 12.0 ± 2.6 11.2 ± 3.9 10.5 ± 5.2 
Cyclohexanol 1.8 ± 0.6 a 7.4 ± 2.2 b 12.0 ± 3.4 c 
Cetylpyridinium bromide 8.4 ± 0.7 a 16.7 ± 7.0 b 29.8 ± 5.0 c 
Sodium hydroxide* 14.9 ± 3.5 10.4 ± 2.3 14.3 ± 2.4 
Benzalkonium chloride 24.8 ± 2.8 a, b 20.6 ± 4.5 a 32.5 ± 2.8 b 
Average 4.5 ± 6.0 5.9 ± 5.9 8.4 ± 9.6 
Values are the mean ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 145 
slugs. 
Two-way ANOVA testing revealed a significant interaction, a significant chemical effect and a significant 
species effect (p < 0.001). 
* For this test substance, there are no significant differences between the mucus productions of the three species 
(p > 0.05, Bonferroni test).  
a, b, c Mucus productions of the slugs treated with this test substance marked with the same superscript are not 
significantly different from each other (p > 0.05, Bonferroni test). 
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Table 4.5  Effects of slug species and test substance on the score for tissue damage 
Test substance Score for tissue damage 
 A. lusitanicus L. flavus L. maximus 
PBS* 30 ± 20 9 ± 4 23 ± 14  
3,3-Dimethylpentane* 15 ± 13 11 ± 4 16 ± 6 
PEG 400* 25 ± 21 11 ± 5 16 ± 6 
3-Methoxy-1,2-propanediol* 11 ± 3  24 ± 10  12 ± 3  
Propylene glycol* 9 ± 5 9 ± 3 21 ± 15 
Glycerol* 23 ± 23 11 ± 3 17 ± 7 
PEG 600* 18 ± 7 11 ± 11 24 ± 24 
Methylcyclopentane* 28 ± 17 16 ± 9 25 ± 6 
Tween 20* 78 ± 14  27 ± 13  56 ± 27  
Methyl isobutyl ketone* 493 ± 365 348 ± 362 217 ± 137 
Toluene* 115 ± 86  108 ± 50  421 ± 220  
2-Methyl-1-pentanol 312 ± 195 a 432 ± 149 a, b 935 ± 749 b 
Ethanol* 20 ± 10 27 ± 13 25 ± 12 
Ammonium nitrate* 218 ± 108 128 ± 149 88 ± 153 
1-Octanol 409 ± 166 a, b 307 ± 145 a 914 ± 530 b 
4-Carboxybenzaldehyde* 35 ± 33 44 ± 54 25 ± 10 
2-Ethyl-1-hexanol* 408 ± 285 430 ± 353 845 ± 379 
Sodium lauryl sulphate 310 ± 220 a 504 ± 176 a 1241 ± 532 b 
1-Hexanol 185 ± 123 a 406 ± 189 a 2192 ± 1807 b 
Acetone* 102 ± 117 124 ± 61 28 ± 14 
Triton X-100 451 ± 369 a 1375 ± 850 b 980 ± 517 b 
p-Fluoroaniline* 103 ± 33  209 ± 96  440 ± 162  
Lauric acid* 34 ± 22  13 ± 4  15 ± 5  
Imidazole* 848 ± 254 492 ± 167 576 ± 368 
Sodium oxalate* 446 ± 134 330 ± 94 408 ± 118 
Cyclohexanol* 43 ± 35  214 ± 127  66 ± 48  
Cetylpyridinium bromide 188 ± 214 a 475 ± 235 a, b 920 ± 395 b 
Sodium hydroxide* 342 ± 317 251 ± 136 324 ± 66 
Benzalkonium chloride  1310 ± 360 a 2869 ± 645 b 3940 ± 1579 c 
Average 228 ± 327 318 ± 599 511 ± 946 
Values are the mean ± standard deviation of 5 slugs; bold values represent the mean ± standard deviation of 145 
slugs. 
Two-way ANOVA testing revealed a significant interaction, a significant chemical effect and a significant 
species effect (p < 0.001). 
* For this test substance, there are no significant differences between the scores for tissue damage of the three 
species (p > 0.05, Bonferroni test).  
a, b, c Scores of the slugs treated with this test substance marked with the same superscript are not significantly 
different from each other (p > 0.05, Bonferroni test). 
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Classification of the chemicals tested with L. flavus into the EU eye irritation 
categories by using the classification prediction model determined for A. lusitanicus (Figure 
3.1) resulted in overestimation of the eye irritation potential of rabbit non-irritants (Table 4.6). 
Overestimation of the eye irritating properties of glycerol and PEG 600 was due to the fact 
that the mucus production of L. flavus was higher than 3% (NI-R36 mucus cut-off value for A. 
lusitanicus). The κ-value for the agreement between the classifications (of the 29 test 
substances) predicted by A. lusitanicus and L. flavus was 0.74 ± 0.10. When the chemicals 
tested with L. flavus were classified into the eye irritation categories by using the L. flavus 
cut-off values presented in Figure 4.1, there was a strong agreement between the 
classifications of both species (κ-value of 0.79 ± 0.10). PBS and 25 out of the 28 chemicals 
were classified into the same irritation category by the two species. L. flavus classified 4-
carboxybenzaldehyde, imidazole, and cyclohexanol into different categories compared to A. 
lusitanicus. 4-Carboxybenzaldehyde and imidazole were classified in different categories 
because of differences in the mucus production. For cyclohexanol, differences in EU 
classification were based on differences in mucus production and score for tissue damage. 
 
 
Figure 4.1 Prediction model of the Slug Mucosal Irritation test for the determination of the EU 
eye irritation category of chemicals using A. lusitanicus, L. flavus or L. maximus as 
test organism (P1 and P2, protein release after 1st and 2nd contact period; LDH2, LDH 
release after 2nd contact period; NI, non-irritant; R36, irritating to eyes; R41, risk of 
serious damage to eyes). 
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Table 4.6  Effects of test organism and test substance on the eye irritation classification 
Test substance Slug Mucosal Irritation test  Draize eye test 
 A. lusitanicus L. flavus L. maximus  Rabbit 
PBS NI a NI a, b NI a, c   
3,3-Dimethylpentane NI a NI a, b NI a, c  NI 
PEG 400 NI a NI a, b NI a, c  NI 
3-Methoxy-1,2-propanediol NI a NI a, b NI a, c  NI 
Propylene glycol NI a NI a, b NI a, c  NI 
Glycerol NI a R36 a / NI b NI a, c  NI 
PEG 600 NI a R36 a / NI b NI a, c  NI 
Methylcyclopentane NI a NI a, b NI a, c  NI 
Tween 20 NI a NI a, b NI a, c  NI 
Methyl isobutyl ketone R36 a R36 a, b R41 a / R36 c  NI 
Toluene R36 a R36 a, b R36 a, c  NI 
2-Methyl-1-pentanol R36 a R36 a, b R41 a / R36 c  NI 
Ethanol NI a NI a, b NI a, c  NI 
Ammonium nitrate R36 a R36 a, b R41 a / R36 c  R36 
1-Octanol R36 a R36 a, b R36 a, c  R36 
4-Carboxybenzaldehyde R36 a R36 a / NI b NI a, c  R36 
2-Ethyl-1-hexanol R36 a R36 a, b R36 a / R41 c  R36 
Sodium lauryl sulphate R41 a R41 a, b R41 a, c  R36 
1-Hexanol R36 a R41 a / R36 b R41 a, c  R36 
Acetone R36 a R36 a, b R36 a, c  R36 
Triton X-100 R41 a R41 a, b R41 a, c  R36 
p-Fluoroaniline R36 a R36 a, b R36 a, c  R36 
Lauric acid NI a NI a, b NI a, c  R41 
Imidazole R36 a R41 a, b R41 a, c  R41 
Sodium oxalate R41 a R41 a, b R41 a, c  R41 
Cyclohexanol NI a R41 a / R36 b R41 a, c  R41 
Cetylpyridinium bromide R41 a R41 a, b R41 a, c  R41 
Sodium hydroxide R41 a R41 a, b R41 a, c  R41 
Benzalkonium chloride R41 a R41 a, b R41 a, c  R41 
a The A. lusitanicus cut-off values presented in Figure 3.1 were used to assign EU eye irritation categories based 
on the data presented in Table 4.4 and Table 4.5. 
b The L. flavus cut-off values presented in Figure 4.1 were used to assign EU eye irritation categories based on 
the data presented in Table 4.4 and Table 4.5. 
c The L. maximus cut-off values presented in Figure 4.1 were used to assign EU eye irritation categories based on 
the data presented in Table 4.4 and Table 4.5. 
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When the chemicals tested with L. maximus were classified into the EU eye irritation 
categories using the prediction model presented in Figure 3.1, the irritation potential of non-
irritants and chemicals labelled with EU risk phrase R36 based on the Draize eye irritation 
test was overestimated with L. maximus (Table 4.6). The κ-value for the agreement between 
the EU categories (of the 29 test substances) predicted by A. lusitanicus and those predicted 
by L. maximus was 0.64 ± 0.11. Classification of the chemicals tested with L. maximus into 
the EU eye irritation categories by using the L. maximus cut-off values presented in Figure 4.1 
resulted in a good agreement between the classifications of both species (κ-value of 0.74 ± 
0.10). PBS and 23 out of the 28 chemicals were classified into the same irritation category by 
the two species. L. maximus classified 4-carboxybenzaldehyde, 2-ethyl-1-hexanol, 1-hexanol, 
imidazole, and cyclohexanol in different categories in comparison with A. lusitanicus. For 4-
carboxybenzaldehyde and imidazole, differences in EU classification were based on 
differences in mucus production. 2-Ethyl-1-hexanol was classified differently because of 
differences in the score for tissue damage. For 1-hexanol and cyclohexanol, differences in EU 
classification were based on differences in mucus production and score for tissue damage. 
 
4.4 DISCUSSION 
 
The slug A. lusitanicus was hitherto always used as test organism in the Slug Mucosal 
Irritation test. In this study, the effects of other slug populations and species on the test end 
points and on the predicted eye irritation classification were evaluated in order to get an idea 
of the robustness of the test. Based on the criteria mentioned in the introduction of this 
chapter, it was opted to compare the data of Belgian A. lusitanicus with two Swiss A. 
lusitanicus populations on the one hand and with Belgian L. flavus and L. maximus species on 
the other hand. 
The effects of the A. lusitanicus population on the mucus production, the score for 
tissue damage, and the EU eye irritation classification were investigated by comparing the 
data of two Swiss A. lusitanicus populations with the data of the Belgian slug population. The 
population had no statistically significant effect on both the mucus production and score for 
tissue damage. Moreover, the mucus production and the score of the negative and positive 
control slugs of the three slug populations met the acceptance criteria determined for Belgian 
A. lusitanicus. The mucus production and score for tissue damage of each of the populations 
treated with PBS were less than 2.0% and 100, respectively. For the A. lusitanicus populations 
treated with benzalkonium chloride, the mucus production and score were more than 11.0% 
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and 850, respectively. When the test substances were classified into EU categories using the 
prediction model presented in Figure 3.1, three of the eight test substances (2-ethyl-1-hexanol, 
4-carboxybenzaldehyde, and imidazole) were classified differently (R36 or R41) by one of the 
A. lusitanicus populations. However, for those chemicals the same switch between R36 and 
R41 was seen in the repeatability study with Belgian A. lusitanicus described in Chapter 3. 
Therefore, the Swiss A. lusitanicus populations can be used as test organism without changing 
the mucus production and score cut-off values determined in Chapter 3. 
Comparison of the eye irritation categories based on the Slug Mucosal Irritation test 
with the categories assigned on the basis of the rabbit eye irritation data (ECETOC, 1998; EC, 
2001) showed that the three rabbit non-irritants were predicted as NI with each of the three 
slug populations. Furthermore, the five chemicals labelled as irritant (R36 or R41) based on 
the rabbit eye test were also classified as irritant with the three slug populations. So the results 
indicate that the Swiss A. lusitanicus populations can be used for the evaluation of the eye 
irritating and damaging properties of chemicals. 
The effect of the slug species on the end points of the Slug Mucosal Irritation test was 
investigated by comparing data of Belgian L. flavus and L. maximus with data of Belgian A. 
lusitanicus. Firstly, the effect of the slug species on the end point mucus production was 
investigated. For PBS and 20 out of the 28 chemicals, the mucus production of L. flavus was 
higher than the mucus production of A. lusitanicus. For nine out of the 28 chemicals (five 
rabbit non-irritants, one chemical labelled as R36 based on the rabbit eye irritation data, and 
three chemicals with EU risk phrase R41 among which five alcohols and ketones), the mucus 
production of L. flavus was also significantly higher than that of A. lusitanicus. When 3% was 
used as NI-R36 mucus production cut-off value (such as in the classification prediction model 
for A. lusitanicus), the irritation potential of non-irritants (e.g. glycerol, PEG 600) was 
overestimated with L. flavus. However, it is important that an alternative test does not 
generate too many false positives (Gilleron et al., 1996; Gilleron et al., 1997; Balls et al., 
1999). Interestingly, the mucus production of the negative control L. flavus slugs did not meet 
the acceptance criteria established for A. lusitanicus in two of the seven experiments, because 
L. flavus slugs treated with PBS produced more than 2% mucus (data not shown). Based on 
linear discriminant analyses and in-house experience, the NI-R36 and R36-R41 mucus 
production cut-off values for L. flavus were elevated to 4% and 8%, respectively. 
For PBS and 23 out of the 28 chemicals, the mucus production of L. maximus was 
higher than the mucus production of A. lusitanicus. For PBS and 13 out of the 28 chemicals 
(four rabbit non-irritants, six chemicals labelled as R36 based on the rabbit eye irritation data, 
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and three chemicals with EU risk phrase R41 among which five alcohols), the mucus 
production of L. maximus was also significantly higher than that of A. lusitanicus. In one of 
the four experiments, the mucus production of the negative control L. maximus slugs did not 
meet the acceptance criteria established for the mucus production of negative control A. 
lusitanicus slugs. Based on statistical analyses and in-house experience, the NI-R36 and R36-
R41 mucus production cut-off values for L. maximus were elevated to 5% and 10%, 
respectively. 
For 18 out of the 28 chemicals, significant differences between the mucus productions 
of the three slug species were observed. It is interesting to note that for ten of these 18 
chemicals, the mucus productions obtained with A. lusitanicus were also significantly 
different throughout the five runs of the repeatability study (Chapter 3). Furthermore, six of 
these 18 chemicals belonged to the chemical classes of the alcohols. The higher mucus 
production of L. flavus and L. maximus in comparison with A. lusitanicus is probably related 
to the fact that the Limax species are more active and move more than A. lusitanicus. Mucus 
secretions namely serve for the locomotion of the slugs (South, 1992; Deyrup-Olsen and 
Luchtel, 1998). This hypothesis is supported by the fact that in several experiments the mucus 
productions of the negative control Limax species did not meet the acceptance criteria 
established for negative control A. lusitanicus slugs.  
Next, the effect of the slug species on the score for tissue damage was evaluated. The 
scores for tissue damage of L. flavus were not significantly different from those of A. 
lusitanicus for PBS and 26 out of the 28 chemicals. For each of the two chemicals that 
induced significantly different scores (Triton X-100 and benzalkonium chloride), the scores 
obtained with A. lusitanicus throughout the repeatability study described in Chapter 3 were 
also significantly different. The scores of L. maximus did not significantly differ from the 
scores of A. lusitanicus for PBS and 22 out of the 28 chemicals. Four of the six chemicals 
with significant differences between the scores of L. maximus and A. lusitanicus induced also 
significantly different scores in the repeatability study with A. lusitanicus (Chapter 3). When 
only those chemicals that induced a mucus production by the Limax species lower than their 
NI-R36 mucus production cut-off values were classified based on the score for tissue damage, 
none of the scores of L. flavus resulted in different predicted eye irritation classes in 
comparison with A. lusitanicus, whereas only the higher score of L. maximus treated with 2-
ethyl-1-hexanol resulted in a different predicted EU category in comparison with A. 
lusitanicus. For 2-ethyl-1-hexanol, a similar switch between R36 and R41 was seen in the 
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repeatability study with A. lusitanicus as described in Chapter 3. Therefore, the score cut-off 
values determined for A. lusitanicus were not modified for L. flavus and L. maximus. 
Further, the effect of the slug species on the eye irritation classification was 
investigated. Classification of the test substances tested with A. lusitanicus, L. flavus, and L. 
maximus into the EU categories by means of their corresponding prediction model (Figure 
4.1) resulted in the same eye irritation categories by the three species for PBS and 23 of the 
28 chemicals. 2-Ethyl-1-hexanol, 1-hexanol, and imidazole were classified as R36 or R41 
dependent on the used slug species. However, for these chemicals, the EU categories obtained 
with both Limax species were comparable to those obtained with A. lusitanicus in the 
repeatability study described in Chapter 3. 4-Carboxybenzaldehyde was classified as NI or 
R36 dependent on the used slug species, whereas cyclohexanol was classified as NI, R36 or 
R41.  
Comparison of the EU eye irritation categories predicted by the Slug Mucosal 
Irritation test with the EU categories assigned on the basis of the rabbit eye irritation data 
(ECETOC, 1998; EC, 2001) revealed that 71% of the 28 chemicals were correctly classified 
into three eye irritation categories by A. lusitanicus and L. flavus, whereas 68% of the 28 
chemicals were correctly classified by L. maximus. For the three species, two of the 16 rabbit 
irritants were falsely predicted non-irritant by the Slug Mucosal Irritation test, which resulted 
in a sensitivity of 88%. A. lusitanicus predicted lauric acid and cyclohexanol falsely as non-
irritants, whereas L. flavus and L. maximus underestimated lauric acid and 4-
carboxybenzaldehyde. For lauric acid, false negative results were also obtained in five 
repeated experiments with A. lusitanicus (Chapter 3). 4-Carboxybenzaldehyde was classified 
as non-irritant by means of the HET-CAM (Gilleron et al., 1997). Three of the 12 rabbit non-
irritants - methyl isobutyl ketone, toluene, and 2-methyl-1-pentanol - were overestimated 
(false positives) by each of the three slug species resulting in a specificity of 75%. However, 
those chemicals were also overestimated in five repeated experiments of the repeatability 
study with A. lusitanicus (Chapter 3). As mentioned in Chapter 3, several studies reported the 
eye irritating potential of these chemicals (Grant, 1986; Hjelm et al., 1990; Vanparys et al., 
1993; Gilleron et al., 1997; Van Goethem et al., 2005). Based on these results, it is concluded 
that L. flavus and L. maximus can be used for the evaluation of the eye irritation/damage 
potential of chemicals without considerable decrease of the concordance and specificity of the 
test.  
It is interesting to note that in case another slug species is effectively used as test 
organism instead of A. lusitanicus, the repeatability of the assay with the selected slug species 
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has also to be evaluated. This study included no investigation of the effects of slug species on 
the repeatability of the assay, because the use of Belgian A. lusitanicus as test organism is 
preferred to the use of other species. Indeed, both an extensive list of data and test validity 
criteria are available for A. lusitanicus, so that future results obtained with A. lusitanicus can 
be compared directly with previous data. 
The results of this study indicate that the geographic and ecological origins of the 
tested slug populations influence neither the end points of the Slug Mucosal Irritation test nor 
the eye irritation classification. So no matter which A. lusitanicus population can probably be 
used as test organism in the Slug Mucosal Irritation test without affecting the test end points. 
However, because this study demonstrates that the use of other slug species can influence the 
test end points and the eye irritation classification, it is important to evaluate the effects of the 
selected species. So if another slug species is used instead of A. lusitanicus, the test procedure 
and prediction model have to be optimised and validated by means of benchmark chemicals.  
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CHAPTER 5: EVALUATION OF MUCOSAL TOLERANCE 
OF BUCCAL POWDER FORMULATIONS  
 
Based on Adriaens, E., Ameye, D., Dhondt, M.M.M., Foreman, P. and Remon, J.P. (2003). 
  
 
 
 
5.1 INTRODUCTION 
 
The buccal mucosa offers an alternative route for the delivery of e.g. peptides. Several 
attempts have been made to increase the bioavailability of buccal administered drugs 
(Veuillez et al., 2001). Buccal powder formulations frequently contain mucoadhesive 
polymers which allow close contact between the formulation and the mucosa and which 
enable high drug concentrations for prolonged periods (Jacques and Buri, 1998). Such 
formulations may be applied frequently over a period of months or years. Because irritation 
and damage of the buccal mucosa can break the protective barrier against micro-organisms 
and noxious substances, it is important to evaluate the mucosal tolerance of buccal 
bioadhesive powder formulations.   
 
5.2 ORAL MUCOSA 
 
 The human oral cavity is lined with a stratified squamous epithelium (Marieb, 1995). 
The mucosae of the soft palate, the sublingual and buccal regions are non-keratinised (Harris 
and Robinson, 1992). The epithelium of the gingiva, hard palate, inner side of the lips, and 
dorsum of the tongue is slightly keratinised for extra protection against mechanical stress 
during eating (Marieb, 1995). Mucus is secreted by the submandibular, buccal and sublingual 
glands. Those glands consist not only of mucous cells, but also of serous cells (Marieb, 1995). 
 
5.3 EVALUATION OF ORAL TOLERANCE OF FORMULATIONS 
 
The evaluation of the local tolerance of newly developed medicinal products has to be 
performed in laboratory experiments prior to human exposure to the product (EC, 1990). 
___________________________________________________________________________
Chapter 5: Evaluation of mucosal tolerance of buccal powder formulations 88 
Buccal tolerance studies of pharmaceuticals are carried out in vertebrates in compliance with 
EU directives and guidelines (EC, 1965; EC, 1975a; EC, 1975b; EC, 1990). Buccal tolerance 
testing is required by regulatory authorities for medicinal products intended for buccal 
administration on the one hand and for products which are not envisaged for buccal delivery 
but can come accidentally into contact with the buccal mucosa on the other hand. Local 
tolerance testing is usually conducted with the definitive formulation consisting of the drug in 
its vehicle at the concentration intended for human use. The frequency and duration of 
administration to animals need to be determined by the proposed conditions of administration 
in clinical use (EC, 1990).   
Several pre-clinical in vivo and in vitro models have been developed to study the 
impact of locally applied drugs, excipients, pharmaceutical formulations, personal care 
products or dental materials on the oral mucosa. Histological changes of the oral mucosa have 
been investigated in vivo using small animals such as rats and hamsters by macroscopic or 
microscopic examination (Cutright et al., 1974; Piliero et al., 1979; Lemons et al., 1980; Roy 
and Wishe, 1986; Harsanyi et al., 1987; Harsanyi et al., 1991; Cummins et al., 1996; Namiki 
et al., 1998). The hamster cheek pouch test is recommended for biocompatibility testing of 
dental materials (Council on Dental Materials and Devices, 1972; ANSI/ADA, 1979). The test 
materials are retained in the hamster cheek pouch by closing the pouch by means of sutures 
(Council on Dental Materials and Devices, 1972), by sewing a perforated disk made of the 
test material directly onto the inside of the cheek pouch (ANSI/ADA, 1979) or by placing the 
disk of test material in a pouch created within the hamster cheek pouch (Harsanyi et al., 1987; 
Harsanyi et al., 1991). However, the use of the hamster cheek pouch as model of the human 
buccal mucosa is not ideal due to the keratinisation of the hamsters’ cheek mucosa (Garren 
and Repta, 1989). Because of the histological similarities between the non-keratinised buccal 
mucosa of dogs and the human buccal mucosa, the effects of locally applied products on the 
oral mucosa have also been evaluated macroscopically or microscopically using dogs (Zhang 
et al., 1994; Redlich et al., 1996; Wirthlin et al., 1997; Tiwari et al., 1999).  
The irritating and tissue damaging properties of products applied locally in the oral 
cavity have also been studied in vitro. The cell viability of immortalised human cell lines 
consisting of buccal cells (Burgalassi et al., 1996) or gingival epithelial cells and gingival 
fibroblasts (Babich and Babich, 1997; Tipton et al., 2003) after exposure to bioadhesive 
formulations or ingredients of orally applied products has been evaluated using various 
assays. The effects of exposure of reconstructed three dimensional human buccal and gingival 
tissue to the products of interest have been evaluated by means of histology and viability 
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assays (Kubilus et al., 2004; SkinEthic, 2005). Furthermore, the HET-CAM is not only used 
as an alternative test for eye irritation (Gilleron et al., 1996; Gilleron et al., 1997; Steiling et 
al., 1999) but also for predicting the irritation potential of dental materials (Schendel et al., 
1994; Schendel et al., 1995; Dahl, 1999; Dahl and Polyzois, 2000; Syverud et al., 2001). 
 
5.4 OBJECTIVES 
 
The availability of a reliable and relevant alternative method for repeated dose local 
tolerance testing would be very useful for academic and pharmaceutical research centres to 
screen pharmaceuticals intended for e.g. repeated buccal application. In the present study, it 
was investigated if the five-day (Slug Mucosal Irritation) test procedure – currently used for 
local tolerance testing of nasal bioadhesive powders at the start of this research work– was 
useful to evaluate the concentration and formulation effects of bioadhesive powder 
formulations intended for buccal administration. In analogy with the studies of Callens et al. 
(2001), Ceulemans et al. (2001) and Dhondt (2001), the slugs were put on 20 mg neat 
formulation for 30 minutes during five successive days. Untreated slugs and slugs treated with 
drum dried waxy maize starch/benzalkonium chloride (DDWM/BAC) 95/5 (w/w) were used 
as negative and positive control, respectively (Callens et al., 2001; Ceulemans et al., 2001; 
Dhondt, 2001). A lyophilised mixture of DDWM/BAC 95/5 (w/v) was used as positive 
control in these studies, because a 12-day nasal administration of this powder to rabbits 
induced ulcerations and an increased protein and LDH release from the nasal mucosa (Callens 
et al., 2001). Moreover, this mixture induced severe irritation and damage of the slug mucosa 
as was demonstrated by a high mucus production, a high protein release and an increased 
enzyme release (Callens et al., 2001; Ceulemans et al., 2001; Dhondt, 2001). 
For Amioca® starch/polyacrylic acid and Amioca® starch/Carbopol® 974P co-spray 
dried powders, the influence of the concentration of linear polyacrylic acid and cross-linked 
polyacrylic acid on the mucosal tolerance was evaluated. Additionally, the effect of heat 
treatment, the influence of dilution of co-spray dried Amioca®/polyacrylic acid powder 
mixtures, and the effect of the mixture process of Amioca®/Carbopol® 974P powders were 
investigated. In order to investigate the repeatability of the test procedure, the negative and 
positive control and some powders were tested independently on two or more separate 
occasions. The results of the Slug Mucosal Irritation test were compared with available in vivo 
data on the local tolerance of the tested powders. Based on the results of this study and data 
previously obtained with the Slug Mucosal Irritation test on the one hand and on pre-clinical 
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and clinical data on the other hand, a classification prediction model was developed for the 
determination of the irritation and tissue damage potential of formulations.  
 
5.5 MATERIALS AND METHODS 
 
5.5.1 Chemicals 
 
Drum-dried waxy maize starch (DDWM), containing 99.9% amylopectin, was 
obtained from Eridania-Béghin Say Cerestar (Vilvoorde, Belgium). Carbopol® 974P (Carb) 
was supplied by B.F. Goodrich (Cleveland, OH, USA). Benzalkonium chloride (BAC) and 
linear polyacrylic acid (PAA, MW 250 000) were purchased from Sigma (St. Louis, MO, 
USA). Amioca® starch, a pregelatinised amylopectin corn starch, was obtained from National 
Starch and Chemical Company (Bridgewater, NJ, USA).  
 
5.5.2 Powder formulations 
 
The positive control powder DDWM/BAC 95/5 (w/w) was prepared by dispersing 
DDWM in a benzalkonium chloride solution. After neutralisation of the dispersion with 
sodium hydroxide 0.2 N, the mixture was lyophilised in vials using an Amsco-Finn Aqua 
GT4 freeze-dryer (Hürth, Germany) and passed through a 63-µm sieve. The sieved powder 
fraction was stored in a desiccator at 4-8°C until use.  
The Amioca®/polyacrylic acid and the Amioca®/Carbopol® 974P co-spray dried 
mixtures were prepared by National Starch and Chemical Company. To obtain the co-spray 
dried Amioca®/polyacrylic acid mixtures, an aqueous mixture of Amioca® starch and a linear 
polyacrylic acid was co-spray dried. The used ratios of Amioca®/PAA were 50/50 and 25/75 
(w/w). After co-spray drying, a part of the yielded powder was additionally heat-treated (HT) 
in an oven at 120°C for 15 minutes.  The dilutions of the co-spray dried Amioca®/PAA 50/50 
(w/w) with the non-irritating DDWM were prepared by physical blending of the two powders. 
The used DDWM concentrations were 10%, 20%, 40%, 60% and 80% (w/w). 
 The co-spray dried Amioca®/Carbopol® 974P mixtures were prepared by co-spray 
drying an aqueous mixture of Amioca® starch and Carbopol® 974P. The tested ratios of 
Amioca®/Carbopol® 974P were 95/5, 90/10, 85/15, 80/20, 75/25, 60/40 and 50/50 (w/w). The 
Amioca®/Carbopol® 974P physical mixtures were prepared by physical blending Amioca® and 
Carbopol® 974P in a mortar with a pestle. The tested ratios were 95/5, 90/10 and 75/25 (w/w). 
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5.5.3 Local tolerance test procedure of the Slug Mucosal Irritation test 
 
Belgian A. lusitanicus slugs were used as test organisms. The housing and feeding 
conditions of the slugs were identical to the ones described in Chapter 3.  
After weighing of the slugs on the one hand and the Petri dishes with the neat test 
substance on the other hand, the slugs were placed individually in the Petri dish on the neat 
test substance for 30 minutes. Each experiment contained five untreated negative control slugs 
(blank), five positive control slugs, and six series of five slugs each treated with the test 
formulations. After the contact period, the amount of mucus produced during the 30-minute 
contact period was measured by reweighing the Petri dishes containing the test substance 
(without the slugs). The mucus production was expressed as a percentage (w/w) of the body 
weight. Additionally, the reduction in body weight caused by the treatment was measured and 
was expressed as a percentage (w/w) of the initial body weight. Immediately after the contact 
period, the slugs were transferred to a fresh Petri dish and 1 ml PBS was added. After 30 
minutes, the PBS samples were collected with a micropipette. Then, the slugs were placed in 
a fresh Petri dish and again 1 ml PBS was added. After one hour, the PBS samples were again 
collected. Subsequently, the slugs were placed in a fresh Petri dish and again 1 ml PBS was 
added for one hour. The PBS samples were analysed immediately for the presence of proteins, 
LDH, and ALP released from the body wall of the slugs. The slugs were placed in a Petri dish 
on a membrane filter (cellulose acetate 0.45 µm, 90 mm; Sartorius AG, Goettingen, Germany) 
moistened with 2 ml PBS until the next contact period and were fed with commercial dog 
food. This procedure was repeated during five successive days. 
  
5.5.4 Analytical procedures 
 
 The protein, LDH, and ALP determinations were performed according to the 
analytical procedures described in Chapter 3. 
 
5.5.5 Data analysis 
 
For each slug, the total mucus production was calculated by adding up the amounts of 
mucus produced during each contact period. Because all the treatments resulted in a high 
protein release on the first day of treatment, the mean protein concentrations were calculated 
without using the data of the samples collected on the first day (Callens et al., 2001), which 
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allowed a more defined distinction between non-irritating and irritating formulations. 
Furthermore for each slug, the mean LDH release and the mean ALP release were calculated 
using the data of all samples collected on the five days. These values were used for the 
statistical analyses using the computer program SPSS (version 12.0; SPSS, Chicago, IL, 
USA). A p value < 0.05 was considered statistically significant.  
Statistically significant differences between repeated experiments or different 
treatments were determined using a one-way ANOVA. The data were tested for normal 
distribution with a Kolmogorov-Smirnov test. The homogeneity of variances was tested with 
the Levene’s test. If the variances were found not to be equal, the data were transformed to 
their logarithm. To further compare the effects of the different treatments, a multiple 
comparison among pairs of means was performed using a Scheffé test.  
A two-way ANOVA was performed to investigate the effect of Amioca®/Carbopol® 
974P ratio and the effect of mixing process on the end points. The normal distribution of the 
data and the homogeneity of variances were tested with the tests mentioned above. Because 
no significant interaction was present, the main effects were interpreted separately from the 
interaction and a multiple comparison among pairs of means was performed using a Scheffé 
post hoc test.  
  
5.6 RESULTS 
 
5.6.1 Repeatability of the test procedure 
 
In order to investigate the repeatability of the test results obtained with the test 
procedure for local tolerance testing of powder formulations, the negative control (blank) and 
the positive control (DDWM/BAC 95/5) were tested independently on seven separate 
occasions. Table 5.1 shows the total mucus production, mean protein and LDH release of the 
negative control slugs and the number of slugs for which ALP release was detected for each 
of the repeated experiments and the mean of the seven experiments. All the blank slugs 
survived a repeated treatment on five successive days. For the negative control, ANOVA 
testing suggested no significant difference in total mucus production and in mean protein 
release between the repeated experiments (p > 0.05) (Table 5.1).  
A daily treatment with DDWM/BAC 95/5 led to 20%, 20%, 0%, 60%, 80%, 0% and 
20% mortality by day 5 (before the 5th treatment) in the 1st, 2nd, 3rd, 4th, 5th, 6th and 7th 
experiment, respectively. For the positive control, ANOVA testing suggested no significant 
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difference in total mucus production, in mean protein release, and in mean LDH release 
between the repeated experiments (p > 0.05) (Table 5.2).  
 
Table 5.1 Intra- and inter-experiment variability for the total mucus production and mean protein 
release of the negative control blank slugs  
Experiment 
 
 
Total mucus 
production 
(%) * 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Experiment 1 1.1 ± 0.4 9 ± 3 −  0  5
Experiment 2 -0.8 ± 0.7 18 ± 12 −  0  5
Experiment 3 -0.6 ± 0.7 8 ± 5 −  0  5
Experiment 4 0.9 ± 0.8 9 ± 5 −  0  5
Experiment 5 0.8 ± 1.0 5 ± 2 −  0  5
Experiment 6 -0.8 ± 1.0 16 ± 14 −  0  5
Experiment 7 -0.8 ± 1.1 12 ± 4 −  0  5
Inter-experiment mean 0.0 ± 0.9 11 ± 5 −    7
Total mucus production and mean protein release data are presented as the mean ± standard deviation of 5 slugs; 
bold values represent the mean ± standard deviation of 7 experiments; -, below the detection limit. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
 
Table 5.2 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the positive control slugs treated with 20 mg DDWM/BAC 
95/5 on 5 successive days 
Experiment 
 
 
Total mucus 
production 
(%) * 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) * 
Number of slugs 
with ALP 
release 
n
Experiment 1 18.8 ± 2.6 165 ± 72 10.8 ± 5.5 4  5
Experiment 2 17.9 ± 5.2 223 ± 122 10.7 ± 6.5 1  5
Experiment 3 17.9 ± 4.1 109 ± 62 2.8 ± 2.3 3  5
Experiment 4 20.0 ± 7.2 111 ± 61 1.8 ± 0.9 4  5
Experiment 5 12.3 ± 8.1 241 ± 93 2.4 ± 2.7 1  5
Experiment 6 17.5 ± 6.7 134 ± 77 5.8 ± 4.6 2  5
Experiment 7 20.0 ± 3.5 126 ± 71 6.2 ± 3.6 3  5
Inter-experiment mean 17.8 ± 2.6 151 ± 54 5.8 ± 3.8   7
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation of 5 slugs; bold values represent the mean ± standard deviation of 7 experiments. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
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5.6.2 Evaluation of local tolerance of buccal powder formulations  
 
5.6.2.1 Local tolerance of Amioca®/PAA co-spray dried mixtures 
 
The mucosal tolerance of Amioca®/PAA co-spray dried powders intended to prepare 
formulations for buccal administration was evaluated by placing the slugs on 20 mg powder 
for 30 minutes during five successive days. All untreated slugs and all slugs exposed to each 
of the heat-treated or not heat-treated Amioca®/PAA mixtures survived the five-day 
experiment. Only a repeated treatment with DDWM/BAC 95/5 caused 20%, 0%, 60%, 80% 
and 20% mortality by day 5 in the 1st, 2nd, 3rd, 4th and 5th experiment, respectively.  
The effects of a repeated treatment on the total mucus production, mean protein and 
enzyme release are summarised in Table 5.3. All the co-spray dried mixtures produced 
significantly more mucus than the untreated slugs (p < 0.001, Scheffé test). The total amount 
of mucus production increased with an increasing PAA concentration. Heat treatment after 
co-spray drying had no effect on the mucus production. The protein release data of the slugs 
treated with the different Amioca®/PAA mixtures were comparable with the negative control 
slugs (p > 0.05, Scheffé test). Only the positive control slugs exhibited a significantly 
increased protein release (p < 0.001, Scheffé test) and the protein release increased with a 
repeated contact period. An increased release of the cytosolic enzyme LDH and the 
membrane-bound enzyme ALP from the mucosa of the slugs is an indication of severe 
membrane damage. Enzyme release was only detected for the positive control slugs.  
 
Table 5.3 Effect of a repeated treatment for 5 successive days with 20 mg of co-spray dried 
Amioca®/PAA mixtures on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Blank 0.8 ± 1.1 a 7 ± 4 a −  0  25
Amioca/PAA 50/50 9.2 ± 3.7  9 ± 5 a −  0  5
Amioca/PAA 50/50 HT 9.7 ± 3.5  7 ± 5 a −  0  5
Amioca/PAA 25/75 14.1 ± 2.5 b 11 ± 2 a −  0  5
Amioca/PAA 25/75 HT 12.7 ± 2.0 b 13 ± 3 a −  0  5
DDWM/BAC 95/5 17.4 ± 6.0 b 160 ± 92 b 5.7 ± 5.7 13 25
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; HT, heat-treated; -, below the detection limit. 
a For this end point, data are not significantly different from blank (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from DDWM/BAC 95/5 (p > 0.05, Scheffé test). 
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Because all tested Amioca®/PAA co-spray dried mixtures resulted in irritation of the 
slug mucosa, the influence of diluting the co-spray dried Amioca®/PAA 50/50 with a non-
irritating starch DDWM was investigated. All the slugs survived a repeated treatment with 
DDWM and each of the Amioca®/PAA/DDWM mixtures. The total mucus production of the 
slugs treated with the co-spray dried Amioca®/PAA 50/50 mixture and with its dilutions 
containing 60% or less DDWM fluctuated between 9.3 and 11.5% indicating mild irritation of 
the slug mucosa (Table 5.4). Only a dilution with 80% DDWM resulted in a decrease of the 
total amount of mucus production compared with the co-spray dried Amioca®/PAA 50/50 
mixture. A repeated treatment with all Amioca®/PAA/DDWM mixtures resulted in a protein 
release comparable to that of the untreated slugs and the DDWM treated slugs (p > 0.05, 
Scheffé test). Moreover, the release of LDH and ALP by slugs treated with these mixtures 
was under the detection limit. Enzyme release was detected only after treatment with 
DDWM/BAC 95/5.   
 
Table 5.4 Effect of a repeated treatment for 5 successive days with 20 mg of co-spray dried 
Amioca®/PAA/DDWM mixtures on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Blank 0.8 ± 1.1 a, b 7 ± 4 a, b −  0  25
Amioca/PAA/DDWM         
     0/0/100 3.0 ± 0.7 a, b 13 ± 10 a, b −  0  5
     10/10/80 6.4 ± 1.5 b 12 ± 5 a, b −  0  5
     20/20/60 9.6 ± 3.0  12 ± 5 a, b −  0  5
     30/30/40 9.7 ± 1.2  3 ± 1 a, b −  0  5
     40/40/20 11.5 ± 3.6 c 11 ± 2 a, b −  0  5
     45/45/10 9.3 ± 1.4  8 ± 8 a, b −  0  5
     50/50/0 10.2 ± 2.5  5 ± 1 a, b −  0  5
DDWM/BAC 95/5 17.4 ± 6.0 c 160 ± 92 c 5.7 ± 5.7 13 25
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not significantly different from blank (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from DDWM (p > 0.05, Scheffé test). 
c For this end point, data are not significantly different from DDWM/BAC 95/5 (p > 0.05, Scheffé test). 
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5.6.2.2 Local tolerance of Amioca®/Carbopol® 974P co-spray dried mixtures 
 
 Next, the influence of the concentration of cross-linked polyacrylic acid – Carbopol® 
974 – on the slug mucosa was evaluated. The mucosal tolerance of Amioca®/Carbopol® 974P 
co-spray dried powders intended for buccal administration was evaluated by placing the slugs 
on 20 mg powder for 30 minutes during five successive days. All the untreated slugs and the 
slugs treated with DDWM or the Amioca®/Carbopol® 974P mixtures survived the five-day 
experiment. Only a repeated treatment with DDWM/BAC 95/5 caused 20%, 20%, 0%, 60%, 
0% and 20% mortality by day 5 in the 1st, 2nd, 3rd, 4th, 5th and 6th experiment, respectively. 
Amioca®/Carbopol® 974P powders in ratios 90/10, 80/20 and 75/25 were tested 
independently on two or more separate occasions. ANOVA testing resulted in no significant 
differences in the total mucus production and in the mean protein release for the repeated 
experiments (p > 0.05). There was only one exception for the repeated experiments with 
Amioca®/Carbopol® 974P 90/10 where the total mucus production of the first experiment (2.9 
± 1.6, n = 5) was significantly lower compared to the second (6.8 ± 1.4, n = 5) and the third 
experiment (7.4 ± 1.4, n = 5). 
 The effect of the Amioca®/Carbopol® 974P co-spray dried mixtures with increasing 
Carbopol® 974P concentrations on the end points of the Slug Mucosal Irritation test is shown 
in Table 5.5. All the Amioca®/Carbopol® 974P co-spray dried mixtures induced a significantly 
higher total mucus production compared to the untreated slugs (p < 0.05, Scheffé test). 
However, the total mucus production induced after treatment with mixtures containing up to 
20% Carbopol® 974P was similar to the mucus production of the slugs treated with DDWM (p 
> 0.05, Scheffé test). The mucus secretion induced by the mixtures containing 25% Carbopol® 
974P was significantly different from the mucus production of the DDWM treated slugs and 
the positive control slugs (p < 0.05, Scheffé test). Slugs treated with a mixture containing 40% 
or more Carbopol® 974P produced a total amount of mucus comparable to that of the positive 
control slugs (p > 0.05, Scheffé test).  
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Table 5.5 Effect of a repeated treatment for 5 successive days with 20 mg of co-spray dried 
Amioca®/Carbopol® 974P mixtures on the end points of the Slug Mucosal Irritation 
test 
Formulation Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Blank -0.3 ± 1.4 a 12 ± 10 a, b −   0  30
DDWM 3.6 ± 1.3 b 11 ± 7 a, b −   0  15
Amioca/Carbopol 974P          
     95/5 3.7 ± 0.8  b 5 ± 4 a, b −   0  5
     90/10 5.7 ± 2.5  b 11 ± 12 a, b −   0  15
     85/15 5.9 ± 1.7  b 13 ± 8 a, b −   0  5
     80/20 7.7 ± 2.5  b 17 ± 14 a, b −   0  10
     75/25 9.2 ± 3.7 15 ± 12 a, b −   0  15
     60/40 17.0 ± 2.2 c 28 ± 30 a, b 0.7 ± 0.8 c  0  5
     50/50 18.5 ± 8.3 c 27 ± 20 a, b 1.2 ± 1.1 c  0  5
     0/100 21.4 ± 3.7 c 55 ± 30 c 0.4 ± 0.3   0  5
DDWM/BAC 95/5 18.7 ± 4.8 c 145 ± 83 c 6.4 ± 5.3 c 17 30
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not significantly different from blank (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from DDWM (p > 0.05, Scheffé test). 
c For this end point, data are not significantly different from DDWM/BAC 95/5 (p > 0.05, Scheffé test). 
 
Co-spray dried mixtures containing up to 25% Carbopol® 974P had no additional 
effect on the protein release in comparison with the untreated slugs and no enzyme release 
was detected. A repeated treatment with co-spray dried powders containing 40% or 50% 
Carbopol® 974P resulted in a (not-significantly) higher protein release in comparison to the 
untreated slugs. Furthermore, the latter two powders induced release of cytosolic LDH which 
was comparable to the positive control slugs (p > 0.05, Scheffé test), but induced no 
detectable ALP release. Repeated treatment with pure Carbopol® 974P resulted in a 
significantly higher protein release compared with the untreated slugs (p < 0.05, Scheffé test) 
and in the release of LDH.  
The effect of co-spray drying of the Amioca®/Carbopol® 974P mixtures on the 
mucosal tolerance was investigated by comparing co-spray dried mixtures containing up to 
25% Carbopol® 974P with their equivalent physical mixtures (Table 5.6). Because a 
Carbopol® 974P concentration up to 25% affected only the total mucus production, only these 
data are shown. Two-way ANOVA testing revealed no significant interaction between the 
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Amioca®/Carbopol® 974P ratio and the mixing process (p = 0.081). However, there was a 
significant main effect of the Carbopol® 974P concentration (p < 0.001). A Scheffé post hoc 
analysis revealed that the total mucus production induced by the Amioca®/Carbopol® 974P 
75/25 mixtures was significantly higher than both the 95/5 and 90/10 mixtures. The mixing 
process had also a significant effect (p = 0.029) on the total mucus production, co-spray dried 
mixtures induced a higher mucus production than the physical mixtures. 
 
Table 5.6 Influence of the mixing process and the Amioca®/Carbopol® 974P ratio on the total 
amount of mucus produced by slugs during a repeated treatment on 5 successive days 
Amioca®/ Carbopol® ratio Total mucus production (%) 
 
Co-spray drying 
 
Physical blending 
 
Average Amioca®/ 
Carbopol® ratio 
Amioca/Carbopol 974P       
     95/5 3.7 ± 0.8 2.7 ± 1.5 3.2 ± 1.3 a 
     90/10 6.8 ± 1.4 2.8 ± 1.0 4.8 ± 2.4 a 
     75/25 8.3 ± 4.1 8.3 ± 1.0 8.3 ± 2.8 b 
Average mixing process 6.3 ± 3.1 c 4.6 ± 2.9 d   
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 10 and 15 slugs, respectively. 
Two-way ANOVA testing revealed no significant interaction effect (p > 0.05), but a significant effect of 
Amioca®/Carbopol® 974P ratio and a significant effect of mixing process (p < 0.05). 
a, b Same letter indicates no significant difference between the Amioca®/Carbopol® ratios (p > 0.05, Scheffé test).  
c, d Same letter indicates no significant difference between the mixing processes (Two-way ANOVA).  
 
5.6.3 Development of prediction model 
 
Based on the results of this study and on Slug Mucosal Irritation test data obtained in 
the previous six years on the one hand and on pre-clinical and clinical safety data on the other 
hand, a classification prediction model was developed that distinguishes into irritation and 
tissue damage. Generally, formulations that cause neither irritation nor tissue damage induce a 
low mucus production, a low protein release and no enzyme release, whereas irritating and 
damaging formulations result in an increased mucus production and an increased protein and 
enzyme release (Adriaens and Remon, 1999; Adriaens et al., 2001a; Callens et al., 2001; 
Ceulemans et al., 2001; Adriaens et al., 2003; Dhondt et al., 2004; Weyenberg et al., 2004; 
Dhondt et al., 2005). Cut-off values were established based on in-house experience. Statistical 
methods such as linear discriminant analysis could namely not be used to determine cut-off 
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values, because the human and animal data against which the relevance of the Slug Mucosal 
Irritation test was assessed were obtained in studies which differed with respect to their 
purpose, administration frequency, administration duration, sample sizes, means and end 
points of assessing safety outcomes. 
Based on this study and the studies of Callens et al. (2001), Ceulemans et al. (2001), 
Dhondt (2001), Adriaens et al. (2003), and Weyenberg et al. (2004), a classification 
prediction model was developed for the determination of the irritation category of bioadhesive 
powders. Powder formulations that induce a low total mucus production (< 7%) are classified 
as non-irritating. Powders that cause a mucus production between 7% and 12% are predicted 
as mildly irritating formulations. Powder formulations that result in 12% to 20% mucus 
production are classified as moderately irritating powders, whereas powders that cause ≥ 20% 
mucus production are classified as severely irritating (Figure 5.1) (Adriaens et al., 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Prediction model for the determination of the irritation category of powders. The total 
mucus production is calculated after a repeated 30-minute treatment of A. lusitanicus 
with the powder on five successive days. (Based on Adriaens et al., 2004) 
 
Furthermore, based on the studies of Adriaens and Remon (1999), Adriaens et al. 
(2001a), Callens et al. (2001), Ceulemans et al. (2001), Adriaens et al. (2003), Dhondt et al. 
(2004), Weyenberg et al. (2004), and Dhondt et al. (2005), a classification prediction model 
was developed for the determination of the tissue damage category of formulations. The 
formulations are classified into four tissue damage classes based on the protein and enzyme 
release as presented in Figure 5.2 (Adriaens et al., 2004).  
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Figure 5.2  Classification prediction model for the determination of the tissue damage category of 
formulations. The mean protein release and mean LDH release are calculated after a 
repeated 30-minute treatment of A. lusitanicus on five successive days. * A 
formulation is considered severely toxic in case of mortality. (Based on Adriaens et 
al., 2004) 
 
5.7 DISCUSSION 
 
A reliable and relevant alternative method for repeated dose mucosal tolerance testing 
would be very useful for academic and pharmaceutical researchers to screen pharmaceuticals 
intended for e.g. buccal application. The objective of this study was to investigate if the five-
day procedure of the Slug Mucosal Irritation test was useful to evaluate the concentration and 
formulation effects of Amioca® starch/polyacrylic acid and Amioca® starch/Carbopol® 974P 
bioadhesive powders intended for buccal administration. The results of the Slug Mucosal 
Irritation test were compared with available pre-clinical and clinical in vivo data on the safety 
of the tested powders.  
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Based on the results of this study and data previously obtained with the Slug Mucosal 
Irritation test on the one hand and on (pre-)clinical data on the other hand, a classification 
prediction model was developed for the determination of the irritation and tissue damage 
potential of formulations. The mucus production is used to classify the formulations into four 
irritation classes (no, mild, moderate and severe irritation), whereas the release of proteins and 
enzymes is a measure of tissue damage (minimal, mild, moderate and severe tissue damage). 
A classification prediction model simplifies the interpretation of the data. A disadvantage of a 
classification model is that it reduces the information about the severity of the irritating and 
damaging properties of test substances (Curren and Harbell, 1998). So especially for 
formulations with a borderline irritation/damage potential, a careful analysis of the data is still 
recommended. It is important to note that the proposed prediction model is susceptible to 
change due to the absence of reference formulations intended for screening the mucosal 
tolerance. The formulations used to develop the classification prediction model are namely 
tested in studies that differed with respect to their purpose, administration frequency, 
administration duration, sample sizes, means and end points of assessing safety outcomes. 
The results of the study indicate that the used PAA concentrations were mildly to 
moderately irritating to the slug mucosal tissue, because a repeated treatment with all tested 
co-spray dried Amioca®/PAA mixtures induced between 9 and 15% mucus production. The 
irritation potential increased with increasing PAA content; 50% PAA was mildly irritating to 
the slug mucosa, whereas 75% PAA was moderately irritating. However, no increased protein 
release and no enzyme release were detected, indicating that no tissue damage occurred. 
These results are in agreement with the outcome of a study in dogs. Amioca®/PAA buccal 
bioadhesive tablets in ratio 50/50 resulted in irritation of the buccal mucosa of dogs after the 
sixth day of application, while the Amioca®/PAA buccal bioadhesive tablets in ratio 25/75 
resulted in irritation after the fourth day of application. Irritation could be observed as 
disappearance of the black pigment of the upper lip (Adriaens et al., 2001b). 
Diluting the co-spray dried Amioca®/PAA 50/50 mixture with DDWM was only 
effective when the physical blend contained 80% DDWM. Some caution about the 
interpretation of the mucus production of the slugs treated with powder formulations should 
be made. Upon contact with the body wall of slugs, dry powder formulations can absorb water 
by dehydration of the mucosal tissue. This absorption of water by the powder is reported as an 
increased mucus production compared to the untreated slugs. Therefore, the effect of the 
different co-spray dried mixtures on the mucus production was also compared with DDWM 
treated slugs. The fact that DDWM does not irritate human buccal mucosa has been 
___________________________________________________________________________
Chapter 5: Evaluation of mucosal tolerance of buccal powder formulations 102 
previously reported. A single application of a buccal bioadhesive tablet consisting of pure 
DDWM did not result in mucosal irritation in each of the 18 human volunteers (Bottenberg et 
al., 1991). DDWM induced no irritation of the slug mucosa, because the increased weight of 
the Petri dish after treatment (reported as mucus production) was probably mainly the result 
of hydration of the dry bioadhesive powder formulation. 
When comparing linear polyacrylic acid (PAA) and cross-linked polyacrylic acid 
(Carbopol® 974P), the mucosal irritation and damage potential of the cross-linked polyacrylic 
acid was more pronounced. Co-spray dried mixtures containing up to 75% PAA induced only 
an increased mucus production, while no increased protein or enzyme release could be 
detected. However, the mixtures containing 40 or 50% Carbopol® 974P resulted in a higher 
mucus production, protein release and LDH release. Both co-spray dried powder mixtures 
induced moderate irritation and mild damage of the slug mucosal tissue. A repeated treatment 
with pure Carbopol® 974P resulted in severe irritation and moderate damage of the slug 
mucosa. The buccal (and nasal) irritation potential of high concentrations of Carbopol® is also 
reported in humans and rabbits. A single application of bioadhesive buccal tablets consisting 
of hydroxypropyl methylcellulose/Carbopol® 934P in ratios of 50/50 resulted in small 
mucosal lesions in 5% of 18 human volunteers (Bottenberg et al., 1991). Pure Carbopol® 
934P tablets caused small buccal lesions in 25% of 16 human volunteers and 44% of the 
volunteers had to remove the tablet due to irritation (Bottenberg et al., 1991). Ugwoke et al. 
(2000) concluded that 85% and 100% Carbopol® 971P induced severe inflammation of the 
nasal mucosa of rabbits; however, no necrosis, squamous metaplasia or ciliary degeneration 
was observed even after a four-week twice daily treatment. 
The increased mucus secretion of the slugs treated with mixtures containing 20 or 25% 
Carbopol® 974P indicated that repeated treatment with these powders induced mild mucosal 
irritation. However, both co-spray dried Amioca®/Carbopol® 974P mixtures induced minimal 
tissue damage as was demonstrated by a low protein release and no detectable enzyme 
release. A single application of a buccal mucoadhesive tablet containing 20 or 30% Carbopol® 
974P was well accepted by 10 human volunteers and caused no irritation (Ceschel et al., 
2001). 
Co-spray dried Amioca®/Carbopol® 974P mixtures containing up to 15% Carbopol® 
974P induced no irritation of the mucosal tissue of slugs. The mixing process had only a 
minor effect on the irritation potential of the powders. Co-spray dried mixtures induced a 
slightly higher mucus production compared to the corresponding physical mixtures. 
Furthermore, all these powders induced minimal damage of the slug mucosa. Irritation studies 
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in other models also indicate that Carbopol® is well tolerated when it is used in small amounts 
(< 10%). Buccal tablets containing 5% Carbopol® together with non-irritating DDWM were 
well accepted by human volunteers (Bottenberg et al., 1991; Bouckaert et al., 1996). A buccal 
erodible tablet containing 7.5% Carbopol® 974P induced no irritation over a period of 6 hours 
in human volunteers (Khanna et al., 1997). A single application of a buccal mucoadhesive 
tablet containing 10% Carbopol® 974P was well accepted by 10 human volunteers and caused 
no irritation (Ceschel et al., 2001). Daily nasal administration of DDWM/Carbopol® 974P in 
ratio 90/10 to rabbits during 28 days led to an intact nasal epithelium and a slightly increased 
number of granulocytes, so that it was concluded that a repeated treatment with the powder 
did not irritate the rabbit nasal mucosa (Callens et al., 2001).  
The results of this study indicate that the Slug Mucosal Irritation test seems to be a 
promising alternative to evaluate the local tolerance of bioadhesive powder formulations 
intended for repeated buccal administration. The test enables to investigate the concentration 
effect of ingredients or drugs – intended to prepare mucosally applied formulations – on the 
mucosal tissue. These concentration response experiments can be a very helpful tool in 
prioritising concentrations of formulation compounds in the drug development phase. 
Furthermore, the test can classify the formulations into four irritation and tissue damage 
categories. Local tolerance data may be obtained accurately, quickly and economically. The 
Slug Mucosal Irritation test seems to be useful to screen new compounds and formulations 
intended for repeated administration early in the development process before pre-clinical 
studies in vertebrates and clinical studies. 
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CHAPTER 6: EVALUATION OF LOCAL TOLERANCE OF 
OCULAR POWDER FORMULATIONS  
 
 
 
 
 
 
6.1 INTRODUCTION 
 
Various methods were investigated to increase the bioavailability of ophthalmic drugs. 
One approach was the prolongation of the contact time between drug and corneal-conjunctival 
epithelium using bioadhesive polymers (Hui and Robinson, 1985; Saettone and Salminen, 
1995). Consequently, the use of mucoadhesive polymers may result locally in a high drug 
concentration. Certain ingredients of ophthalmic formulations (e.g. preservatives) may cause 
ocular irritation and damage (Gasset et al., 1974; Collin and Carroll, 1986). Adverse effects 
may be more pronounced after frequent application over a long period. Because irritation and 
damage of the eye can have serious consequences, it is important to evaluate the local 
tolerance of ophthalmic formulations – including formulations based on bioadhesive powders 
– before clinical use. 
 
6.2 EVALUATION OF OCULAR TOLERANCE OF FORMULATIONS 
 
For medicinal products intended for ophthalmic administration, regulatory authorities 
require a single dose ocular tolerance test on the one hand and a repeated dose ocular 
tolerance test on the other hand. Single dose ocular tolerance testing is also necessary to 
investigate accidental exposure for products which are not envisaged for ocular delivery, but 
which can come into contact with the eyes during their normal clinical use (e.g. medicinal 
facial lotions, facial gels or shampoos). Ocular tolerance testing is usually conducted in 
rabbits with the definitive formulation consisting of the drug in its vehicle at the concentration 
intended for human use. In case of repeated dose ocular tolerance tests, the frequency and 
duration of administration to animals are determined based on the proposed administration 
frequency and duration in clinical use (EC, 1990).  
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Ocular irritation caused by single or repeated application of ophthalmic adhesive 
delivery systems has been evaluated in rabbits by scoring ocular effects such as conjunctival 
redness (Gurtler et al., 1995; Gurtler et al., 1996; Bayens et al., 1998; Srividya et al., 2001).  
  
6.3 OBJECTIVES 
 
The objective of the present study was to optimise and evaluate the five-day procedure 
of the Slug Mucosal Irritation test (as described in Chapter 5) for the evaluation of the local 
tolerance of powder formulations intended for repeated ocular administration. Because 
analysis of the data of Chapter 5 and of previously obtained data (Adriaens, 2000; Callens et 
al., 2001; Ceulemans et al., 2001) indicated that for irritating and damaging formulations the 
highest release of proteins and enzymes occurred during the first two hours after treatment of 
the slugs (analysis not shown) and that a better discrimination between minimally, mildly, 
moderately and severely damaging formulations could be made on the basis of two samples, it 
was decided to reduce the number of samples from three to two.  
Firstly, it was determined if a repeated treatment on five successive days was 
necessary. Based on the results of Chapter 5 and on the fact that ocular minitablets containing 
94% DDWM were well accepted by human volunteers (Ceulemans et al., 2001), DDWM was 
used as negative control. Because the preparation of the lyophilised positive control powder 
DDWM/BAC 95/5 (used in Chapter 5) is laborious, it was decided to look for another 
positive control powder. Sodium lauryl sulphate was selected for the preparation of the novel 
positive control powder, because it induces ocular irritation in several models (Gilleron et al., 
1997; ECETOC, 1998; personal communication with F. Van Goethem and Ph. Vanparys, J & 
J, Beerse, Belgium, 2004; Adriaens et al., 2005) and because treatment of the slugs with 
sodium lauryl sulphate causes a mucus production comparable to the mucus production of 
slugs treated with benzalkonium chloride as was demonstrated in Chapter 3.  
Furthermore, the influence of the amount of powder on the end points of the test was 
evaluated. In previous studies, the slugs were put on 20 mg powder formulation (Adriaens, 
2000; Callens et al., 2001; Ceulemans et al., 2001; Dhondt, 2001). However, preliminary 
studies had shown that the amount of formulation influences especially the mucus production 
of the slugs and the end points of the Slug Mucosal Irritation test in general. Next, the 
repeatability of the optimised test procedure and prediction model (described in Chapter 5) 
was assessed. For this purpose, the negative control and the positive control were tested on 
four separate occasions. Both the intra-laboratory reproducibility of the test results and the 
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intra-laboratory reproducibility of the classifications obtained with the Slug Mucosal Irritation 
test were evaluated. Finally, the optimised test procedure was used to evaluate the local 
tolerance of ingredients and bioadhesive powder mixtures intended to prepare ocular 
minitablets.  
 
6.4 MATERIALS AND METHODS 
 
6.4.1 Chemicals  
 
DDWM was obtained from Eridania-Béghin Say, Cerestar (Vilvoorde, Belgium). 
Benzalkonium chloride (BAC), sodium lauryl sulphate (SLS), gentamycin sulphate, and 
vancomycin hydrochloride were purchased from Sigma (St. Louis, MO, USA). Carbopol® 
974P (Carb) was obtained from B.F. Goodrich (Cleveland, OH, USA). Sodium stearyl 
fumarate (NaSF) and ciprofloxacin hydrochloride were a gift of Edward Mendell Co. Inc. 
(New York, NY, USA) and Dr. Reddy’s Laboratories (Hyderabad, India). Amioca® starch 
was obtained from National Starch and Chemical Company (Bridgewater, NJ, USA). All 
other reagents used were of analytical grade.  
 
6.4.2 Powder formulations 
 
The lyophilised powder DDWM/BAC 95/5 (w/w) was prepared as described in 
Chapter 5. The powders containing DDWM/SLS in ratios 95/5, 90/10, 80/20 and 50/50 (w/w) 
were prepared by homogeneously mixing the different compounds with a pestle in a mortar.  
 The non-sterilised and sterilised powder mixtures DDWM/Carb/NaSF/ciprofloxacin 
HCl and Amioca®/Carb/NaSF/gentamycin sulphate/vancomycin HCl were prepared by the 
Laboratory of Pharmaceutical Technology and Biopharmacy (University of Antwerp, 
Antwerp, Belgium). The DDWM/Carb/NaSF/ciprofloxacin HCl powders contained DDWM,  
5% (w/w) Carbopol® 974P, 1% (w/w) sodium stearyl fumarate, and 0 to 10% (w/w) 
ciprofloxacin HCl. The Amioca®/Carb/NaSF/gentamycin sulphate/vancomycin HCl powder 
mixtures consisted of 1% (w/w) sodium stearyl fumarate, 5% (w/w) gentamycin sulphate, and 
5% (w/w) vancomycin HCl on the one hand and 89% (w/w) co-spray dried 
Amioca®/Carbopol® 974P 95/5 (w/w) or 85/15 (w/w) (National Starch and Chemical 
Company) on the other hand. A part of some powder mixtures was sterilised by γ-irradiation 
at 25kGy (Gammir-I-Sulzer irradiator unicell; Sterigenics, IBA-Mediris, Fleurus, Belgium).  
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6.4.3 Local tolerance test procedure of the Slug Mucosal Irritation test 
 
Belgian A. lusitanicus slugs were used as test organisms. The housing and feeding 
conditions of the slugs were identical to the ones described in Chapter 3.  
The local tolerance of both bioadhesive powder formulations intended for repeated 
ocular administration and their ingredients was assessed according to a slightly modified 
version of the procedure described in Chapter 5. During five successive days, the slugs were 
placed on the neat test substance for 30 minutes and the mucus production of the slugs was 
measured. After each of the five contact periods, however, only two samples were collected 
instead of three samples. The first samples were collected one hour after each contact period, 
whereas the second samples were collected two hours after each contact period. The samples 
were analysed immediately for the presence of proteins, LDH, and ALP released from the 
body wall of the slugs. 
 
6.4.4 Analytical procedures 
 
 The protein, LDH, and ALP determinations were performed according to the 
analytical procedures described in Chapter 3. 
 
6.4.5 Data analysis 
 
For each slug, the total mucus production, mean protein release, mean LDH release 
and mean ALP release were calculated as described in the data analysis section of Chapter 5. 
These values were used for the statistical analyses using the computer program SPSS (version 
12.0; SPSS, Chicago, IL, USA). A p value < 0.05 was considered statistically significant.  
Statistically significant differences between different treatments or repeated 
experiments were determined using a one-way ANOVA. The data were tested for normal 
distribution with a Kolmogorov-Smirnov test. The homogeneity of variances was tested with 
the Levene’s test. If the variances were found not to be equal, the data were transformed to 
their logarithm or inverse. To compare further the effects of the different treatments or 
experiments, a multiple comparison among pairs of means was performed with a Scheffé test.  
A two-way ANOVA was performed to investigate the test amount effect and 
formulation effect on the total mucus production and mean protein release. The normal 
distribution of the data and the homogeneity of variances were tested with the tests mentioned 
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above. Because a significant interaction between both factors was present for the total mucus 
production, the test amount effect for each formulation and the formulation effect for each test 
amount were investigated with a Bonferroni post hoc test. Because transformation of the 
mean protein release data did not result in equal variances and no significant interaction was 
present, a multiple comparison among pairs of means was performed using a Dunnett T3 post 
hoc test.  
Using the cut-off values presented in Figures 5.1 and 5.2, the powders were classified 
into one of the irritation and tissue damage categories. 
 
6.5 RESULTS 
 
6.5.1 Optimisation of the test procedure 
 
Firstly, it was investigated if a repeated treatment on five successive days was 
necessary. For this purpose, DDWM, DDWM/BAC 95/5 and powders containing DDWM 
and SLS in different ratios were tested. All the slugs treated with 20 mg DDWM, 
DDWM/SLS 95/5, DDWM/SLS 90/10 or DDWM/BAC 95/5 survived a repeated treatment 
on five successive days. A daily treatment with DDWM/SLS 80/20 led to 40% mortality by 
day 4 (before the 4th treatment) and to 80% mortality by day 5. Two out of the five slugs 
treated with DDWM/SLS 50/50 were dead by day 3 and finally all slugs were dead by day 4. 
 In order to enable discrimination between minimally, mildly, moderately and severely 
irritating and damaging formulations, it is important that for the different end points the 
difference between non-irritating/damaging formulations on the one hand and 
irritating/damaging formulations on the other hand is as large as possible. Figure 6.1 
illustrates that discrimination between the mucus productions of the slugs treated with the 
different powders became more pronounced after a repeated treatment and the best 
discrimination could be made after five treatments.  
Table 6.1 shows that the total mucus production of the slugs treated for five successive 
days with DDWM/SLS 90/10, DDWM/SLS 80/20, DDWM/SLS 50/50 or DDWM/BAC 95/5 
were significantly higher than the total mucus production of the negative control slugs. 
Because DDWM/SLS 50/50 caused high mortality, its use as positive control was not 
recommended. Consequently, DDWM/SLS in ratios 90/10 and 80/20 were considered 
possible positive control powders and were investigated in more detail. 
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Figure 6.1  Total mucus production of slugs treated with 20 mg DDWM (●), DDWM/SLS 95/5 
(○), DDWM/SLS 90/10 (□), DDWM/SLS 80/20 (∆), DDWM/SLS 50/50 (■) or 
DDWM/BAC 95/5 (▲) for 5 successive days. Data points are presented as the mean 
values (n = 5) and standard deviation bars are indicated. 
 
Table 6.1 Effect of a repeated treatment for 5 successive days with the negative control DDWM 
and several positive controls on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
DDWM 6.2 ± 2.5 a 17 ± 10 a −  0  5
DDWM/SLS 95/5 11.6 ± 5.6 a, b 46 ± 38 a 0.06 ± 0.12 a 0  5
DDWM/SLS 90/10 23.2 ± 6.7 c 74 ± 38 a, b 1.02 ± 0.94 a 0  5
DDWM/SLS 80/20 23.6 ± 5.3 c 172 ± 45 b 1.65 ± 0.48 a 3  5
DDWM/SLS 50/50 24.4 ± 3.9 c 335 ± 59 c 2.22 ± 2.14 a 4  5
DDWM/BAC 95/5 19.8 ± 3.9  b, c 99 ± 81 a, b 3.10 ± 3.14 a 1  5
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a, b, c For this end point, the values marked with the same superscript are not significantly different from each 
other (p > 0.05, Scheffé test). 
 
 
Figure 6.2 shows that all the powders induced a high protein release after the first 
treatment. However, the negative control powder DDWM resulted in low protein release 
levels comparable to the ones of untreated slugs (described in Chapter 5) from the second day 
on. The protein release by the slugs treated with DDWM/SLS 90/10, DDWM/SLS 80/20 and 
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DDWM/BAC 95/5 increased with a repeated treatment. For the end point protein release, the 
best discrimination between the different powders could also be made after five successive 
treatments. Table 6.1 shows that the protein release of the slugs treated with DDWM/SLS 
80/20 was significantly higher than that of the negative control slugs (p < 0.05, Scheffé test).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2  Mean protein release of slugs treated with 20 mg DDWM (●), DDWM/SLS 90/10 (□), 
DDWM/SLS 80/20 (∆) or DDWM/BAC 95/5 (▲) for 5 successive days. Data points 
are presented as the mean values (n = 5) and standard deviation bars are indicated. 
 
An increased release of the cytosolic enzyme LDH and the membrane-bound ALP 
from the slug mucosa is an indication of tissue damage. Increased LDH release was detected 
for slugs treated with DDWM/SLS in ratios 90/10 and 80/20 and DDWM/BAC 95/5. LDH 
release was induced after the 2nd treatment with DDWM/SLS 80/20 or DDWM/BAC 95/5 and 
after the 4th treatment with DDWM/SLS 90/10. LDH release increased with a repeated 
treatment (left graph of Figure 6.3). ALP release occurred at least one day after LDH release 
and increased with a repeated treatment (right graph of Figure 6.3). 
The results indicated that with respect to the irritation and tissue damage potential, the 
best discrimination between the different powders can be made after a repeated treatment on 
five successive days. Prolongation of the experiment was not useful, because the mortality of 
the slugs treated with severely irritating formulations would increase so that the end point 
range between non-irritating and irritating formulations would not further increase. 
Furthermore, DDWM/SLS 80/20 seemed to be a good replacement powder for DDWM/BAC 
95/5 and was therefore selected as positive control powder for future experiments. 
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Figure 6.3  Mean LDH release and ALP release of slugs treated with 20 mg DDWM (●), 
DDWM/SLS 90/10 (□), DDWM/SLS 80/20 (∆) or DDWM/BAC 95/5 (▲) for 5 
successive days. Data points are presented as the mean values (n = 5) and standard 
deviation bars are indicated. 
 
Next, the influence of the amount of powder on the end points of the Slug Mucosal 
Irritation test was investigated. Several amounts (20, 50, 100 and 200 mg) of DDWM and 
DDWM/SLS 80/20 were tested on five successive days. All the slugs treated with the 
different amounts of DDWM survived a repeated treatment on five successive days. A 
repeated treatment with 20 mg DDWM/SLS 80/20 caused 20% mortality by day 5. A 
repeated treatment with 50 mg DDWM/SLS 80/20 led to 40% mortality by day 4 and to 80% 
mortality by day 5. At least 40% of the slugs treated with 100 mg or 200 mg DDWM/SLS 
80/20 were dead by day 3 and finally all the slugs were dead by day 5.  
The effect of the amount of powder was investigated by comparing the total mucus 
production and mean protein release data of the negative and positive control powders. For 
the total mucus production, two-way ANOVA testing revealed a significant interaction 
between the test amount and the powder formulation (p = 0.001) (Table 6.2). Subsequently, a 
Bonferroni post hoc analysis was performed to investigate the test amount effect for each 
formulation. Bonferroni post hoc testing revealed that the total mucus production induced by 
20 mg and 50 mg of DDWM was significantly lower than the total mucus production induced 
by 200 mg of DDWM. Although the total amount of mucus secreted by the slugs treated with 
DDWM/SLS 80/20 decreased with increasing amount of powder, Bonferroni testing revealed 
0
1
2
3
4
5
6
7
day 1 day 1-2 day 1-3 day 1-4 day 1-5
LD
H
 re
le
as
e 
(IU
/l.
g)
 
0
1
2
3
4
5
6
7
day 1 day 1-2 day 1-3 day 1-4 day 1-5
A
LP
 re
le
as
e 
(IU
/l.
g)
 
___________________________________________________________________________
Chapter 6: Evaluation of local tolerance of ocular powder formulations 117 
no significant differences between the mucus productions induced by the four test amounts of 
DDWM/SLS 80/20 (p > 0.05). This decrease in mucus production can be explained by the 
earlier onset of mortality of the slugs treated with larger amounts of the positive control 
powder. Next, a Bonferroni post hoc analysis was performed to investigate the formulation 
effect for each test amount. Bonferroni post hoc testing revealed that the total mucus 
production of slugs treated with each of the four amounts of DDWM was significantly lower 
than the total mucus productions of the slugs treated with the corresponding amount of 
DDWM/SLS 80/20. The largest difference in mucus production between the negative and the 
positive control was obtained after a repeated treatment with 20 mg powder formulation on 
five successive days. 
 
Table 6.2 Influence of the test amount and the powder formulation on the total amount of mucus 
produced by slugs during a repeated treatment on 5 successive days 
Formulation Total mucus production (%) 
 20 mg 
 
50 mg 100 mg 200 mg Average 
formulation 
DDWM 6.0 ± 3.3 a, c 7.9 ± 2.8 a, c 13.1 ± 2.8 a, b, c 20.3 ± 6.2 b, c 11.8 ± 6.8 
DDWM/SLS 80/20 30.9 ± 4.9 a, d 29.3 ± 3.4 a, d 28.5 ± 4.0 a, d 27.7 ± 4.4 a, d  29.1 ± 4.1 
Average test amount 18.5 ± 13.7 18.6 ± 11.7 20.8 ± 8.8 24.0 ± 6.4   
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 20 and 10 slugs, respectively. 
Two-way ANOVA testing revealed a significant interaction and a significant formulation effect (p ≤ 0.001). 
a, b For this formulation, total mucus productions marked with the same superscript are not significantly different 
from each other (p > 0.05, Bonferroni test).  
c, d For this test amount, total mucus productions marked with the same superscript are not significantly different 
from each other (p > 0.05, Bonferroni test).  
 
For the mean protein release, two-way ANOVA testing revealed no significant 
interaction between the test amount and the powder formulation (p = 0.099) (Table 6.3). 
There was a significant main effect of the formulation (p < 0.001). The mean protein release 
of the slugs treated with DDWM was significantly lower than that of the slugs treated with 
DDWM/SLS 80/20. Table 6.3 shows that treatment of the slugs with the different amounts of 
the negative control powder resulted in low protein concentrations. The mean protein release 
of the positive control slugs increased with increasing amount of powder. However, Dunnett 
T3 post hoc testing revealed no significant differences between the mean protein release data 
induced by the four test amounts (p > 0.05).  
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Table 6.3 Influence of the test amount and the powder formulation on the mean protein release 
induced by a repeated treatment of the slugs on 5 successive days 
Formulation Mean protein release (µg/ml.g) 
 20 mg 
 
50 mg 100 mg 200 mg Average 
formulation 
DDWM 6 ± 3  8 ± 4  9 ± 6  15 ± 9  10 ± 6 a 
DDWM/SLS 80/20  82 ± 65  162 ± 35  176 ± 69  219 ± 66  160 ± 75 b 
Average test amount * 41 ± 49 69 ± 64 75 ± 80 112 ± 107   
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 20 and 10 slugs, respectively. 
Two-way ANOVA testing revealed no significant interaction (p = 0.099), but a significant formulation effect (p 
< 0.05). 
a, b Same letter indicates no significant difference between the powder formulations (Two-way ANOVA).  
* There are no significant differences between the mean protein release data induced by the four test amounts (p 
> 0.05, Dunnett T3 test).  
 
For the slugs treated with 20 and 50 mg DDWM, the LDH release was under the 
detection limit. Repeated treatment with 100 and 200 mg DDWM caused comparable mean 
LDH release data (p > 0.05, One-way ANOVA). Treatment of the slugs with different 
amounts of DDWM/SLS 80/20 resulted in comparable LDH release data (p > 0.05, One-way 
ANOVA). ALP release was detected only for the positive control slugs. Different amounts of 
DDWM/SLS 80/20 caused comparable mean ALP release data (p > 0.05, One-way ANOVA). 
Three, two, two, and five out of the five slugs treated with 20, 50, 100 and 200 mg 
DDWM/SLS 80/20, respectively, released ALP. 
Based on the fact that the largest difference between the mucus productions of the 
slugs treated with DDWM and DDWM/SLS 80/20 was obtained when the slugs were placed 
on 20 mg powder and on the fact that the statistical analyses revealed no significant 
differences between the protein release data induced by the four test amounts on the one hand 
and taking into account the low availability of certain test compounds on the other hand, 20 
mg was selected as test amount to evaluate the local tolerance of powder formulations. 
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6.5.2 Repeatability of the test procedure and prediction model 
 
In order to investigate the repeatability of the test results obtained with the optimised 
test procedure for local tolerance testing of powder formulations, the negative control 
(DDWM) and the positive control (DDWM/SLS 80/20) were tested independently on four 
separate occasions. Table 6.4 shows the total mucus production and mean protein and enzyme 
release of the negative control slugs measured in each of the repeated experiments and the 
mean of the four experiments. All the slugs treated with DDWM survived a repeated 
treatment on five successive days. For the negative control, Scheffé post hoc testing suggested 
two homogenous subsets for the total mucus production. One subset comprised only the total 
mucus production of the fourth experiment, whereas another subset contained the total mucus 
productions of the first, second and third experiment. However, no significant difference in 
mean protein release was detected between the repeated experiments (p > 0.05, One-way 
ANOVA). Based on the prediction models presented in Figures 5.1 and 5.2, DDWM was 
classified as a non-irritating and minimally damaging formulation in each of the repeated 
experiments.  
 
Table 6.4 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the negative control slugs treated with 20 mg DDWM on 5 
successive days 
Experiment 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Experiment 1 6.2 ± 2.5 a 17 ± 10  −  0  5
Experiment 2 5.9 ± 0.8 a 15 ± 4  −  0  5
Experiment 3 6.0 ± 0.7 a 18 ± 20  −  0  5
Experiment 4 2.7 ± 1.7 b 4 ± 3  −  0  5
Inter-experiment mean 5.2 ± 1.7 13 ± 6 −    4
Total mucus production and mean protein release data are presented as the mean ± standard deviation of 5 slugs; 
bold values represent the mean ± standard deviation of 4 experiments; -, below the detection limit. 
a, b For this end point, the values marked with the same superscript are not significantly different from each other 
(p > 0.05, Scheffé test). 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
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A daily treatment with DDWM/SLS 80/20 led to 80%, 100%, 80% and 20% mortality 
by day 5 in the 1st, 2nd, 3rd and 4th experiment, respectively. For the positive control, ANOVA 
testing revealed no significant difference in total mucus production, in mean protein release 
and in mean LDH release between the repeated experiments (p > 0.05) (Table 6.5). ALP 
release was detected for three, two, three, and three out of the five slugs in the 1st, 2nd, 3rd and 
4th experiment, respectively. Based on the data presented in Table 6.5 and on the mortality 
induced, DDWM/SLS 80/20 was classified as a severely irritating and severely damaging 
formulation in each of the four experiments. 
 
Table 6.5 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the positive control slugs treated with 20 mg DDWM/SLS 
80/20 on 5 successive days 
Experiment 
 
 
Total mucus 
production 
(%) * 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) * 
Number of slugs 
with ALP 
release 
n
Experiment 1 23.6 ± 5.3  172 ± 45  1.65 ± 0.48 3  5
Experiment 2 23.0 ± 4.1  164 ± 58  1.86 ± 1.41 2  5
Experiment 3 25.2 ± 1.7  141 ± 65  3.54 ± 1.80 3  5
Experiment 4 30.9 ± 4.9  82 ± 65  1.24 ± 1.43 3  5
Inter-experiment mean 25.6 ± 3.6 140 ± 41 2.07 ± 1.01   4
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation of 5 slugs; bold values represent the mean ± standard deviation of 4 experiments. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
 
6.5.3 Evaluation of local tolerance of ocular powder formulations 
 
6.5.3.1 Local tolerance of ingredients intended to prepare ocular minitablets 
 
 The local tolerance of ingredients envisaged to prepare ocular minitablets was 
evaluated by placing the slugs on 20 mg powder for 30 minutes on five successive days. All 
the slugs survived a repeated treatment with DDWM, sodium stearyl fumarate, Amioca®, 
ciprofloxacin HCl, gentamycin sulphate, vancomycin HCl, and Carbopol® 974P. Only a 
repeated treatment with DDWM/SLS 80/20 caused 40% mortality by day 4 and 80% 
mortality by day 5.  
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The effects of a repeated treatment on the total mucus production, mean protein and 
enzyme release are presented in Table 6.6. Slugs treated with sodium stearyl fumarate or 
Amioca® produced a smaller or comparable amount of mucus compared to the negative 
control slugs. Based on the prediction model presented in Figure 5.1, sodium stearyl fumarate 
and Amioca® were classified as non-irritating compounds. Ciprofloxacin HCl and gentamycin 
sulphate induced a mucus production that was significantly higher than the mucus production 
of the negative control slugs, but significantly lower than the positive control slugs (p < 0.05, 
Scheffé test). These ingredients were classified as mildly irritating. Vancomycin HCl and 
Carbopol® 974P induced a mucus production that was comparable to the mucus production of 
the positive control slugs (p > 0.05, Scheffé test). Vancomycin HCl and Carbopol® 974P were 
classified as severely irritating ingredients. 
 
Table 6.6 Effect of a repeated treatment for 5 successive days with 20 mg of ingredients 
intended to prepare ocular minitablets on the end points of the Slug Mucosal Irritation 
test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
DDWM 3.3 ± 1.5 a 7 ± 4 a  −   0  5
Sodium stearyl fumarate 0.1 ± 0.8  17 ± 9 a  −   0  5
Amioca 6.2 ± 1.4 a 23 ± 12 a  −   0  5
Ciprofloxacin HCl  10.2 ± 3.4  24 ± 36 a  −   0  5
Gentamycin sulphate 10.1 ± 0.6  not interpretable  −   0  3
Vancomycin HCl 27.2 ± 5.0 b 16 ± 7 a  −   0  5
Carbopol 974P 21.4 ± 3.7 b 61 ± 44 b 0.55 ± 0.46   0  5
DDWM/SLS 80/20 23.6 ± 5.3 b 172 ± 45 b 1.65 ± 0.48 b 3   5
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not significantly different from DDWM (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from DDWM/SLS 80/20 (p > 0.05, Scheffé test). 
 
The protein release of the slugs treated with sodium stearyl fumarate, Amioca®, 
ciprofloxacin HCl, and vancomycin HCl was comparable to protein release of the negative 
control slugs (p > 0.05, Scheffé test). Based on the prediction model presented in Figure 5.2, 
these ingredients were classified as minimally damaging compounds. Because gentamycin 
sulphate interfered with the NanoOrange® protein determination assay, the end point protein 
release could not be interpreted for this ingredient. However, because no enzyme release was 
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detected and the body weight of the slugs after a five-day treatment with gentamycin sulphate 
was 80% of the initial body weight which was comparable to the reduction in body weight of 
the negative control slugs (whereas the body weight of positive control slugs was reduced to 
50% after the fifth treatment), tissue damage was very unlikely and gentamycin sulphate was 
classified as a minimally damaging ingredient. The protein release of the slugs treated with 
Carbopol® 974P was comparable to the protein release of the positive control slugs (p > 0.05, 
Scheffé test). Furthermore, LDH release was detected for the slugs treated with Carbopol® 
974P. Based on the protein and enzyme release data, Carbopol® 974P was classified as a 
moderately damaging ingredient.  
 
6.5.3.2 Local tolerance of powder mixtures intended to prepare ocular minitablets 
 
Taking into account these test results, powder mixtures intended to prepare ocular 
minitablets were made. The local tolerance of DDWM/Carbopol® 974P/NaSF/ciprofloxacin 
HCl mixtures containing different ratios of ciprofloxacin and Amioca®/Carbopol® 974P/ 
NaSF/gentamycin sulphate/vancomycin HCl mixtures containing different ratios of Carbopol® 
974P was evaluated using the optimised test procedure (Table 6.7). All the slugs survived a 
repeated treatment on five successive days with DDWM/Carbopol® 974P/NaSF/ciprofloxacin 
HCl powders and Amioca®/Carbopol® 974P/NaSF/gentamycin sulphate/vancomycin HCl 
mixtures. Only a repeated treatment with DDWM/SLS 80/20 caused 20% mortality by day 5. 
The total mucus production of the slugs treated with each of the different 
DDWM/Carbopol® 974P/NaSF/ciprofloxacin HCl mixtures was comparable to that of the 
negative control slugs (p > 0.05, Scheffé test). No statistically significant differences were 
detected between the non-sterilised and the sterilised powder mixtures. The different 
DDWM/Carbopol® 974P/NaSF/ciprofloxacin HCl mixtures were classified as non-irritating 
powders. Slugs treated with the two Amioca®/Carbopol® 974P/NaSF/gentamycin 
sulphate/vancomycin HCl powders produced significantly more mucus than the negative 
control slugs and significantly less mucus than the positive control slugs (p ≤ 0.001, Scheffé 
test). These two powder mixtures were classified as mildly irritating formulations. 
A repeated treatment with all DDWM/Carbopol® 974P/NaSF/ciprofloxacin HCl and 
Amioca®/Carbopol® 974P/NaSF/gentamycin sulphate/vancomycin HCl mixtures resulted in a 
protein release comparable to that of the negative control slugs (p > 0.05, Scheffé test). 
Moreover, the LDH and ALP release by the slugs treated with these mixtures was under the 
detection limit. Each of the DDWM/Carbopol® 974P/NaSF/ciprofloxacin HCl and 
___________________________________________________________________________
Chapter 6: Evaluation of local tolerance of ocular powder formulations 123 
Amioca®/Carbopol® 974P/NaSF/gentamycin sulphate/vancomycin HCl mixtures was 
classified as a minimally damaging powder formulation.  
 
Table 6.7 Effect of a repeated treatment for 5 successive days with 20 mg of ocular powder 
mixtures on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
DDWM 2.7 ± 1.7 a 4 ± 3 a  −   0  5
DDWM/Carb/NaSF/ciprofloxacin HCl         
     94/5/1/0 NS 3.9 ± 1.0 a 11 ± 4 a  −   0  5
     94/5/1/0 S 4.7 ± 1.3 a 11 ± 9 a  −   0  5
     92/5/1/2 NS 4.7 ± 1.8 a 6 ± 2 a  −   0  5
     90.5/5/1/3.5 NS 3.9 ± 0.9 a 4 ± 2 a  −   0  5
     90.5/5/1/3.5 S 2.5 ± 0.7 a 8 ± 7 a  −   0  4
     89/5/1/5 NS 5.3 ± 0.9 a 4 ± 1 a  −   0  5
     84/5/1/10 NS 5.5 ± 2.0 a 7 ± 3 a  −   0  5
Amioca/Carb/NaSF/gentamycin sulphate/vancomycin HCl       
     84.55/4.45/1/5/5 S 8.5 ± 1.9 7 ± 2 a  −   0  5
     75.65/13.35/1/5/5 S 9.3 ± 1.8 10 ± 3 a  −   0  5
DDWM/SLS 80/20 30.9 ± 4.9 b 82 ± 65 b 1.24 ± 1.43  3   5
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; Carb, Carbopol 974P; NaSF, sodium stearyl fumarate; NS, not sterilised; S, sterilised; -, below the 
detection limit. 
a For this end point, data are not significantly different from DDWM (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from DDWM/SLS 80/20 (p > 0.05, Scheffé test). 
 
6.6 DISCUSSION 
  
Irritation and damage of the eye can have serious consequences. Therefore, the 
evaluation of the local tolerance of formulations intended for repeated ocular administration is 
performed by academic, pharmaceutical and cosmetic research centres. The objective of this 
study was to optimise and evaluate the five-day procedure of the Slug Mucosal Irritation test 
(described in Chapter 5) for local tolerance testing of bioadhesive powder formulations 
intended for repeated ocular administration.  
It was investigated if a repeated treatment on five successive days was necessary by 
testing a negative control powder (DDWM), a positive control powder DDWM/BAC 95/5 
and powders containing DDWM and SLS in different ratios. The results demonstrated that a 
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repeated treatment on five successive days was necessary to obtain a good discrimination 
between the mucus productions and protein and enzyme release data of the negative and 
positive control slugs. Prolongation of the experiment was not useful, because the mortality of 
the slugs treated with severely irritating formulations would increase so that the end point 
range between non-irritating and irritating formulations would not further increase. 
Furthermore, the powder DDWM/SLS 80/20 was selected as replacement for DDWM/BAC 
95/5. 
Next, the influence of the amount of powder on the end points of the Slug Mucosal 
Irritation test was investigated in order to select the most suitable test amount. The results 
indicated that after treatment with 20 mg powder the largest difference between the negative 
and positive control was achieved for the mucus production. Based on this observation and on 
statistical analyses, 20 mg was selected as test amount to evaluate the local tolerance of 
powder formulations. It is interesting to note that 20 mg was also the amount that was used to 
evaluate the mucosal tolerance of nasal and buccal bioadhesive powder formulations in 
Chapter 5 and in previous studies (Adriaens, 2000; Callens et al., 2001).  
The optimised test procedure was used to evaluate the local tolerance of ingredients 
intended to prepare ocular minitablets. By means of the classification prediction model 
described in Chapter 5, DDWM, sodium stearyl fumarate, and Amioca® were classified as 
non-irritating ingredients because of the low total mucus production. Furthermore, low 
protein release and no enzyme release by the slugs treated with DDWM, sodium stearyl 
fumarate, and Amioca® indicated minimal tissue damage. For DDWM, the results obtained 
with the Slug Mucosal Irritation test were in agreement with clinical data. Ocular minitablets 
containing 94% DDWM were well accepted by human volunteers (Ceulemans et al., 2001). 
Based on the mucus production, ciprofloxacin HCl and gentamycin sulphate were 
classified as mildly irritating compounds. Furthermore, these ingredients induced minimal 
tissue damage as was indicated by low protein release and enzyme release below the detection 
limit. Little is known about the eye irritating properties of pure ciprofloxacin HCl and 
gentamicin sulphate, but ophthalmic preparations containing ciprofloxacin or gentamicin 
resulted only occasionally in eye irritation (see below).  
Vancomycin HCl and Carbopol® 974P induced a total mucus production comparable 
to the positive control slugs which is an indication of severe irritation. Furthermore, the 
increased protein release and LDH release of the slugs with Carbopol® 974P indicated that 
this compound causes moderate tissue damage. The irritation potential of vancomycin HCl 
and Carbopol® is also reported in animals and humans. Animal studies indicated that 
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vancomycin is irritating to eyes (Eli Lilly, 2004). Furthermore, an oral solution containing 
95% vancomycin HCl was identified as eye irritant (Eli Lilly, 2004). Carbopol® is often 
considered to be irritating for the eye (B.F. Goodrich, 1986). Furthermore, a single application 
of bioadhesive buccal tablets consisting of pure Carbopol® 934P caused small buccal lesions 
in 25% of 16 human volunteers; 44% of the volunteers had to remove the tablet due to 
irritation (Bottenberg et al., 1991).  
Taking into account these results, powder mixtures intended to prepare ocular 
minitablets were made. The local tolerance of DDWM/Carbopol® 974P/NaSF/ciprofloxacin 
HCl mixtures containing different ratios of ciprofloxacin and the local tolerance of 
Amioca®/Carbopol® 974P/NaSF/gentamycin sulphate/vancomycin HCl mixtures containing 
different ratios of Carbopol® 974P were evaluated using the optimised test procedure of the 
Slug Mucosal Irritation test. Powders containing DDWM, 5% Carbopol® 974P, 1% NaSF and 
up to 10% ciprofloxacin HCl were classified as non-irritating formulations based on the low 
mucus production of the slugs. Furthermore, enzyme release below the detection limit and 
low protein release induced by these powders indicated that treatment of the slugs with these 
powders caused minimal damage of the mucosa. No significant differences were detected 
between the non-sterilised and the sterilised powder mixtures. Ophthalmic formulations 
containing DDWM, 5% Carbopol®, 1% NaSF and/or 3.5% or more ciprofloxacin HCl were 
also described to be non-irritating to human and rabbit eyes. When ocular minitablets made of 
DDWM/Carbopol® 974P/NaSF/ciprofloxacin HCl 94/5/1/0 were applied three times to each 
of eight healthy volunteers, the general irritation score was low, indicating that the minitablet 
was well accepted by the volunteers (Ceulemans et al., 2001). A single application of an 
ocular insert containing 5% Carbopol® to rabbit eyes did not cause eye irritation (Gurtler et 
al., 1995). A single administration of an ocular minitablet made of DDWM/Carbopol® 
974P/NaSF/ciprofloxacin HCl 90.5/5/1/3.5 to six healthy volunteers demonstrated that the 
minitablets were well tolerated as was indicated by a low general irritation score (Weyenberg 
et al., 2004). A single application of a bioadhesive formulation containing 32.2% 
ciprofloxacin HCl resulted in minimal irritation of rabbit eyes. Moderate lacrimation observed 
during the study was ascribed to the nature of the formulation (Bhadra et al., 2004).  
A repeated treatment of the slugs with powder mixtures containing Amioca®, 1% 
NaSF, 5% gentamycin sulphate, 5% vancomycin HCl and 4.45% or 13.35% Carbopol® 974P 
resulted in mild irritation of the slug mucosa. The low protein release and enzyme release 
below the detection limit indicated that minimal damage of the slug mucosa occured. Because 
a single application of an ocular insert containing 25% gentamycin sulphate and 2.2% 
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Carbopol® 934P in the rabbit eye caused minimal irritation (Baeyens et al., 1998) on the one 
hand and co-spray dried Amioca®/Carbopol® 974P mixtures containing up to 15% Carbopol® 
974P induced no irritation of the slug mucosal tissue (Adriaens et al., 2003) on the other 
hand, the mild irritation potential of these powder mixtures is probably due to the presence of 
vancomycin HCl.  
The results of this study indicate that the Slug Mucosal Irritation test seems to be a 
promising alternative to evaluate the local tolerance of both ingredients of bioadhesive 
powder formulations and powder formulations intended for repeated ocular administration.  
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CHAPTER 7: EVALUATION OF MUCOSAL TOLERANCE 
OF SUPPOSITORIES 
 
 
 
 
 
 
7.1 INTRODUCTION 
 
The rectal route is not only interesting for achieving local action of drugs, but it is also 
a useful alternative administration route for systemic delivery of drugs when oral or invasive 
administration of medication is impractical or impossible (van Hoogdalem et al., 1991).  
Because administration of suppositories can cause rectal irritation on the one hand and 
irritation and damage of the rectal mucosa can break the protective barrier against micro-
organisms and noxious substances on the other hand, it is important that the local tolerance of 
suppositories is evaluated pre-clinically. 
 
7.2 RECTAL MUCOSA 
 
The human rectal mucosa is a simple columnar epithelium with goblet cells (van 
Hoogdalem et al., 1991; Marieb, 1995).  The lubricating mucus produced by the goblet cells 
eases the passage of faeces to the end of the digestive tract and protects the intestinal wall 
from irritating acids and gases released by bacteria in the colon (Marieb, 1995). The mucosa 
of the anal canal consists of a stratified squamous epithelium (van Hoogdalem et al., 1991; 
Marieb, 1995). The mucus produced in the anal canal aids in emptying the anal canal (Marieb, 
1995).   
 
7.3 EVALUATION OF RECTAL TOLERANCE OF FORMULATIONS 
 
The regulatory authorities require that the mucosal tolerance of medicinal products 
intended for rectal administration is evaluated by a repeated dose rectal tolerance test. Local 
tolerance testing is usually conducted in rabbits or dogs once or twice daily for at least seven 
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days. For this purpose, the definitive formulation consisting of the drug in its vehicle at the 
concentration intended for human use is administrated. During the treatment period, the 
animals are examined for clinical signs of irritation or pain and for anal discharge. After 
administration, the animals are sacrificed and the rectal mucosa is examined macroscopically 
and eventually microscopically (EC, 1990).   
Several pre-clinical in vivo and in vitro models have been used to study the local 
tolerance of rectal formulations or their ingredients. Histological changes of the rectal mucosa 
induced by repeated or single administration of suppositories or rectal gels have been 
investigated in vivo in rabbits (De Muynck et al., 1991; De Muynck et al., 1993; De Muynck 
et al., 1994; Stei et al., 1996; Watanabe et al., 1996; Yagahi et al., 2000; Berryman et al., 
2002; Peeters et al., 2004) or dogs (Berryman et al., 2002) by light microscopy. Rectal 
irritation and damage of rectally applied formulations or their ingredients have been 
investigated in mice and rats by light microscopy (Reid et al., 1987; Thomas et al., 1988; 
Oberle et al., 1995; Kinouchi et al., 1996; Phillips and Zacharapoulos, 1998; Miyake et al., 
2004) and/or the in vivo or in situ release of mucus, proteins and LDH from the rectal mucosa 
(Oberle et al., 1995; Miyake et al., 2004). The disruption of the rectal tissues induced by 
rectal administration of gels has been investigated in monkeys by microscopic examination of 
rectal lavage 15 minutes after the rectal application (Patton et al., 2002). Furthermore, the 
cytotoxicity of suppositories and their ingredients has been evaluated in vitro using Caco-2 
cells (Dash et al., 1999).  
 
7.4 OBJECTIVES 
 
The objective of the present study was to optimise and evaluate the five-day procedure 
of the Slug Mucosal Irritation test for the evaluation of the local tolerance of suppositories 
intended for repeated administration. The irritation and tissue damaging properties of the 
suppositories were evaluated after grinding the suppositories into powder with a pestle in a 
mortar. The influence of the amount of grinded suppository on the test end points was 
evaluated. For the selection of the test amounts, the contact surface between the slug mucosa 
and the grinded suppository was taken into account. Because 20 mg of grinded suppository 
takes up a smaller surface than 20 mg bioadhesive powder formulation, the contact surface 
between the slug mucosa and 20 mg grinded suppository would be too small. Consequently, it 
was opted to put the slugs on larger amounts of suppository (50 and 75 mg) than in case of 
bioadhesive powders. Furthermore, Novata® B was used as negative control. Several ratios of 
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Novata® B/SLS were tested as positive control. It was opted to use SLS to prepare the positive 
control suppositories, because SLS was also used for the preparation of the positive control 
powders in Chapter 6. 
Next, the repeatability of the optimised assay was assessed. For this purpose, the 
negative control and the positive control were tested on three separate occasions. Finally, the 
optimised test procedure was used to evaluate the local tolerance of suppositories. The 
classification prediction model developed for the determination of the irritation and tissue 
damage category of bioadhesive powders (described in Chapter 5) was used to classify the 
suppositories. 
 
7.5 MATERIALS AND METHODS 
 
7.5.1 Suppositories 
 
Novata® B suppositories consisted of pure Novata® B (Cognis, Dusseldorf, Germany), 
a glyceride base mainly consisting of C12-C14 glycerides (78.6% (w/w) triglycerides, 19.5% 
(w/w) diglycerides, and 1.9% (w/w) monoglycerides). Suppocire® AM suppositories were 
made of pure Suppocire® AM (Gattefossé, Saint-Priest, France), a glyceride base mainly 
consisting of C12-C14 glycerides (96.5% (w/w) triglycerides, 3.0% (w/w) diglycerides, and 
0.5% (w/w) monoglycerides). The hydrophilic PEG 1500/PEG 4000 3/7 (w/w) suppositories 
were prepared using 30% (w/w) polyethylene glycol 1500 (Sigma, St. Louis, MO, USA) and 
70% (w/w) polyethylene glycol 4000 (Sigma). Novata® B/SLS suppositories in ratios 95/5, 
90/10 and 80/20 (w/w) were prepared using Novata® B (Cognis) and sodium lauryl sulphate 
(SLS, Sigma).  
Colitofalk® 500 suppositories (n.v. Codali, Brussels, Belgium) contain 500 mg (or 
23% (w/w)) mesalazine and a fatty suppository base. Pentasa® suppositories (Ferring, Aalst, 
Belgium) are composed of 1 g (or 63% (w/w)) mesalazine, povidone, magnesium stearate, 
and PEG 6000. 
 
7.5.2 Local tolerance test procedure of the Slug Mucosal Irritation test 
 
The local tolerance of the suppositories was assessed according to the procedure 
described in Chapter 6. During five successive days, the slugs were placed on the (neat) 
grinded suppository for 30 minutes and the mucus production of the slugs was measured. One 
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and two hours after each of the five contact periods, the samples were collected. The samples 
were analysed immediately for the presence of proteins, LDH, and ALP released from the 
body wall of the slugs. 
 
7.5.3 Analytical procedures 
 
The protein, LDH, and ALP determinations were performed according to the 
analytical procedures described in Chapter 3. 
 
7.5.4 Data analysis 
 
For each slug, the total mucus production, mean protein release, mean LDH release 
and mean ALP release were calculated as described in the data analysis section of Chapter 5. 
These values were used for the statistical analyses using the computer program SPSS (version 
12.0; SPSS, Chicago, IL, USA). A p value < 0.05 was considered statistically significant.  
A two-way ANOVA was performed to investigate the test amount effect and 
formulation effect on the total mucus production and mean protein release. The data were 
tested for normal distribution with a Kolmogorov-Smirnov test. The homogeneity of 
variances was tested with the Levene’s test. If variances were unequal, the data were log-
transformed. Because no significant interaction was present for both end points, the main 
effects were interpreted separately from the interaction and a multiple comparison among 
pairs of means was performed using a Scheffé post hoc test.  
Statistically significant differences between repeated experiments or different 
treatments were determined using a one-way ANOVA. The normal distribution of the data 
and the homogeneity of variances were tested with the tests mentioned above. If the variances 
were found to be not equal, the data were transformed to their logarithm. To further compare 
the effects of the different experiments or treatments, a multiple comparison among pairs of 
means was performed using a Scheffé test.  
Using the cut-off values presented in Figures 5.1 and 5.2, the formulations were 
classified into one of the irritation and tissue damage categories. 
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7.6 RESULTS 
 
7.6.1 Optimisation of the test procedure  
 
The effect of the amount of suppository on the test end points was evaluated in order 
to select the most suitable amount. For this purpose, 50 and 75 mg of grinded suppositories 
consisting of neat Novata® B on the one hand and grinded Novata® B/SLS suppositories in 
ratios 95/5, 90/10 and 80/20 on the other hand were tested. All the slugs treated with the 
different amounts of Novata® B survived a repeated treatment on 5 successive days. A daily 
treatment with 50 mg of Novata® B/SLS 95/5 and 90/10 led to 20% and 60% mortality on day 
5, respectively. 40% of the slugs treated with 50 mg Novata® B/SLS 80/20 were dead on day 
3 and all the slugs were finally dead on day 4. Repeated treatment with 75 mg Novata® B/SLS 
95/5 and 90/10 resulted respectively in 40% and 100% mortality on day 5. All the slugs 
treated with 75 mg Novata® B/SLS 80/20 were already dead on day 3.  
For the total mucus production, two-way ANOVA testing revealed no significant 
interaction between the test amount and the suppository formulation (p = 0.252) (Table 7.1). 
The test amount had no significant effect on the total mucus production (p = 0.625). However, 
there was a significant main effect of the formulation (p < 0.001). Scheffé post hoc testing 
revealed that the total mucus production of slugs treated with Novata® B was significantly 
lower than the total mucus productions of the slugs treated with Novata® B/SLS ratios.  
 
Table 7.1 Influence of the test amount and the suppository formulation on the total amount of 
mucus produced by slugs during a repeated treatment on 5 successive days 
Formulation Total mucus production (%) 
 50 mg 75 mg Average formulation
Novata B 0.8 ± 1.4 2.4 ± 2.4 1.6 ± 2.0 a 
Novata B/SLS 95/5 29.3 ± 4.0 28.4 ± 2.7 28.8 ± 3.2 b 
Novata B/SLS 90/10 31.1 ± 6.0 34.2 ± 6.2 32.6 ± 6.0 b 
Novata B/SLS 80/20 33.5 ± 3.8 29.6 ± 3.3 31.5 ± 4.0 b 
Average test amount * 23.7 ± 14.1  23.6 ± 13.3    
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 10 and 20 slugs, respectively. 
Two-way ANOVA testing revealed no significant interaction and no significant test amount effect (p > 0.05), but 
a significant formulation effect (p < 0.05). 
a, b Same letter indicates no significant difference between the suppository formulations (p > 0.05, Scheffé test).  
* There are no significant differences between the mucus productions induced by the two test amounts (p > 0.05, 
Two-way ANOVA).  
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For the mean protein release, two-way ANOVA testing revealed no significant 
interaction between the test amount and the suppository formulations (p = 0.971) (Table 7.2). 
The test amount had no significant effect on the mean protein release (p = 0.080). However, 
there was a significant main effect of the formulation (p < 0.001). Scheffé post hoc testing 
suggested the following three homogeneous subsets for the mean protein release: (1) Novata® 
B, (2) Novata® B/SLS 95/5 and Novata® B/SLS 90/10, and (3) Novata® B/SLS 90/10 and 
Novata® B/SLS 80/20.  
 
Table 7.2 Influence of the test amount and the suppository formulation on the mean protein 
release induced by a repeated treatment of the slugs on 5 successive days 
Formulation Mean protein release (µg/ml.g) 
 50 mg 75 mg Average formulation
Novata B 10 ± 3 13 ± 7 12 ± 5 a 
Novata B/SLS 95/5 76 ± 38 135 ± 86 105 ± 70 b 
Novata B/SLS 90/10 153 ± 102 187 ± 68 170 ± 83 b, c 
Novata B/SLS 80/20 223 ± 117 320 ± 148 272 ± 136 c 
Average test amount * 116 ± 110  164 ± 141   
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 10 and 20 slugs, respectively. 
Two-way ANOVA testing revealed no significant interaction and no significant test amount effect (p > 0.05), but 
a significant formulation effect (p < 0.05). 
a, b, c Same letter indicates no significant difference between the suppository formulations (p > 0.05, Scheffé test).  
* There are no significant differences between the mean protein release data induced by the two test amounts (p 
> 0.05, Two-way ANOVA).  
 
For the slugs treated with 50 mg or 75 mg Novata B, the LDH release was under the 
detection limit. For the mean LDH release of the slugs treated with the different amounts of 
Novata B/SLS in different ratios, two-way ANOVA testing revealed also no significant 
interaction between the test amount and the suppository formulations (p = 0.899). The test 
amount (p = 0.377) and the formulation (p = 0.310) had no significant effect on the mean 
LDH release (data not shown). LDH release was detected after the 1st treatment with 50 or 75 
mg Novata B/SLS 95/5, 90/10 or 80/20. There were only two exceptions: (1) for treatment 
with 50 mg of Novata B/SLS 95/5 where LDH release was detected after the 3rd treatment 
and (2) for treatment with 75 mg of Novata B/SLS 90/10 where LDH release was detected 
after the 2nd treatment. LDH release increased with a repeated treatment. ALP release was 
only detected for one slug treated with 50 mg Novata B/SLS 95/5, 50 mg Novata B/SLS 
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80/20, 75 mg Novata B/SLS 95/5 or 75 mg Novata B/SLS 90/10 and for three slugs treated 
with 75 mg Novata B/SLS 80/20. ALP release occurred on the same day of LDH release or 
one day after LDH release. 
Because statistical analyses revealed no significant differences between the mucus 
productions and mean protein release data induced by 50 mg and 75 mg of the tested 
suppositories on the one hand and treatment with 75 mg of severely irritating and damaging 
suppositories resulted in a higher mortality, 50 mg was selected as test amount to evaluate the 
local tolerance of suppositories. Furthermore, Novata B was a good negative control, 
because the suppository base induced a low mucus production and protein release, and no 
enzyme release was detected. The Novata B/SLS 95/5, 90/10 and 80/20 suppositories 
induced a high mucus production, an increased protein release, and the release of enzymes. 
However, the protein release after a repeated treatment with 50 mg Novata B/SLS 95/5 was 
lower than protein release after treatment with 50 mg Novata B/SLS in ratios 90/10 and 
80/20. Furthermore, a repeated treatment with 50 mg Novata B/SLS 80/20 resulted in an 
early onset of mortality. Consequently, Novata B/SLS 90/10 was chosen as positive control.  
 
7.6.2 Repeatability of the test procedure and prediction model 
 
In order to investigate the repeatability of the test results obtained with the optimised 
test procedure for local tolerance testing of suppository formulations, the negative and 
positive control were tested independently on three separate occasions. Table 7.3 shows the 
total mucus production and mean protein and enzyme release of the negative control slugs 
measured in each of the repeated experiments and the mean of the three experiments. All the 
slugs treated with Novata B survived a repeated treatment on five successive days. For the 
negative control, Scheffé post hoc testing suggested two homogenous subsets for the total 
mucus production. One subset comprised only the total mucus production of the first 
experiment, whereas another subset contained the total mucus productions of the second and 
third experiment. However, no significant difference in mean protein release was detected 
between the repeated experiments (p > 0.05, One-way ANOVA). Based on the prediction 
models presented in Figures 5.1 and 5.2, Novata B was classified as a non-irritating and 
minimally damaging formulation in each of the repeated experiments.  
A daily treatment with Novata B/SLS 90/10 led to 60%, 100% and 0% mortality by 
day 5 in the first, second and third experiment, respectively. For the positive control, ANOVA 
testing revealed no significant difference in total mucus production, in mean protein release 
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and in mean LDH release between the repeated experiments (p > 0.05) (Table 7.4). Repeated 
treatment with Novata/SLS 90/10 resulted in severe irritation and damage of the slug mucosa 
in each of the three experiments. 
 
Table 7.3 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the negative control slugs treated with 50 mg Novata B on 5 
successive days 
Experiment 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Experiment 1 0.8 ± 1.4 a 10 ± 3  −  0   5
Experiment 2 3.6 ± 1.4 b 22 ± 22  −  0   4
Experiment 3 3.9 ± 1.2 b 7 ± 2  −  0   5
Inter-experiment mean 2.8 ± 1.7 13 ± 8 −    3
Total mucus production and mean protein release data are presented as the mean ± standard deviation of 4-5 
slugs; bold values represent the mean ± standard deviation of 3 experiments; -, below the detection limit. 
a, b For this end point, the values marked with the same superscript are not significantly different from each other 
(p > 0.05, Scheffé test). 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
 
Table 7.4 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the positive control slugs treated with 50 mg Novata /SLS 
90/10 on 5 successive days 
Experiment 
 
 
Total mucus 
production 
(%) * 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) * 
Number of slugs 
with ALP 
release 
n
Experiment 1 31.7 ± 6.0  153 ± 102 2.18 ± 1.92 0   5
Experiment 2 27.1 ± 5.7  238 ± 80  2.60 ± 2.05 0   5
Experiment 3 35.3 ± 4.3  110 ± 16  2.53 ± 0.80 4    5
Inter-experiment mean 31.1 ± 4.1 167 ± 65 2.44 ± 0.22   3
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation of 5 slugs; bold values represent the mean ± standard deviation of 3 experiments. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
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7.6.3 Evaluation of local tolerance of suppositories 
 
The local tolerance of four additional suppositories was evaluated by placing the slugs 
on 50 mg grinded suppository for 30 minutes on five successive days. All the slugs survived a 
repeated treatment with Novata® B, Suppocire® AM, Colitofalk®, Pentasa®, and PEG 
1500/PEG 4000 3/7. A daily treatment with Novata B/SLS 90/10 led to 60%, 100% and 0% 
mortality by day 5 in the first, second and third experiment, respectively. 
The effects of a daily treatment on the total mucus production, mean protein and 
enzyme release are presented in Table 7.5. The total mucus production of the slugs treated 
with Suppocire® AM or Colitofalk® was comparable to that of the negative control slugs (p > 
0.05, Scheffé test). Based on the prediction model presented in Figure 5.1, these suppositories 
were classified as non-irritating formulations. Slugs treated with Pentasa® or PEG 1500/PEG 
4000 3/7 produced significantly more mucus than the negative control slugs and significantly 
less mucus than the positive control slugs (p < 0.05, Scheffé test). Pentasa® was classified as a 
mildly irritating formulation, whereas PEG 1500/PEG 4000 3/7 was classified as a severely 
irritating formulation. 
 
Table 7.5 Effect of a repeated treatment for 5 successive days with 50 mg of different 
suppositories on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Novata B 2.8 ± 2.0 a 13 ± 13 a −  0  14
Suppocire AM 3.8 ± 1.1 a 6 ± 5 a −  0  5
Colitofalk 4.6 ± 0.8 a 14 ± 8 a −  0  5
Pentasa  8.7 ± 2.9 9 ± 3 a −  0  5
PEG 1500/PEG 4000 3/7 21.7 ± 2.7 11 ± 3 a −  0  5
Novata B/SLS 90/10 31.1 ± 6.1 b 167 ± 89 b 2.44 ± 1.57 4  15
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not significantly different from Novata® B (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from Novata® B/SLS 90/10 (p > 0.05, Scheffé test). 
 
A repeated treatment with Suppocire® AM, Colitofalk®, Pentasa® or PEG 1500/PEG 
4000 3/7 resulted in a protein release comparable to that of the negative control slugs (p > 
0.05, Scheffé test). Moreover, the release of LDH and ALP by slugs treated with these 
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suppositories was under the detection limit. Each of these suppositories was classified as a 
minimally damaging formulation.  
 
7.7 DISCUSSION 
 
A reliable and relevant alternative method for repeated dose rectal tolerance testing 
would be very useful to select non-irritating suppository formulations early in the 
development process. The objective of this study was to optimise and evaluate the five-day 
procedure of the Slug Mucosal Irritation test for local tolerance testing of suppositories 
intended for repeated administration.  
The influence of the amount of grinded suppository on the end points of the Slug 
Mucosal Irritation test was investigated. The statistical analyses revealed that treatment with 
50 mg and 75 mg of the tested suppositories did not result in statistical significant differences 
in the total mucus production and in the mean protein release. Because treatment with 75 mg 
of severely irritating and damaging suppositories resulted in a higher mortality, it was opted to 
select 50 mg as test amount to evaluate the local tolerance of suppositories. Furthermore, 
Novata B served well as negative control, because the suppository base induced a low mucus 
production and protein release, and no enzyme release was detected. Novata® B/SLS 90/10 
was selected as positive control, because it induced a high mucus production, a high protein 
release, and the release of enzymes.  
The optimised test procedure was used to evaluate the local tolerance of a few 
suppositories. When the classification prediction model developed for the determination of 
the irritation and tissue damage category of bioadhesive powders (described in Chapter 5) was 
used to classify the suppositories, Novata® B and Suppocire® AM were classified as non-
irritating formulations because of the low total mucus production. Furthermore, repeated 
treatment with Novata® B or Suppocire® AM caused minimal tissue damage as was 
demonstrated by low protein release and enzyme release below the detection limit. The total 
mucus production and mean protein release data of the slugs treated with Novata® B or 
Suppocire® AM were comparable to the ones of the negative control slugs described in 
Chapter 6. Fatty suppository bases are generally considered to be non-irritating to the rectal 
mucosa. Several authors reported that repeated rectal administration of suppositories 
containing semi-synthetic triglycerides did not provoke irritation of the rectal tissues of 
rabbits (Yahagi et al., 2000; Peeters et al., 2004), dogs (Neuwald and Meyer-Lohmann, 
1959), and rats (Reid et al., 1987; Thomas et al., 1988). Although most of the literature on the 
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irritation and damage properties of fatty suppository bases describes that they are non-
irritating, De Muynck et al. (1991) reported that a repeated treatment of rabbits with pure 
Novata® B or Suppocire® AM suppositories during 14 consecutive days unexpectedly caused 
severe mucosal damage. 
A repeated treatment of the slugs with Novata® B/SLS 90/10 resulted in a high mucus 
production (± 31%), indicating severe irritation of the slug mucosa. Furthermore, the high 
protein release and increased enzyme release of these slugs indicated that Novata® B/SLS 
90/10 caused also severe damage of the slug mucosa. The total mucus production, mean 
protein and enzyme release data of the slugs treated with Novata® B/SLS 90/10 were 
comparable to the ones of the positive control slugs described in Chapters 5 and 6. 
Colitofalk® suppositories (containing mesalazine and a fatty suppository base) were 
classified by the Slug Mucosal Irritation test as non-irritating formulations. Furthermore, 
repeated treatment with Colitofalk® resulted in low protein release and enzyme release below 
the detection limit, indicating that minimal tissue damage occurred. The results obtained with 
the Slug Mucosal Irritation test are in good agreement with available preclinical data. 
Berryman et al. (2002) reported that twice daily administration of suppositories containing 
500 mg mesalazine (similar to Colitofalk® suppositories) for 14 consecutive days to rabbits 
and dogs did not result in microscopically observable lesions of the rectum. 
A repeated treatment with Pentasa® suppositories (containing mesalazine and a PEG 
suppository base) induced mild irritation and minimal damage of the slug mucosa as was 
indicated by the mucus production, protein and enzyme release data. After administration of 
Pentasa® suppositories once daily during 14-21 days, 11% of 132 patients with active 
idiopathic proctitis reported pain or anal irritation. Three of the six patients that stopped 
treatment because of intolerance, reported anal or rectal burning as reason for treatment 
discontinuation. Notwithstanding the adverse events, the overall acceptability was rated as 
good or fair (Lucidarme et al., 1997). In another study, 77% of 125 patients with active 
cryptogenic proctitis reported that a once daily administration of Pentasa® suppositories for 
14-21 days was well tolerated (Marteau et al., 2000). It is interesting to note that the active 
substance in both Pentasa® and Colitofalk® suppositories is mesalazine. Pentasa® suppositories 
not only contain more mesalazine than Colitofalk® suppositories, but are also made of PEG, 
whereas the suppository base of Colitofalk® is a fatty base. The mild irritation potential of 
Pentasa® suppositories is probably due to the presence of PEG (see below).  
A repeated treatment with PEG 1500/PEG 4000 3/7 induced severe irritation of the 
slug mucosa as was indicated by the high total mucus production. However, the suppository 
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formulation induced minimal tissue damage as was demonstrated by a low protein release and 
no detectable enzyme release. Throughout the experiments, it became clear that (grinded) 
suppositories containing PEG absorb water present in the slug mucosa. The PEG mixture was 
namely solid before the 30 minute contact period, whereas the PEG mixture became fluid 
after contact with the slug mucosa. In contrast with the dehydration observed after treatment 
with bioadhesive powders such as DDWM (Chapters 5 and 6), the dehydration induced by 
treatment with the PEG suppositories was much more pronounced. Ito (1980) suggested that 
the absorption of water present in the rectal mucosa by PEG is responsible for the irritation 
potential of PEG containing suppositories. Several authors reported that single or repeated 
administration of PEG suppositories resulted in irritation of the rectal mucosa. A repeated 
treatment of rabbits with PEG 1500/PEG 4000 3/7 suppositories during 14 consecutive days 
resulted in severe mucosal damage with severe mucosal hyperemia, diffuse infiltration of 
granulocytes, erosion, regeneration of the mucosal damage, and inflammatory polyps (De 
Muynck et al., 1991). A single administration of PEG 1500/PEG 4000 1/3 suppositories to 
rabbits caused severe mucosal irritation with marked erosion and inflammatory cell 
infiltration of the lamina propria (Watanabe et al., 1996). A single administration of 2.5 g 
PEG 1000/PEG 4000 suppositories to rabbits resulted in severe irritation with erosion of the 
mucosa, whereas 1.2 g PEG 1000/PEG 4000 suppositories generated moderate to severe 
erythema (Peeters et al., 2004).  
The results of this study indicate that the Slug Mucosal Irritation test seems to be a 
promising alternative to evaluate the local tolerance of suppositories intended for repeated 
administration. However, it has to be noted that the relevance and reliability of the optimised 
assay have to be further evaluated with additional suppository formulations that have been 
evaluated for their rectal irritating and damaging properties in animals and/or humans. 
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CHAPTER 8: EVALUATION OF MUCOSAL TOLERANCE 
OF SEMI-SOLID VAGINAL FORMULATIONS 
 
Based on Dhondt, M.M.M., Adriaens, E. and Remon, J.P. (2004) and on Dhondt, M.M.M., 
Adriaens, E., Van Roey, J. and Remon, J.P. (2005). 
 
 
 
8.1 INTRODUCTION 
 
To date, research on novel vaginal formulations is focused on local or systemic 
delivery of microbicides, spermicides, hormones, anti-infectious agents, proteins, and 
peptides. Vaginal formulations may be applied frequently over a period of months or years. 
Frequent use of some vaginal formulations can induce mucosal irritation and damage of the 
vaginal epithelium (Roddy et al., 1993; Stafford et al., 1998). Vaginal inflammation and 
ulceration might increase the susceptibility to sexually transmitted pathogens upon sexual 
intercourse (Stephenson, 2000; Fichorova et al., 2001; Van Damme et al., 2002). Therefore, 
the safety and vaginal tolerance of newly developed pharmaceutical products are important 
issues to be addressed by manufacturers and drug licensing companies.  
The importance of an adequate safety assessment of vaginal formulations can be 
illustrated by the history of the non-ionic surfactant nonoxynol-9 (N-9). N-9 has been widely 
available as a contraceptive for many years and has been shown to be effective against a 
number of sexually transmitted pathogens in laboratory studies (Hicks et al., 1985; Harrison 
and Chantler, 1998). Unfortunately, the repeated vaginal application of N-9 in humans has 
been associated with irritation or disruption of the vaginal and cervical epithelia (Roddy et al., 
1993; Stafford et al., 1998), and with induction of an inflammatory response (Stafford et al., 
1998). Serious public health concerns have been raised by a recent phase II/III clinical trial 
that showed that a gel containing 3.5% N-9 (Advantage S®) may increase transmission of 
human immunodeficiency virus by causing lesions (Van Damme et al., 2002).  
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8.2 VAGINAL MUCOSA 
 
 The human vagina is lined with a stratified squamous epithelium (Marieb, 1995) 
which is predominantly non-keratinised (Thompson et al., 2001). Generally, no glands are 
present in the vaginal mucosa (Marieb, 1995; Beresford, 2005). Lubrication of the vaginal 
mucosa is provided by the cervical mucous glands (Marieb, 1995).  
 
8.3 EVALUATION OF VAGINAL TOLERANCE OF FORMULATIONS 
 
Regulatory authorities require that the mucosal tolerance of medicinal products 
intended for vaginal administration is evaluated by a repeated dose vaginal tolerance test. 
Local tolerance testing has to be conducted with the preparation being developed for human 
use (EC, 1990). It is generally recommended that both the active agent and the clinical 
formulation of the product are tested in a rabbit vaginal irritation model (standard 10-day 
application) early in the development process (IWGVM, 1996). During the treatment period, 
the animals are examined for clinical signs of irritation or pain and for vaginal discharge or 
bleeding. After administration, the animals are sacrificed and the vaginal mucosa is examined 
macroscopically and eventually microscopically (EC, 1990).   
Several pre-clinical in vivo and in vitro models have been developed to study the 
irritating and damaging properties of formulations and their ingredients on the vaginal 
epithelium. Because rabbits have a simple cuboidal or columnar epithelium that is highly 
sensitive compared to the stratified squamous epithelium of the human vagina (Eckstein et al., 
1969), they are frequently used for vaginal irritation tests (Eckstein et al., 1969; Chvapil et 
al., 1980; Kaminsky and Willigan, 1982; Balzarini et al., 1998; Gagné et al., 1999; D’Cruz et 
al., 2001; Zaneveld et al., 2001; Dhondt et al., 2005). Furthermore, histological changes of 
the vaginal mucosa induced by locally applied ingredients and formulations have been studied 
in vivo in mice (Neyts et al., 2000; Achilles et al., 2002; Milligan et al., 2002; Catalone et al., 
2004), rats (Chvapil et al., 1980; Kaminsky and Willigan, 1982), and non-human primates 
(Eckstein et al., 1969; Patton et al., 1998; Patton et al., 1999; Zaneveld et al., 2001) by light 
microscopy, scanning electron microscopy or by the release of markers.  
The cytotoxicity of vaginally applied products and their ingredients has also been 
studied in vitro by evaluation of cell viability, histological changes or release of marker 
compounds. For this, primary human vaginal keratinocytes (Krebs et al., 2000), immortalised 
human vaginal and cervical epithelial cells (Fichorova et al., 1997; Maguire et al., 2001; 
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Krebs et al., 2002) or reconstructed three dimensional human vaginal tissue (Kubilus et al., 
2002; SkinEthic, 2005) are exposed to the products of interest. The cytotoxic effects of 
ingredients of vaginal formulations have also been investigated by in vitro erythrocyte 
hemolysis (Fowler et al., 2003).  
 
8.4 OBJECTIVES 
 
In the present study, the five-day procedure of the Slug Mucosal Irritation test was 
optimised for the evaluation of the local tolerance of semi-solid vaginal formulations. It was 
determined if a repeated treatment on five successive days was necessary. The influence of 
the amount of semi-solid formulation on the end points of the test was evaluated. For this 
purpose, a gel containing 4.0% N-9 (Conceptrol®) was used as positive control like it is 
recommended by the International Working Group on Vaginal Microbicides (IWGVM, 
1996). Nowadays, there is no generally accepted negative control vaginal formulation 
available; hence two gels that possibly could serve as negative control were selected. On the 
one hand hydroxyethyl cellulose gel was chosen, because Ballagh et al. (2002) used this gel 
as a negative control product. On the other hand Replens® was selected, because it was used 
as placebo in placebo-controlled trials (Van Damme et al., 2000; Van Damme et al., 2002).  
Next, the repeatability of the optimised test procedure was assessed. For this purpose, 
the negative control and the positive control and some semi-solid vaginal formulations were 
tested on separate occasions. Finally, the optimised test procedure was used to evaluate the 
mucosal tolerance of semi-solid vaginal formulations that have been evaluated for the vaginal 
tolerance in animals and/or humans. Based on the results of this study on the one hand and on 
pre-clinical and clinical data on the other hand, a classification prediction model was 
developed for the determination of the irritation potential of semi-solid formulations.  
 
8.5 MATERIALS AND METHODS 
 
8.5.1 Semi-solid formulations 
 
5% Hydroxyethyl cellulose (HEC) gel consisted of 5.0% (w/w) HEC, 10% (w/w) 
glycerol, 0.07% (w/w) methylparaben, 0.02% (w/w) propylparaben, 0.8% (w/w) propylene 
glycol, and water. The gels containing dapivirine, a human immunodeficiency virus-specific 
vaginal microbicide, were kindly provided by Tibotec BVBA (Mechelen, Belgium). The gels 
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were made up of 2.0% HEC and contained 22.5 µM, 225 µM or 10 mM dapivirine. The 
placebo dapivirine gel contained the same ingredients with the exception of dapivirine. 
The over-the-counter (OTC) vaginal antifungal cream Monistat 7® (McNeil-PPC, 
Skillman, NJ, USA) contains 2% (w/w) miconazole nitrate, benzoic acid, cetyl alcohol, 
stearyl alcohol, isopropyl myristate, polysorbate 60, potassium hydroxide, propylene glycol, 
and purified water. The OTC vaginal lubricant Replens® (Columbia Laboratories, Hitchin, 
United Kingdom) contains carbomer, polycarbophil, glycerol, paraffin, hydrogenated palm oil 
glyceride, sorbic acid, sodium hydroxide, and 78.82% (w/w) purified water. K-Y® jelly 
(McNeil-PPC) is an OTC vaginal lubricant that is composed of chlorhexidine gluconate, 
HEC, glucono delta lactone, glycerol, methylparaben, sodium hydroxide, and purified water. 
The vaginal contraceptive Gynol II® (McNeil-PPC) contains 2.0% N-9, sodium 
carboxymethylcellulose, povidone, propylene glycol, sorbitol solution, sorbic acid, 
methylparaben, lactic acid, and purified water. Gynol II® Extra Strength (McNeil-PPC) is a 
vaginal contraceptive gel that is composed of 3.0% N-9, sodium carboxymethylcellulose, 
povidone, propylene glycol, sorbitol solution, sorbic acid, methylparaben, lactic acid, and 
purified water. The OTC vaginal contraceptive gel Advantage S® (Columbia Laboratories, NJ, 
USA) uses Replens® as a vehicle base and contains 3.5% N-9, carbomer 934P, polycarbophil, 
glycerol, paraffin, hydrogenated palm oil glyceride, methylparaben, sorbic acid, sodium 
hydroxide, and purified water. Protectaid® (Pirri Pharma Canada Inc., Montreal, Canada) is an 
OTC contraceptive sponge that is impregnated with a gel containing 0.125% N-9, 0.125% 
benzalkonium chloride, 0.5% sodium cholate, hydroxypropyl methylcellulose, glycerol, 
dimethicone, and purified water. The OTC vaginal contraceptive foam Delfen® (McNeil-PPC) 
contains 12.5% N-9, sodium carboxymethylcellulose, benzoic acid, cetyl alcohol, acetic acid, 
perfume, phosphoric acid, polyvinyl alcohol, propellant A-31, propylene glycol, 
stearamidoethyl diethylamine, stearic acid, sorbic acid, methylparaben, and purified water. 
Conceptrol® gel (McNeil-PPC) is an OTC vaginal contraceptive gel containing 4.0% N-9, 
sodium carboxymethylcellulose, propylene glycol, methylparaben, povidone, sorbitol 
solution, sorbic acid, lactic acid, and purified water. 
 
8.5.2 Local tolerance test procedure of the Slug Mucosal Irritation test 
 
The local tolerance of the semi-solid vaginal formulations was assessed according to 
the procedure described in Chapter 6. During five successive days, the slugs were placed on 
the neat semi-solid formulation for 30 minutes and the mucus production of the slugs was 
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measured. One and two hours after each of the five contact periods, the samples were 
collected. The samples were analysed immediately for the presence of proteins, LDH, and 
ALP released from the body wall of the slugs. 
  
8.5.3 Analytical procedures 
 
 The protein, LDH, and ALP determinations were performed according to the 
analytical procedures described in Chapter 3. 
 
8.5.4 Data analysis  
 
For each slug, the total mucus production, mean protein release, mean LDH release 
and mean ALP release were calculated as described in the data analysis section of Chapter 5. 
These values were used for the statistical analyses using the computer program SPSS (version 
12.0; SPSS, Chicago, IL, USA). A p value < 0.05 was considered statistically significant.  
A two-way ANOVA was performed to investigate the test amount effect and 
formulation effect on the total mucus production and mean protein release. The data were 
tested for normal distribution with a Kolmogorov-Smirnov test. The homogeneity of 
variances was tested with the Levene’s test. If variances were unequal, the data were log-
transformed. Because a significant interaction between both factors was present for the total 
mucus production, the test amount effect for each formulation and the formulation effect for 
each test amount were investigated with a Bonferroni post hoc test. No significant interaction 
was present for the mean protein release. Consequently, the main effects were interpreted 
separately from the interaction and a multiple comparison among pairs of means was 
performed using a Scheffé post hoc test.  
Statistically significant differences between repeated experiments or different 
treatments were determined using a one-way ANOVA. The normal distribution of the data 
and the homogeneity of variances were tested with the tests mentioned above. If the variances 
were found to be not equal, the data were transformed to their logarithm. To further compare 
the effects of the different experiments or treatments, a multiple comparison among pairs of 
means was performed using a Scheffé test.  
Using the cut-off values presented in Figure 5.2, the formulations were classified into 
one of the tissue damage categories. Based on in-house experience, cut-off values were 
established for the classification of semi-solid formulations into irritation categories. 
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8.6 RESULTS 
 
8.6.1 Optimisation of the test procedure 
 
The procedure was optimised for the evaluation of semi-solid vaginal formulations by 
testing several amounts (50, 100, 150, and 200 mg) of two gels that possibly could serve as 
negative control (HEC gel and Replens®) and a positive control gel containing 4.0% N-9 
(Conceptrol®). All the slugs treated with the different amounts of HEC gel and Replens® 
survived a repeated treatment on five successive days. A daily treatment with 50 mg or 100 
mg of Conceptrol® led to 20% mortality on day 5. 60% of the slugs treated with 150 mg or 
200 mg Conceptrol® were dead on day 4 and all the slugs were finally dead on day 5.  
Firstly, the data were analysed in order to find out if a repeated treatment on five 
successive days was necessary. The mucus production profiles of the slugs treated with 50 mg 
of each gel were comparable to those of the slugs treated with 100 mg of the same gel, hence 
only the latter are shown in Figure 8.1 (left graph). The mucus production profiles after 
treatment with 200 mg gel were similar to those of 150 mg gel and are presented in Figure 8.1 
(right graph). Figure 8.1 illustrates that one treatment did not suffice to make a distinction 
between the mucus productions induced by the three gels. For the total mucus production, 
discrimination between the mucus productions of the slugs treated with the three gels became 
more pronounced after a repeated treatment and the best discrimination could be made after 
five treatments.  
Only the protein release profiles after treatment with 100 mg gel are shown (Figure 
8.2). After the first treatment, all gels induced a high protein release. However, from the 
second day on HEC gel and Replens® resulted in low protein release levels comparable to the 
ones of the negative control slugs in previous studies (Chapters 5, 6 and 7). The protein 
release by the Conceptrol® slugs increased with a repeated treatment. For the end point 
protein release, the best discrimination between the different semi-solid formulations could 
also be made after five successive treatments.  
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Figure 8.1  Total mucus production of the slugs treated with 100 mg (left graph) and 200 mg 
(right graph) HEC gel (●), Replens® (○) or Conceptrol® (▲) for 5 successive days. 
Data points are presented as the mean values (n = 5) and standard deviation bars are 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2  Mean protein release of the slugs treated with 100 mg HEC gel (●), Replens® (○) or 
Conceptrol® (▲) for 5 successive days. Data points are presented as the mean values 
(n = 5) and standard deviation bars are indicated. 
 
Enzyme release was only detected for the slugs treated with Conceptrol. 50 mg 
Conceptrol induced LDH release after the third contact period. Amounts of 100 mg 
Conceptrol and more resulted in LDH release after the second contact period. ALP release 
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appeared one day after LDH release except for 150 mg Conceptrol that induced ALP release 
after the second contact period. Figure 8.3 illustrates that the LDH and ALP release induced 
by Conceptrol increased with a repeated treatment. 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 8.3  Mean LDH release (▲) and ALP release (∆) of the slugs treated with 100 mg 
Conceptrol® for 5 successive days. Data points are presented as the mean values (n = 
5) and standard deviation bars are indicated. 
 
The results indicated that with respect to the irritation and tissue damage potential, the 
best discrimination between the different semi-solid formulations can be made after a 
repeated treatment on five successive days. As described in Chapter 6, prolongation of the 
experiment was not useful, because the mortality of the slugs treated with irritating 
formulations would increase. 
Next, the effect of the amount of semi-solid formulation on the end points of the test 
was evaluated (Table 8.1). For the total mucus production, two-way ANOVA testing revealed 
a significant interaction between the test amount and the semi-solid formulation (p = 0.029). 
Firstly, a Bonferroni post hoc analysis was performed to investigate the test amount effect for 
each formulation. Bonferroni testing revealed (1) that the total mucus production induced by 
50 mg and 100 mg of 5% HEC gel was significantly lower than the total mucus production 
induced by 150 mg and 200 mg of this gel, (2) that the total mucus production induced by 50 
mg of Replens® was significantly lower than the mucus production induced by 150 mg and 
200 mg of this gel and (3) that the total mucus productions induced by the four test amounts 
of Conceptrol® were not significantly different. Furthermore, a Bonferroni post hoc analysis 
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was performed to investigate the formulation effect for each test amount. Bonferroni testing 
revealed that the total mucus production of slugs treated with 50 mg or 100 mg of 5% HEC 
gel or Replens® was significantly lower than the total mucus productions of the slugs treated 
with the corresponding amount of Conceptrol®. However, neither the total mucus productions 
of the slugs treated with 150 mg of the three gels, nor the total mucus productions of the slugs 
treated with 200 mg of the three gels were significantly different. The largest difference in 
mucus production between the slugs exposed to Conceptrol® and the other two gels was 
obtained when the slugs were placed on 100 mg gel. 
 
Table 8.1 Influence of the test amount and the semi-solid formulation on the total amount of 
mucus produced by slugs during a repeated treatment on 5 successive days 
Formulation Total mucus production (%) 
 50 mg 
 
100 mg 150 mg 200 mg Average 
formulation 
5% HEC gel 11.4 ± 2.3 a, c 13.4 ± 3.1 a, c 19.0 ± 1.9 b, c 21.1 ± 1.3 b, c 16.2 ± 4.5 
Replens 14.0 ± 1.6 a, c 16.6 ± 2.7 a, b, c 19.9 ± 3.6 b, c 20.6 ± 1.6 b, c 17.7 ± 3.6 
Conceptrol 20.5 ± 5.3 a, d  24.6 ± 5.3 a, d 22.5 ± 4.2 a, c 25.0 ± 2.2 a, c 23.1 ± 4.5 
Average test amount 15.3 ± 5.1 18.2 ± 6.1 20.5 ± 3.5 22.2 ± 2.6   
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 20 and 15 slugs, respectively. 
Two-way ANOVA testing revealed a significant interaction and a significant test amount and formulation effect 
(p < 0.05). 
a, b For this formulation, total mucus productions marked with the same superscript are not significantly different 
from each other (p > 0.05, Bonferroni test).  
c, d For this test amount, total mucus productions marked with the same superscript are not significantly different 
from each other (p > 0.05, Bonferroni test).  
 
Table 8.2 shows that treatment with each of the amounts of HEC gel and Replens® 
resulted in low protein release, whereas treatment with an increasing amount of Conceptrol® 
induced increased protein release. For the mean protein release, two-way ANOVA testing 
revealed no significant interaction between the test amount and the semi-solid formulation (p 
= 0.707). The test amount had no significant effect on the mean protein release (p = 0.140). 
However, there was a significant main effect of the formulation (p < 0.001). Scheffé post hoc 
testing suggested that treatment with Conceptrol® induced a significantly increased protein 
release compared to HEC gel and Replens®. Treatment of the slugs with different amounts of 
Conceptrol® resulted in comparable mean LDH release data and in comparable ALP release 
data (One-way ANOVA, p > 0.05). 
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Table 8.2 Influence of the test amount and the semi-solid formulation on the mean protein 
release induced by a repeated treatment of the slugs on 5 successive days 
Formulation Mean protein release (µg/ml.g) 
 50 mg 
 
100 mg 150 mg 200 mg Average 
formulation 
5% HEC gel 11 ± 5  10 ± 4  12 ± 8  17 ± 12  13 ± 8 a 
Replens 17 ± 9 20 ± 15  21 ± 13  23 ± 18  20 ± 13 a 
Conceptrol 144 ± 102  233 ± 69  228 ± 151  306 ± 92  228 ± 115 b 
Average test amount * 57 ± 84  88 ± 113 92 ± 135  115 ± 148    
Values are the mean ± standard deviation of 5 slugs; bold values in column and row represent the mean ± 
standard deviation of 20 and 15 slugs, respectively. 
Two-way ANOVA testing revealed no significant interaction and no significant test amount effect (p > 0.05), but 
a significant formulation effect (p < 0.05). 
a, b Same letter indicates no significant difference between the semi-solid formulations (p > 0.05, Scheffé test).  
* There are no significant differences between the mean protein release data induced by the four test amounts (p 
> 0.05, Two-way ANOVA).  
 
Based on the fact that the largest difference between the mucus productions induced 
by the three semi-solid formulations was obtained when the slugs were placed on 100 mg gel 
and on the fact that the statistical analyses revealed no significant differences between the 
protein release data induced by the four test amounts, 100 mg was selected as test amount to 
evaluate the local tolerance of semi-solid formulations. Furthermore, Conceptrol was a good 
positive control, because the gel induced a high mucus production, a high protein release, and 
enzyme release. 5% HEC gel and Replens® induced a low mucus production and protein 
release, and no enzyme release was detected. Because 5% HEC gel induced a (non-
significantly) lower mucus production than Replens, 5% HEC gel was chosen as negative 
control.  
 
8.6.2 Repeatability of the test procedure  
 
In order to investigate the repeatability of the test results obtained with the optimised 
test procedure for local tolerance testing of semi-solid vaginal formulations, the negative 
control and the positive control were tested independently on three separate occasions. Table 
8.3 shows the total mucus production and mean protein and enzyme release of the negative 
control slugs measured in each of the repeated experiments and the mean of the three 
experiments. All the slugs treated with 5% HEC gel survived a repeated treatment on five 
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successive days. For the negative control, ANOVA testing revealed no significant difference 
in total mucus production and in mean protein release between the repeated experiments (p > 
0.05).  
 
Table 8.3 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the negative control slugs treated with 100 mg HEC gel on 5 
successive days 
Experiment 
 
 
Total mucus 
production 
(%) * 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release  
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
Experiment 1 13.4 ± 3.1 10 ± 4 −  0   5
Experiment 2 12.9 ± 2.6 6 ± 6 −  0   5
Experiment 3 12.2 ± 1.3 8 ± 7 −  0   5
Inter-experiment mean 12.9 ± 0.6 8 ± 2 −    3
Total mucus production and mean protein release data are presented as the mean ± standard deviation of 5 slugs; 
bold values represent the mean ± standard deviation of 3 experiments; -, below the detection limit. 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
 
A daily treatment with Conceptrol led to 20%, 0% and 60% mortality by day 5 in the 
first, second and third experiment, respectively. The total mucus production of the slugs 
treated with Conceptrol in the second experiment was significantly higher than that of the 
slugs in the first and third experiment (Scheffé test, p < 0.05) (Table 8.4). For the positive 
control, ANOVA testing revealed no significant difference in mean protein release and in 
mean LDH release between the repeated experiments (p > 0.05).  
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Table 8.4 Intra- and inter-experiment variability for the total mucus production, mean protein 
and enzyme release of the positive control slugs treated with 100 mg Conceptrol on 5 
successive days 
Experiment 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) * 
Mean LDH 
release       
(IU/l.g) * 
Number of slugs 
with ALP 
release 
n
Experiment 1 24.6 ± 5.3 a 233 ± 69 6.0 ± 1.5 5  5
Experiment 2 37.9 ± 5.7 b 147 ± 63 4.2 ± 4.2 5  5
Experiment 3 27.6 ± 3.3 a 228 ± 148 2.7 ± 2.2 3   5
Inter-experiment mean 30.0 ± 7.0 202 ± 48 4.3 ± 1.7    3
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation of 5 slugs; bold values represent the mean ± standard deviation of 3 experiments. 
a, b For this end point, the values marked with the same superscript are not significantly different from each other 
(p > 0.05, Scheffé test). 
* For this end point, there are no significant differences between the test results of the repeated experiments (p > 
0.05, One-way ANOVA). 
 
8.6.3 Evaluation of local tolerance of semi-solid vaginal formulations 
 
The local tolerance of semi-solid vaginal formulations was evaluated by placing the 
slugs on 100 mg semi-solid formulation for 30 minutes during five successive days. All the 
slugs survived a repeated treatment with 5% HEC gel, Monistat 7®, placebo dapivirine gel, 
22.5 µM dapivirine gel, 225 µM dapivirine gel, 10 mM dapivirine gel, Replens®, K-Y® jelly, 
Gynol II®, Advantage S®, Protectaid® or Gynol II® Extra Strength. A repeated treatment with 
Delfen® caused 20% mortality by day 5. A daily treatment with Conceptrol led to 20%, 0% 
and 60% mortality by day 5 in the first, second and third experiment, respectively.   
Placebo dapivirine gel, Replens®, Gynol II®, Protectaid®, and Gynol II® Extra Strength 
were tested independently on two or more separate occasions. ANOVA testing resulted in no 
significant differences in the total mucus production, in mean protein release, and in mean 
LDH release between the repeated experiments (p > 0.05).  
The effects of a repeated treatment on the total mucus production, mean protein and 
enzyme release are presented in Table 8.5. Slugs treated with Monistat 7®, placebo dapivirine 
gel, 22.5 µM dapivirine gel, 225 µM dapivirine gel, 10 mM dapivirine gel or Replens® 
produced an amount of mucus comparable to that of the negative control slugs treated with 
5% HEC gel (p > 0.05, Scheffé test). K-Y® jelly, Gynol II®, Advantage S®, Protectaid®, Gynol 
II® Extra Strength, and Delfen® induced a mucus production that was comparable to the 
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mucus production of the positive control slugs treated with Conceptrol (p > 0.05, Scheffé 
test).  
The protein release of the slugs treated with Monistat 7®, placebo dapivirine gel, 22.5 
µM dapivirine gel, 225 µM dapivirine gel, 10 mM dapivirine gel, Replens®, K-Y® jelly or 
Advantage S® was comparable to that of the negative control slugs (p > 0.05, Scheffé test). 
Gynol II® and Protectaid® induced a protein release that was significantly higher than the 
protein release of the negative control slugs, but significantly lower than the protein release of 
the positive control slugs (p < 0.05, Scheffé test). The protein release of the slugs treated with 
Gynol II® Extra Strength or Delfen® was comparable to that of the positive control slugs (p > 
0.05, Scheffé test). Slugs treated with Gynol II®, Protectaid®, Gynol II® Extra Strength, 
Delfen® or Conceptrol also released LDH and ALP. The mean LDH release of the slugs 
treated with Delfen® was comparable to the mean LDH release of the positive control slugs (p 
> 0.05, Scheffé test). 
 
Table 8.5 Effect of a repeated treatment for 5 successive days with 100 mg of different semi-
solid vaginal formulations on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
5% HEC gel  12.9 ± 2.3 a 8 ± 6 a −  0  15
Monistat 7  9.8 ± 1.2 a 5 ± 3 a −  0  5
Placebo dapivirine gel 13.3 ± 2.1 a 15 ± 6 a −  0  10
22.5 µM Dapivirine gel 10.6 ± 1.4 a 16 ± 8 a −  0  4
225 µM Dapivirine gel 10.0 ± 2.2 a 12 ± 3 a −  0  5
10 mM Dapivirine gel 12.0 ± 1.7 a 11 ± 4 a −  0  5
Replens 17.9 ± 2.4 a 16 ± 15 a −  0  15
K-Y jelly  20.9 ± 2.3 b 5 ± 2 a −  0  5
Gynol II  23.4 ± 4.3 b 37 ± 26 0.5 ± 0.4 3  10
Advantage S 32.3 ± 1.4 b 31 ± 29 a −  0  5
Protectaid 25.8 ± 6.6 b 36 ± 31 0.3 ± 0.3 4  10
Gynol II Extra Strength  27.7 ± 5.5 b 67 ± 45 b 1.0 ± 1.1 5  10
Delfen 46.6 ± 9.7 b 241 ± 146 b 4.4 ± 3.0 b 4  5
Conceptrol 30.0 ± 7.4 b 202 ± 102 b 4.3 ± 3.0 b 13 15
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not statistically different from 5% HEC gel (p > 0.05, Scheffé test).  
b For this end point, data are not statistically different from Conceptrol® (p > 0.05, Scheffé test). 
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8.6.4 Development of prediction model 
 
Based on the results of this study on the one hand and on pre-clinical and clinical 
safety data on the other hand, a classification prediction model was developed for the 
determination of the irritation category of semi-solid formulations. Semi-solids that induce a 
low total mucus production (< 15%) are classified as non-irritating. Semi-solids that cause a 
mucus production between 15% and 20% are predicted as mildly irritating formulations. 
Semi-solid formulations that result in 20% to 25% mucus production are classified as 
moderately irritating semi-solids, whereas semi-solids that cause ≥ 25% mucus production are 
classified as severely irritating (Figure 8.4) (Adriaens et al., 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 8.4 Classification prediction model for the determination of the irritation category of 
semi-solid formulations. The total mucus production is calculated after a repeated 30-
minute treatment of A. lusitanicus on five successive days with 100 mg semi-solid 
formulation. (Based on Adriaens et al., 2004) 
 
8.7 DISCUSSION 
 
The vaginal route offers a promising approach for the administration of for instance 
microbicides and spermicides. Frequent use of some vaginal formulations can damage the 
vaginal epithelium (Roddy et al., 1993; Stafford et al., 1998). Mucosal irritation and damage 
might favour the entry of sexually transmitted pathogens (Stephenson, 2000; Fichorova et al., 
2001; Van Damme et al., 2002). Therefore, pre-clinical safety studies that document the 
safety and local tolerance of newly developed vaginal formulations are required by regulatory 
authorities. The objective of this study was to optimise and evaluate the five-day procedure of 
the Slug Mucosal Irritation test for local tolerance testing of semi-solid vaginal formulations.  
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It was investigated if a repeated treatment on five successive days was necessary by 
testing two semi-solid formulations that possibly could serve as negative control (5% HEC 
gel and Replens®) and a positive control semi-solid formulation (Conceptrol®). The results 
showed that a repeated treatment on five successive days was necessary to obtain a good 
discrimination between the mucus production, protein release and enzyme release data of the 
slugs exposed to HEC gel or Replens® on the one hand and the data of the slugs treated with 
Conceptrol® on the other hand. 
Next, the influence of the amount of semi-solid formulation on the end points of the 
Slug Mucosal Irritation test was investigated. Based on the fact that the largest difference 
between the total mucus productions induced by the three semi-solid formulations was 
obtained when the slugs were placed on 100 mg gel and on the fact that the statistical analyses 
revealed no significant differences between the mean protein release data induced by the four 
test amounts, 100 mg was selected as test amount to evaluate the local tolerance of semi-solid 
formulations.  
The results obtained with the Slug Mucosal Irritation test were compared with 
available in vivo (pre-) clinical local tolerance data. Based on the results of this study on the 
one hand and on pre-clinical and clinical data on the other hand, a classification prediction 
model was developed for the determination of the irritation potential of semi-solid 
formulations. As mentioned previously, the major obstacle to interpreting the available 
clinical data was the difference in study design. Furthermore, genital lesions were often 
assessed by means of colposcopy which is a visual diagnostic tool with several limitations 
(Van Damme et al., 2000).  
Slugs treated with 5% HEC gel produced a low amount of mucus in each of the three 
experiments, indicating that no irritation of the slug mucosa occurred. Furthermore, repeated 
treatment with 5% HEC gel caused minimal tissue damage as was demonstrated by low 
protein release and enzyme release below the detection limit. 5% HEC gel was selected as 
negative control. Indeed, the non-irritating properties of HEC gel were reported by several 
authors. Ballagh et al. (2002) reported that vaginal application of HEC gel once daily for 
seven consecutive days by 20 sexually inactive women resulted in genital heat and burning in 
5% of the cases. 10% of the women reported itching. Colposcopic examination revealed no 
serious lesions that were not related to applicator use. HEC gel was found to be acceptable in 
that study (Ballagh et al., 2002). Furthermore, microscopic examination of the vaginal and 
cervical tissues of five rabbits treated intravaginally for 10 consecutive days with a placebo 
gel containing 2% HEC revealed an intact epithelium and the lack of leukocyte influx. It was 
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concluded that intravaginal administration of HEC gel to rabbits did not cause vaginal 
irritation (Dhondt et al., 2005). 
A repeated treatment of the slugs with Conceptrol® resulted in high mucus production 
in each of the three repeated experiments, indicating severe irritation of the slug mucosa. 
Furthermore, the high protein release and increased LDH and ALP release of these slugs 
indicated that Conceptrol® caused severe damage of the slug mucosa. Because it is 
recommended that a gel containing 4.0% N-9 is used as a positive control in the rabbit vaginal 
irritation model (IWGVM, 1996), Conceptrol® was selected as positive control for mucosal 
tolerance testing of semi-solid vaginal formulations with the Slug Mucosal Irritation test. 
Several in vivo studies showed vaginal irritation and damage after single or repeated use of 
Conceptrol®. A single vaginal application of Conceptrol® resulted in the entry of 
inflammatory leukocytes into the vagina of mice within four hours (Milligan et al., 2002). 
Intravaginal administration of Conceptrol® to five rabbits once daily for 10 consecutive days 
caused epithelial loss and atrophy and leukocyte infiltration in the vaginal and cervical tissues 
(Dhondt et al., 2005). When monkeys were treated daily for three days, not treated for two 
days and then treated for three additional days with Conceptrol®, epithelial disruption and 
inflammatory response were noted (Patton et al., 1999). Twice daily use of Conceptrol® for 
14 days by 90 sexually active women resulted in genital burning and itching in 8% and 19% 
of the cases, respectively; epithelial disruptions were observed in 13% of the women 
(Hoffman et al., 2004). Poindexter et al. (1996) reported that the use of Conceptrol® by 31 
sexually inactive women once daily for seven consecutive nights caused cervical redness in 
19% of the subjects and a combination of redness and ulceration in 7% of the women. 
Monistat® 7 Vaginal Cream (containing 2% (w/w) miconazole nitrate) did not irritate 
the slug mucosa, as was indicated by an amount of mucus comparable to that of the negative 
control slugs. Furthermore, the formulation was classified as a minimally tissue damaging 
formulation by the Slug Mucosal Irritation test. The results obtained with the Slug Mucosal 
Irritation test are in good agreement with clinical data. Only 2% of 114 women suffering from 
vulvovaginal candidiasis that applied a vaginal cream containing 2% miconazole nitrate once 
daily for seven days complained of increased vulvovaginal irritation (burning and itching) 
(Brown et al., 1999). Upmalis et al. (2000) described two studies that evaluated the safety of 
vaginal application of Monistat® 7 Vaginal Cream once daily for seven successive days by 
265 patients suffering from vulvovaginal candidiasis. Less than 10% of all adverse events 
(such as vaginal irritation or burning) were considered to be treatment-related.  
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The placebo dapivirine gel and the 22.5 µM, 225 µM and 10 mM dapivirine gels (each 
containing 2% HEC) were classified as non-irritating formulations based on the mucus 
production of the slugs. Furthermore, repeated treatment with these gels resulted in minimal 
damage of the slug mucosa. These data are in good agreement with results obtained with the 
rabbit vaginal irritation test. Microscopic examination of the vaginal and cervical tissues of 
rabbits treated intravaginally once daily for 10 successive days with these gels revealed an 
intact vaginal and cervical epithelium and no leukocyte infiltration. Each of the gels was 
considered to be non-irritating to the rabbit vaginal tissue (Dhondt et al., 2005). 
Based on the results of the Slug Mucosal Irritation test, Replens® was classified as a 
mildly irritating formulation that causes minimal tissue damage. On the one hand, Replens® is 
considered to be safe and without adverse effects on the vaginal or cervical mucosa. After a 
daily administration of Replens® for 10 consecutive days to one rabbit, light microscopic 
examination revealed a normal non-keratinised squamous epithelium (Balzarini et al., 1998). 
On the other hand, application of Replens® once daily for 14 consecutive days by 178 healthy 
sexually active women resulted in genital itching and vaginal discharge in 9% and 19% of the 
women, respectively. Treatment with Replens® induced a higher incidence of oedema than the 
no-treatment control group. Notwithstanding these results, it was concluded that Replens® 
was fairly innocuous (Van Damme et al., 1998).  
Based on the slug mucus production, protein and enzyme release data, K-Y® jelly was 
classified as a moderately irritating formulation that induces minimal tissue damage. The 
moderate irritation of the mucosal tissue might be due to the presence of chlorhexidine 
gluconate, because a single 15-minute exposure to a 0.5% chlorhexidine gluconate gel 
damaged a major portion of the vaginal epithelium of mice (Achilles et al., 2002). Vaginal 
administration of K-Y® jelly to rabbits for 10 consecutive days has also been shown to cause 
mild irritation to the vagina (personal communication, Emilia Lonardo, Personal Products 
Company, 2000) (Mauck et al., 2001). Vaginal application of K-Y® jelly by 12 healthy 
sexually inactive women once daily for six successive nights resulted in product-related 
colposcopic findings (disruption of epithelium or blood vessels) in 25% of the women. The 
colposcopic findings and signs of irritation reported during follow-up were lower than in the 
Conceptrol® group (Mauck et al., 2001).  
A repeated treatment of the slugs with Gynol II® resulted in moderate irritation of the 
slug mucosa. Furthermore, the mean protein release of the slugs treated with Gynol II® was 
significantly higher than that of the negative control slugs, but significantly lower than that of 
the positive control slugs. Gynol II® was classified as a mildly tissue damaging formulation. 
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The irritating and tissue damaging properties of Gynol II® are probably due to the presence of 
2% N-9 and are also reported by Ballagh et al. (2002). Vaginal application of Gynol II® once 
daily for seven consecutive days by 20 sexually inactive women resulted in genital heat or 
burning in 25% of the cases. 40% of the women reported itching. Colposcopic examination 
revealed serious vaginal lesions that were not related to applicator use (multiple areas of 
epithelial loss) in 10% of the women (Ballagh et al., 2002).  
Treatment of the slugs with Advantage S® (containing 3.5% N-9) induced severe 
irritation of the mucosa as was demonstrated by a high total mucus production which was 
comparable to that of the positive control slugs. Furthermore, the formulation was classified 
as mildly tissue damaging based on the (non-significantly) increased protein release of the 
slugs. It is interesting to note that Advantage S® is formulated by the addition of 3.5% N-9 to 
the vaginal lubricant Replens® and that it contains less carbomer than Replens® (Van Damme 
et al., 2002). So the irritation and tissue damage caused by Advantage S® is probably due to 
the presence of N-9. Various phases of clinical trials were completed before the adverse 
effects of Advantage S® became clear. The application of Advantage S® once daily for 14 
consecutive days by 179 healthy sexually active women induced genital itching and vaginal 
discharge in 14% and 32% of the women, respectively. Ulceration and abrasion – lesions 
associated with epithelial disruption – were observed in 2% of the women, but did not occur 
significantly more than in the Replens® and the no-treatment control group (Van Damme et 
al., 1998). A phase II trial involving the application of Advantage S® multiple times a day by 
female sex workers revealed no difference between Advantage S® and Replens® with respect 
to incidence of lesions (Van Damme et al., 2000). A recent phase II/III trial in the same target 
population finally concluded that frequent use of Advantage S® increased women’s 
susceptibility to human immunodeficiency virus infection by causing lesions (Van Damme et 
al., 2002). Another recent publication reported that vaginal application of Advantage S® by 
296 healthy sexually active women upon intercourse during seven months resulted in vulvar 
or vaginal irritation in 22% of the subjects (Raymond et al., 2004). 
A repeated treatment with Protectaid® induced severe irritation of the slug mucosa as 
was demonstrated by a high total mucus production which was comparable to that of the 
positive control slugs. Furthermore, the mean protein release induced by Protectaid® was 
significantly higher than that induced by the negative control, but significantly lower than the 
protein release induced by Conceptrol®. Protectaid® was classified as a mildly tissue damaging 
formulation. The observed irritation and tissue damage may be due to the presence of 0.125% 
N-9, 0.125% benzalkonium chloride and 0.5% sodium cholate. Patton et al. (1999) reported 
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that a repeated application of N-9 plus benzalkonium chloride induced a more robust 
inflammatory response in monkeys than repeated applications of either N-9 or benzalkonium 
chloride alone. Our results contrast with studies involving the vaginal use of the Protectaid® 
sponge by women. Creatsas et al. (2002) concluded that use of the sponge by 15 women upon 
intercourse during one year caused no colposcopic findings of vaginal lesions or irritation. 
The apparent discrepancy in results may be explained by the fact that we tested only the gel 
that is impregnated in the Protectaid® sponge. A sponge releases smaller amounts of gel over a 
long period of time, possibly leading to less exposure to gel (Poindexter et al., 1996).  
Treatment of the slugs with Gynol II® Extra Strength (containing 3% N-9) induced 
severe irritation of the mucosa as was demonstrated by a high total mucus production which 
was comparable to that of the positive control slugs. Furthermore, the formulation caused a 
protein release comparable to the positive control slugs. Gynol II® Extra Strength was 
classified as a moderately tissue damaging formulation by the Slug Mucosal Irritation test. 
Use of Gynol II® Extra Strength once daily for seven consecutive days resulted in vaginal 
irritation in 87% of the 15 women. Product-related colposcopic findings (especially erythema) 
were observed in 47% of the women. Furthermore, the vaginal and cervical epithelia or blood 
vessels of 20% of the women were disrupted (Mauck et al., 2004). The irritating and tissue 
damaging properties of Gynol II® Extra Strength are possibly due to the presence of 3% N-9. 
A repeated treatment with Delfen® (containing 12.5% N-9) induced severe irritation of 
the slug mucosa as was demonstrated by a high total mucus production which was 
comparable to that of the positive control slugs. Furthermore, the formulation caused a protein 
and LDH release comparable to the positive control slugs and ALP release in four out of the 
five slugs which indicated severe tissue damage. Taking into account the reported irritation 
and tissue damage induced by a semi-solid formulation containing 4% N-9 (Conceptrol®) 
(Poindexter et al., 1996; Patton et al., 1999; Mauck et al., 2001; Milligan et al., 2002; 
Hoffman et al., 2004; Dhondt et al., 2005), the severely irritating and tissue damaging 
properties of Delfen® can be ascribed to the presence of 12.5% N-9. 
The Slug Mucosal Irritation test seems to be able to classify the formulations into 
more irritation categories than commonly practiced in vitro cytotoxicity tests. Maguire et al. 
classified several vaginal formulations as non-irritating or irritating by using an immortalized 
cell line derived from human vaginal cells. This in vitro study concluded that Replens® and K-
Y® jelly were not cytotoxic to human vaginal cells, whereas Gynol II® and Advantage S® had 
a cytotoxic effect on the cells. Gynol II® and Advantage S® namely exhibited a 50% cytotoxic 
effect at concentrations of 300 µg/ml and 250 µg/ml, respectively (Maguire et al., 2001).  
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In order to compare the Slug Mucosal Irritation test data with the clinical data in a 
more structured way, those clinical studies were selected that lasted one to two weeks and that 
mentioned the number of patients experiencing vaginal burning or itching during treatment 
with the semi-solid vaginal formulations. Table 8.6 shows that for clinical studies that 
included at least 90 women, an increasing irritation category predicted by the Slug Mucosal 
Irritation test corresponds with an increasing percentage of women that reported vaginal 
burning and/or itching. The results indicate that the mucus production of the slugs is related to 
the burning and itching sensation that is reported by women in clinical studies. Hitherto, no 
other pre-clinical tests are available that can predict the burning/itching sensation induced by 
formulations. The results of this study indicate that the Slug Mucosal Irritation test seems to 
be a promising alternative to evaluate the mucosal tolerance of semi-solid vaginal 
formulations intended for repeated administration.  
 
Table 8.6 Comparison of irritation categories obtained with the Slug Mucosal Irritation test on 
the one hand with clinical data concerning vaginal burning and itching induced by a 
repeated treatment (1-2 weeks) with some semi-solid vaginal formulations on the 
other hand 
Formulation Clinical data 
 
Irritation category 
obtained with Slug 
Mucosal Irritation test 
Women with vaginal 
burning or itching (%) 
Women 
(n) 
Source 
HEC gel No irritation 5% burning, 10% itching 20 Ballagh et al., 2002 
Monistat 7  No irritation 2% burning and itching 114 Brown et al., 1999 
Replens Mild irritation 9% itching 178 Van Damme et al., 1998
Gynol II  Moderate irritation 25% burning, 40% itching 20 Ballagh et al., 2002 
Advantage S Severe irritation 14% itching 179 Van Damme et al., 1998
Conceptrol Severe irritation 8% burning, 19% itching 90 Hoffman et al., 2004 
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CHAPTER 9: EVALUATION OF MUCOSAL TOLERANCE 
OF LIQUID NASAL FORMULATIONS 
 
 
 
 
 
 
9.1 INTRODUCTION 
 
Nasal decongestants, antihistamines, and steroids are widely used topical drugs that 
often are administered as liquid formulations. Such formulations may be applied frequently 
over a period of months or years. Some substances can damage the nasal mucosa or affect the 
nasal mucociliary defensive system (Quadir et al., 1999). Because irritation and damage of 
the nasal mucosa can break the protective barrier against micro-organisms and noxious 
substances, it is important that nasal formulations do not irritate or damage the nasal mucosa 
and that their local tolerance is evaluated before clinical use. 
 
9.2 NASAL MUCOSA  
 
The anterior part of the human nasal cavity is lined with a stratified squamous 
epithelium without cilia and transitional epithelium. The olfactory epithelium covers the 
upper part of the nasal cavity (Mygind and Dahl, 1998; Quadir et al., 1999). This epithelium 
is pseudostratified and contains olfactory receptor cells, columnar supporting cells, and basal 
cells (Marieb, 1995). The remaining part of the nasal cavity is lined with pseudostratified 
respiratory epithelium that comprises ciliated and non-ciliated columnar cells with microvilli, 
goblet cells, and basal cells (Mygind and Dahl, 1998; Quadir et al., 1999).  
An important nasal mechanism contributing to the body’s primary non-specific 
defence mechanism is nasal mucociliary clearance. By this, potentially hazardous materials 
(as dust and micro-organisms) and cellular debris are captured within the mucus layer, are 
then moved by the coordinated beating of the cilia within the periciliary liquid toward the 
pharynx and are subsequently swallowed or expectorated (Proctor, 1977).  
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9.3 EVALUATION OF NASAL TOLERANCE OF FORMULATIONS 
 
Nasal tolerance testing is required by regulatory authorities for medicinal products 
intended for nasal administration on the one hand and for products which are not envisaged 
for nasal delivery but can come accidentally into contact with the nasal mucosa on the other 
hand. Local tolerance testing is usually conducted with the definitive formulation consisting 
of the drug in its vehicle at the concentration intended for human use (EC, 1990).   
Several pre-clinical in vivo and in vitro models have been developed to study the 
impact of drugs and excipients on the nasal epithelium. Histological changes of the nasal 
mucosa induced by locally applied ingredients and formulations have been investigated in 
vivo in rabbits (Suh et al., 1995; Ugwoke et al., 2000; Callens et al., 2001; Cüreoglu et al., 
2002; Çankaya et al., 2003), rats (Marttin et al., 1996; Zhou and Donovan, 1996; Berg et al., 
1997; Lebe et al., 2004), pigs (Tas et al., 2005), and monkeys (Ainge et al., 1994) by light 
microscopy or scanning electron microscopy. The effect of compounds and formulations on 
the nasal mucosa has also been evaluated by the release of markers from the nasal cavity of 
rats and rabbits in vivo or in situ (Shao and Mitra, 1992; Shao et al., 1992; Krishnamoorthy et 
al., 1995; Marttin et al., 1995; Tengamnuay et al., 2000; Callens et al., 2001). Furthermore, 
the effects of ingredients of nasal formulations on the nasal mucociliary clearance have been 
studied in the frog palate model (Batts et al., 1989; Gizurarson et al., 1990).  
The irritating and tissue damaging properties of nasal compounds and formulations 
have also been studied in vitro by evaluation of histological changes and release of marker 
compounds. For this, cultured human adenoid tissue (Berg et al., 1995; Steinsvag et al., 1996) 
or reconstructed three dimensional human nasal tissue (El-Shafy et al., 2001) is exposed to 
the products of interest. The ciliary beat frequency has been evaluated in vitro using human 
nasal epithelial cells cultured as monolayer (Hermens et al., 1990) or suspension (Agu et al., 
2000; Ugwoke et al., 2000), freshly harvested chicken embryo trachea (Van de Donk et al., 
1980; Merkus et al., 1991; Boek et al., 1999), and cryopreserved human sphenoidal sinus 
mucosa (Boek et al., 1999). The cytotoxic effects of absorption enhancers have been 
investigated by in vitro erythrocyte hemolysis (Martin et al., 1992; Vermehren and Hansen, 
1998) and using intestinal Caco-2 cell monolayers (Anderberg and Artursson, 1993). 
However, it has to be noted that in vitro cells and tissues are generally less resistant to the 
effects of nasal compounds and formulations than the corresponding in vivo tissues because of 
several reasons. Firstly, the normal overlaying protective mucous layer is usually absent in in 
vitro models, so that under in vitro conditions compounds and formulations are not diluted by 
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mucus and come directly into contact with the cells or tissues (Merkus et al., 1991; Boek et 
al., 1999; Merkus et al., 1999; Lebe et al., 2004). Furthermore, the exposure time of in vitro 
cells or tissues to the nasal products is generally longer than that of in vivo tissues because of 
the absence of the nasal mucociliary clearance mechanism under in vitro conditions (Merkus 
et al., 1991; Steinsvag et al., 1996; Boek et al., 1999; Merkus et al., 1999; Lebe et al., 2004). 
Thirdly, reversion of irritation or damage due to constant renewal of epithelial cells is also not 
possible in vitro (Ohashi et al., 1991; Schipper et al., 1991; Lebe et al., 2004). 
 
9.4 OBJECTIVES  
 
Previously, the irritation potential of dilutions of various absorption enhancers used in 
nasal pharmaceutical formulations was evaluated with the Slug Mucosal Irritation test. The 
results were in agreement with other in vivo and in vitro nasal irritation data (Adriaens and 
Remon, 1999). In the present study, a slightly modified version of the five-day procedure 
described by Adriaens and Remon (1999) was used to evaluate the mucosal tolerance of 
liquid nasal formulations. The 15-minute contact period was namely prolonged to 30 minutes 
in analogy with previous studies (Chapters 5, 6, 7 and 8). Furthermore, only 500 µl of 
undiluted test formulation was used instead of 2 ml because of the low availability of certain 
liquid test formulations.  
In analogy with previous studies (Adriaens and Remon, 1999), PBS was used as 
negative control, whereas benzalkonium chloride was selected as positive control. 
 
9.5 MATERIALS AND METHODS 
 
9.5.1 Liquid formulations  
 
The OTC nasal solution Naaprep® (GlaxoSmithKline, Genval, Belgium) contains 
0.9% (w/v) sodium chloride and purified water. The homeopathic nasal solution Luffeel® 
(Homeoden-Heel, Ghent, Belgium) is composed of Luffa operculata D4, Luffa operculata 
D12, Luffa operculata D30, Galphimia glauca D4, Galphimia glauca D12, Galphimia glauca 
D30, Histaminum D12, Histaminum D30, Histaminum D200, Sulphur D12, Sulphur D30, 
Sulphur D200, 0.01% benzalkonium chloride, and isotonic solution. The nasal suspension 
Flixonase Aqua (GlaxoSmithKline, Genval, Belgium) contains 0.05% (w/w) fluticasone 
propionate, glucose, microcrystalline cellulose, sodium carboxymethylcellulose, polysorbate, 
___________________________________________________________________________
Chapter 9: Evaluation of mucosal tolerance of liquid nasal formulations 170 
hydrochloric acid, phenylethyl alcohol, benzalkonium chloride, and purified water. Nasonex® 
(Schering-Plough NV/SA, Brussels, Belgium) is a nasal suspension containing 0.05% 
mometasone furoate, colloidal cellulose BP 65 cps, glycerol, sodium citrate dihydrate, citric 
acid monohydrate, polysorbate 80, phenylethyl alcohol, benzalkonium chloride, and purified 
water. The OTC nasal solution Nesivine® (Merck KGaA, Darmstadt, Germany) contains 
0.05% (w/v) oxymetazoline hydrochloride, monobasic sodium phosphate, dibasic sodium 
phosphate, sodium hydroxide, sodium edetate, 0.015% (w/v) benzalkonium chloride, and 
purified water. Allergodil® (Viatris, Brussels, Belgium) is an OTC nasal solution containing 
0.1% (w/v) azelastine hydrochloride, methyl hydroxypropylcellulose, sodium edetate, citric 
acid, dibasic sodium phosphate, sodium chloride, and purified water. The nasal solution 
Syntaris® (Northon Healthcare Ltd, London, United Kingdom) contains 0.025% (w/v) 
flunisolide, citric acid, butyl hydroxytoluene, PEG 400, sodium citrate, polysorbate 20, 
propylene glycol, sorbitol, sodium edetate, benzalkonium chloride, and purified water.  
PBS was used as negative control, whereas a 1% (w/v) dilution of benzalkonium 
chloride (Sigma, St. Louis, MO, USA) was used as a positive control.  
 
9.5.2 Local tolerance test procedure of the Slug Mucosal Irritation test 
 
The local tolerance of the liquid nasal solutions was assessed using the procedure 
described in Chapter 6. During five successive days, the slugs were placed in a Petri dish on a 
quarter of a membrane filter (cellulose acetate, 0.45 µm, 90 mm, Sartorius AG, Goettingen, 
Germany) moistened with 500 µl of the undiluted test formulation for 30 minutes and the 
mucus production of the slugs was measured. One and two hours after each of the five contact 
periods, the samples were collected. The samples were analysed immediately for the presence 
of proteins, LDH, and ALP released from the body wall of the slugs. 
 
9.5.3 Analytical procedures 
 
 The protein, LDH, and ALP determinations were performed according to the 
analytical procedures described in Chapter 3. 
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9.5.4 Data analysis 
 
For each slug, the total mucus production, mean protein release, mean LDH release 
and mean ALP release were calculated as described in the data analysis section of Chapter 5. 
These values were used for the statistical analyses using the computer program SPSS (version 
12.0; SPSS, Chicago, IL, USA). A p value < 0.05 was considered statistically significant.  
Statistically significant differences between different treatments were determined 
using a one-way ANOVA. The data were tested for normal distribution with a Kolmogorov-
Smirnov test. The homogeneity of variances was tested with the Levene’s test. If the 
variances were found not to be equal, the data were transformed to their logarithm. To 
compare further the effects of the different treatments, a multiple comparison among pairs of 
means was performed with a Scheffé test.  
Using the cut-off values presented in Figure 5.2, the formulations were classified into 
one of the tissue damage categories. Based on in-house experience, cut-off values were 
established for the classification of liquid formulations into irritation categories. 
 
9.6 RESULTS 
 
9.6.1 Evaluation of local tolerance of nasal liquid formulations 
 
 The five-day test procedure was used to evaluate the mucosal tolerance of liquid nasal 
formulations. All the slugs survived a repeated treatment with PBS, Naaprep®, Luffeel®, 
Flixonase Aqua, Nasonex®, Nesivine®, Allergodil®, and Syntaris®. Only a daily treatment 
with 1% benzalkonium chloride caused 20% mortality by day 3 and finally all the slugs were 
dead by day 5.  
The effects of a daily treatment on the total mucus production, mean protein and 
enzyme release are presented in Table 9.1. Scheffé post hoc testing suggested the following 
four homogeneous subsets for the total amount of mucus secreted: (1) Luffeel®, PBS and 
Naaprep®, (2) Flixonase Aqua, Nasonex®, Nesivine®, and Allergodil®, (3) Syntaris® and (4) 
1% benzalkonium chloride. 
Furthermore, a repeated treatment with Naaprep®, Luffeel®, Flixonase Aqua, 
Nasonex®, Nesivine®, Allergodil® or Syntaris® resulted in a protein release comparable to that 
of the negative control slugs treated with PBS (p > 0.05, Scheffé test). Moreover, the release 
of LDH and ALP by slugs treated with these liquid nasal formulations was under the detection 
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limit. Only treatment with 1% benzalkonium chloride caused an increased protein, LDH and 
ALP release from the slug mucosa. ALP release was detected for four out of the five slugs 
treated with 1% benzalkonium chloride. ALP release occurred one day after LDH release and 
increased with a repeated treatment. 
 
Table 9.1 Effect of a repeated treatment for 5 successive days with 500 µl of different liquid 
nasal formulations on the end points of the Slug Mucosal Irritation test 
Formulation 
 
 
Total mucus 
production 
(%) 
Mean protein 
release 
(µg/ml.g) 
Mean LDH 
release       
(IU/l.g) 
Number of slugs 
with ALP 
release 
n
PBS -8.2 ± 3.4 a 13 ± 6 a −   0  5
Naaprep -8.9 ± 2.2 a 15 ± 27 a −   0  5
Luffeel -17.5 ± 5.0 a 8 ± 6 a −   0  5
Flixonase Aqua 4.7 ± 2.6 5 ± 2 a −   0  5
Nasonex 5.2 ± 2.5 3 ± 0 a −   0  5
Nesivine  8.0 ± 2.5 6 ± 2 a −   0  5
Allergodil 8.9 ± 2.5 5 ± 2 a −   0  5
Syntaris 18.4 ± 2.7 30 ± 9 a −   0  5
1% benzalkonium chloride 28.3 ± 3.3 b 349 ± 137 b 8.5 ± 3.9  4  5
Total mucus production, mean protein release and mean LDH release data are presented as the mean ± standard 
deviation; -, below the detection limit. 
a For this end point, data are not significantly different from PBS (p > 0.05, Scheffé test). 
b For this end point, data are not significantly different from 1% benzalkonium chloride (p > 0.05, Scheffé test). 
 
9.6.2 Development of prediction model 
 
Based on the results of this study and the studies of Adriaens and Remon (1999), 
Adriaens (2000), and Adriaens et al. (2001) on the one hand and on pre-clinical and clinical 
safety data on the other hand, a classification prediction model was developed for the 
determination of the irritation category of liquid formulations. Liquids that induce a low total 
mucus production (< 0%) are classified as non-irritating. Liquids that cause a mucus 
production between 0% and 5% are predicted as mildly irritating formulations. Liquid 
formulations that result in 5% to 10% mucus production are classified as moderately 
irritating, whereas liquids that cause ≥ 10% mucus production are classified as severely 
irritating (Figure 9.1) (Adriaens et al., 2004).  
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Figure 9.1 Classification prediction model for the determination of the irritation category of 
liquid formulations. The total mucus production is calculated after a repeated 30-
minute treatment of A. lusitanicus with liquid formulation on five successive days. 
(Based on Adriaens et al., 2004) 
 
9.7 DISCUSSION 
 
Irritation and damage of the nasal mucosa can break the protective barrier against 
micro-organisms and noxious substances. Therefore, repeated dose local tolerance testing of 
nasally applied formulations is important. The objective of this study was to evaluate the five-
day procedure of the Slug Mucosal Irritation test for local tolerance testing of liquid 
formulations intended for repeated nasal administration. The results of the Slug Mucosal 
Irritation test were compared with available clinical and pre-clinical in vivo and in vitro data 
on the safety of the tested liquids. Based on the results of this study and the studies of 
Adriaens and Remon (1999), Adriaens (2000), and Adriaens et al. (2001) on the one hand and 
on pre-clinical and clinical data on the other hand, a classification prediction model was 
developed for the determination of the irritation potential of liquid formulations. It has to be 
stressed that comparing the available clinical data was difficult because of the difference of 
study design on the one hand and because the nasal mucosa in patients suffering from allergic 
rhinitis generally differs morphologically from the corresponding tissue in healthy subjects 
(Lim et al., 1995; Mygind et al., 1974) on the other hand. The protective function of the 
mucociliary transport mechanism may not be effective in patients with rhinitis (Toremalm, 
1980; Wilson et al., 1985). This can consequently result in an increased exposure time of the 
nasal mucosa to topically administered formulations (Berg et al., 1995). On the other hand, 
the amount of nasal mucus produced in patients with allergic rhinitis can be increased, so that 
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nasally applied substances may be more diluted and better tolerated in noses with rhinitis than 
in healthy noses (Lebe et al., 2004).  
Slugs treated with PBS produced a low amount of mucus, indicating that no irritation 
of the slug mucosa occurred. Furthermore, repeated treatment with PBS caused minimal 
tissue damage as was demonstrated by low protein release and enzyme release below the 
detection limit. These results are in agreement with in vitro data. Exposure of human adenoid 
tissue in vitro to PBS once a day during 10 days did not change the epithelium. A normal 
pseudostratified epithelium consisting of ciliated and non-ciliated columnar cells with 
microvilli and goblet cells was detected (Steinsvag et al., 1996). 
A repeated treatment of the slugs with a 1% (w/v) dilution of benzalkonium chloride – 
which was used as positive control – resulted in a high mucus production (± 28%), indicating 
severe irritation of the slug mucosa. Furthermore, the high protein release and increased LDH 
and ALP release of these slugs indicated that 1% benzalkonium chloride caused severe 
damage of the slug mucosa. The safety of benzalkonium chloride as preservative in liquid 
nasal formulations has been extensively studied. However, most of the studies established the 
irritation and tissue damage potential of benzalkonium chloride at concentrations lower than 
1%, because this compound is generally present in liquid nasal formulations at concentrations 
ranging from 0.005 to 0.01%. With regard to the safety of benzalkonium chloride at these low 
concentrations, conflicting reports have been published. It was opted to summarise especially 
the results of those studies which evaluated the effect of solutions containing benzalkonium 
chloride without additional active compounds, because the presence of other compounds can 
influence the effect on the nasal mucosa. Nasal application of 0.001% benzalkonium chloride 
to rabbits twice daily for 14 and 28 days resulted in squamous cell metaplasia of the nasal 
epithelium. Furthermore, a reduction of the height of the epithelium and a decrease of the 
number of ciliated cells and goblet cells were observed. However, no morphological changes 
occurred in the subepithelial tissue (Cüreoglu et al., 2002). In the frog palate model, one or 
two treatments with 0.01% benzalkonium chloride caused an irreversible ciliostatic effect 
(Batts et al., 1989). A 0.01% benzalkonium chloride solution intranasally administered to 
anaesthetised rats for 15 minutes resulted in minor to major morphological changes (Marttin 
et al., 1996). Nasal administration of 0.05% or 0.1% benzalkonium chloride eight times on 
one day to rats induced nasal lesions such as epithelial desquamation, degeneration, oedema 
or neutrophilic cellular infiltration (Kuboyama et al., 1997). On the contrary, nasal 
administration of 0.01% benzalkonium chloride to six healthy volunteers was well tolerated 
and did not change nasal clearance after a single administration (Batts et al., 1991). 
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Furthermore, a cosmetic ingredient review panel concluded that benzalkonium chloride can 
be safely used as preservative at concentrations up to 0.1% (Liebert, 1989).  
Naaprep® (containing 0.9% sodium chloride) did not irritate the slug mucosa as was 
indicated by a mucus production comparable to that of the negative control slugs treated with 
PBS. Furthermore, Naaprep® was classified as a minimally damaging formulation based on 
the protein and enzyme release data. The results obtained with the Slug Mucosal Irritation test 
are in good agreement with available in vitro and in vivo data. Exposure of human adenoid 
tissue in vitro to 0.9% sodium chloride once a day during 10 days did not change the 
epithelium. A normal pseudostratified epithelium consisting of ciliated and non-ciliated 
columnar cells with microvilli and goblet cells was detected (Steinsvag et al., 1996). 
Treatment of the nasal mucosa of healthy rats and rabbits with 0.9% sodium chloride solution 
twice daily for 21 to 28 days revealed no histological alterations (Berg et al., 1997; Cüreoglu 
et al., 2002; Lebe et al., 2004). The thick pseudostratified epithelium consisted of tall 
columnar cells with cilia and goblet cells and was covered with a mucus layer. Furthermore, 
normal submucosal structures were observed (Berg et al., 1997; Cüreoglu et al., 2002). Only 
two adverse events (pain) were reported in a multicentre study of 209 rhinosinusitis patients 
who irrigated two to six times daily for 20 days with isotonic saline (Seppey et al., 1995). 
Based on the results obtained with the Slug Mucosal Irritation test, Luffeel® was 
classified as a non-irritating formulation that causes minimal tissue damage. These results are 
in agreement with in vivo data obtained after daily treatment for six weeks of 72 patients 
suffering from seasonal allergic rhinitis with Luffa comp.-Heel nasal spray (containing the 
same ingredients as Luffeel®). Only 1% of the patients reported mild to moderate nasal 
burning and 1% of the cases reported minor, intermittent epistaxis. These adverse events were 
possibly, probably or very probably related to treatment. However, all adverse events 
disappeared spontaneously (Weiser et al., 1999). 
A repeated treatment with Flixonase Aqua induced mild irritation and minimal 
damage of the slug mucosa. Local adverse effects, such as irritation of the nose and throat or 
minor epistaxis, have been associated with the use of Flixonase Aqua (GlaxoSmithKline, 
2000). Nasal burning and epistaxis were respectively reported by 4% and 4% of 25 patients 
with seasonal allergic rhinitis that were treated with fluticasone propionate nasal spray (100 
µg/day) during four weeks (van As et al., 1991). A daily treatment with fluticasone 
propionate nasal spray (200 µg/day) during 6 months resulted in nasal irritation, nasal 
burning, and epistaxis in respectively 0%, 5% and 8% of 128 patients suffering from 
perennial allergic rhinitis (Banov et al., 1994). With regard to the tissue damage potential of 
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Flixonase Aqua, in vitro and in vivo data are not in line with each other.  Exposure of 
human respiratory mucosa in vitro to undiluted fluticasone propionate spray for 10 minutes 
once a day during 10 days resulted in loss of the morphological characteristics of the tissue 
fragments. However, the authors suggest that formulations cause generally more pronounced 
effects under in vitro conditions than under in vivo conditions (Steinsvag et al., 1996). Indeed, 
several in vivo studies demonstrated that a repeated treatment with fluticasone propionate 
nasal spray did not damage the nasal mucosa. Neither reduction of the number of ciliated 
cells, nor damage of the ciliated cells was microscopically observed after treatment of 
monkeys for 28 successive days with fluticasone propionate nasal spray (400 µg/day) (Ainge 
et al., 1994). Treatment of 22 patients suffering from perennial allergic rhinitis with 
fluticasone propionate spray (200 µg/day) for six weeks caused neither decrease of the 
number of ciliated cells nor damage of the nasal mucosa (Braat et al., 1995). In addition, nasal 
biopsies taken before and after 12 months treatment of 16 patients suffering from perennial 
allergic rhinitis with intranasal fluticasone propionate (200 µg/day) revealed no damage of the 
nasal mucosa (Holm et al., 1998).  
The amount of mucus produced by the slugs treated with Nasonex® was significantly 
larger than that of the negative control slugs, but significantly smaller than that of the positive 
control slugs. The formulation was classified as moderately irritating. Furthermore, Nasonex® 
induced minimal damage of the slug mucosa as was demonstrated by the protein and enzyme 
release data. In 2%, 2%, 8% and 1% of the cases, the use of Nasonex® has been respectively 
associated with nasal irritation, nasal burning, epistaxis, and nasal ulceration (Schering-
Plough, 2000). After administration of Nasonex® once daily during 28 days, 6% of 126 
patients with seasonal allergic rhinitis reported mild to moderate nasal burning rated as at 
least possibly related to treatment; 3% of the patients reported epistaxis (Hebert et al., 1996). 
A daily treatment with Nasonex® during 12 months of adult patients with perennial rhinitis 
was not associated with changes in the nasal mucosa. Evaluation of pre-treatment and post-
treatment nasal biopsy samples revealed no significant differences in epithelial atrophy. 
Furthermore, comparison of the nasal mucosa before and after treatment with Nasonex® 
revealed a higher percentage of pseudostratified ciliated columnar epithelium after treatment 
(Minshall et al., 1998).  
A repeated treatment of the slugs with Nesivine® (a 0.05% (w/v) oxymetazoline 
hydrochloride nasal solution) resulted in a total mucus production that was significantly larger 
than that of the negative control slugs, but significantly smaller than that of the positive 
control slugs. Nesivine® was classified as a moderately irritating formulation that induced 
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minimal damage of the slug mucosa. Local adverse effects, such as nasal stinging, have been 
associated with the use of Nesivine® (Merck, 1996). Treatment of 20 healthy volunteers three 
times daily for 30 days with 0.05% (w/v) oxymetazoline nasal spray (containing 0.01% 
benzalkonium chloride) led to epistaxis in 10% of the cases and a statistically significant 
increase in mucosal swelling and stuffiness (Graf et al., 1995). With regard to the tissue 
damage potential of Nesivine®, in vitro and rabbit data are not in line with each other. 
Exposure of human respiratory mucosa in vitro to undiluted 0.05% (w/v) oxymetazoline 
hydrochloride spray for one to 30 minutes once daily during 14 days resulted in viability loss 
of all the tissue fragments and in reduction of the number of ciliated microvillous cells. 
However, tissue fragments exposed for 10 minutes during 14 days to a 3% (v/v) dilution of 
the spray did not change morphologically compared to those exposed to 0.9% sodium 
chloride solution (Berg et al., 1995). Nasal administration of 0.05% (w/v) oxymetazoline 
hydrochloride spray twice daily for 1 week to healthy rabbits resulted in mild to moderate 
ciliary loss and mild epithelial ulceration. The ciliary loss and epithelial ulceration were more 
pronounced with increasing administration duration (Suh et al., 1995).  
The amount of mucus produced by the slugs treated with Allergodil® (a 0.1% (w/v) 
azelastine hydrochloride nasal solution) was significantly larger than that of the negative 
control slugs, but significantly smaller than that of the positive control slugs. Allergodil® was 
classified as a moderately irritating formulation by the Slug Mucosal Irritation test. 
Allergodil® induced minimal tissue damage as was indicated by the protein and enzyme 
release data. Symptoms of rhinitis or irritation of the nasal mucosa occurred in 8% of 489 
children with perennial or seasonal allergic rhinitis after twice daily treatment with 
Allergodil® for four weeks. Epistaxis was reported by 1.2% of the 489 children (Lassig et al., 
1996). During a twice daily treatment with Allergodil® for six months, 6.5% of 185 patients 
with perennial allergic rhinitis reported itching or burning of the nasal mucosa. Epistaxis 
occurred in 0.5% of the patients. Rhinoscopic examination of the nasal mucosa and nasal 
biopsies revealed no evidence of drug related mucosal damage (Gastpar et al., 1993). 
A repeated treatment with Syntaris® (a nasal solution containing 0.025% (w/v) 
flunisolide) induced severe irritation of the slug mucosa as was demonstrated by the high total 
mucus production. Furthermore, the formulation caused a (non-significantly) increased 
protein release compared to the negative control slugs which is an indication of mild tissue 
damage. Adverse effects seen in patients treated with Syntaris® were nasal burning, nasal 
irritation, epistaxis, runny and stuffy nose, throat irritation, change or loss in the sense of 
smell or taste, and nasal septal perforation. During clinical studies, the dose needed to be 
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reduced or the treatment had to be discontinued in 3% of the subjects because of the 
occurrence of nasal burning. Rarely, a permanent loss in the sense of smell and/or taste was 
reported (Roche, 1995). Exposure of human respiratory mucosa in vitro to undiluted 0.025% 
flunisolide spray for 10 minutes once a day during 10 days resulted in loss of cilia of the 
tissue fragments and even loss of the continuous epithelial lining (Steinsvag et al., 1996). 
Nasal administration of 0.025% (w/v) flunisolide nasal spray twice daily for 21 days to rats 
resulted in squamous cell metaplasia of the nasal epithelium. Furthermore, a reduction of the 
height of the epithelium, a decrease of the number of ciliated cells, a reduction of the number 
of goblet cells, and the absence of the mucus layer were observed. However, no 
morphological changes occurred in the subepithelial tissue (Berg et al., 1997).  
 
Table 9.2 Comparison of irritation categories obtained with the Slug Mucosal Irritation test on 
the one hand with clinical data concerning nasal irritation or burning induced by a 
repeated treatment (4-6 weeks) with some liquid nasal formulations on the other hand 
Formulation Clinical data 
 
Irritation category 
obtained with Slug 
Mucosal Irritation test 
Patients with nasal 
irritation or burning (%) 
Patients  
(n) 
Source 
Luffeel No irritation 1 72 Weiser et al., 1999
Flixonase Aqua Mild irritation 4 25 van As et al., 1991
Nasonex Moderate irritation 6 126 Hebert et al., 1996
Allergodil Moderate irritation 8 489 Lassig et al., 1997
 
In order to compare the Slug Mucosal Irritation test data with the clinical data in a 
more structured way, those clinical studies were selected that lasted four to six weeks and that 
mentioned the number of patients experiencing nasal irritation or burning during treatment 
with the liquid nasal formulations. Table 9.2 shows that an increasing irritation potential 
predicted by the Slug Mucosal Irritation test corresponds with an increasing percentage of 
patients that reported nasal irritation or burning. The results indicate that the mucus 
production of the slugs is also related to the burning sensation that is reported by patients in 
clinical studies. As mentioned before, no other pre-clinical tests that can predict the burning 
sensation induced by formulations are hitherto available. So it can be concluded that the 
results of this study indicate that the Slug Mucosal Irritation test seems to be a promising 
alternative to evaluate the mucosal tolerance of liquid nasal formulations intended for 
repeated administration.  
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 CHAPTER 10: GENERAL CONCLUSIONS 
 
  
 
 
 
 
 
The first objective of this research was the optimisation and validation of the Slug 
Mucosal Irritation test procedure and prediction model for the evaluation of the eye irritation 
and damage potential of chemicals. For this purpose, 28 chemicals with known rabbit eye 
irritation data were used. The test procedure was reduced to one day by increasing the test 
concentration of the second contact period to 3.5%. A classification prediction model was 
developed that classifies the chemicals based on the amount of mucus produced during a 60-
minute contact period with a 1% dilution of the chemical on the one hand and on the protein 
and LDH release of the slugs induced by the two contact periods (score for tissue damage) on 
the other hand. The mean κ-value for the agreement between the irritation categories of five 
repeated trials was 0.74, indicating substantial reproducibility. 71% of the 28 chemicals were 
correctly predicted into the three EU eye irritation categories with a sensitivity and specificity 
of 94% and 75%, respectively. Evaluation of the data of the 28 chemicals and 12 additional 
chemicals revealed that chemicals with anaesthetizing properties were generally classified 
differently by the Slug Mucosal Irritation test compared to the rabbit eye irritation test. Lauric 
acid (a chemical that causes mechanical injury), sodium lauryl sulphate, and Triton X-100® 
were also classified differently. For most of these differently classified chemicals, however, 
the results obtained with the Slug Mucosal Irritation test are in good agreement with available 
in vivo data or data of other alternative eye irritation tests. The eye irritation and damage test 
procedure of the Slug Mucosal Irritation test seems to be a promising screening method in a 
stepwise scheme for eye irritation testing. In this way, the number of rabbits used for eye 
irritation tests can be reduced and the rabbits’ suffering can be limited. It is interesting to note 
that the transferability of the optimised test still has to be evaluated. 
In order to evaluate the robustness of the Slug Mucosal Irritation test, the effect of the 
slug population and species on the test end points and the eye irritation classification was 
investigated using the optimised one-day test procedure. The results indicate that the tested A. 
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lusitanicus populations influence neither the test end points nor the classification. However, 
because the results demonstrate that the use of other slug species instead of A. lusitanicus can 
influence the test end points and the eye irritation classification, it is important to optimise 
and validate the test procedure and prediction model if another slug species is used.  
Another research objective was the optimisation of the five-day procedure of the Slug 
Mucosal Irritation test for local tolerance testing of solid, semi-solid and liquid formulations 
intended for repeated administration via the ocular, buccal, nasal, rectal or vaginal route. 
Because no list of reference formulations intended for screening the mucosal tolerance is 
available, formulations with known in vivo or in vitro irritation data were selected for this 
purpose. The test procedure was optimised for each of the different formulation types (i.e. 
bioadhesive powders, suppositories, semi-solids, and liquids) by selecting an appropriate test 
amount, negative and positive control. A classification prediction model was developed that 
classifies the formulations into four irritation and tissue damage categories (non/minimal, 
mild, moderate and severe). Investigation of the repeatability of the test procedures by means 
of the negative and positive control and some formulations shows that the test results and 
classifications are reproducible. A good agreement between the Slug Mucosal Irritation test 
results and available in vivo and in vitro data indicates that the test seems to be a promising 
screening tool to evaluate the mucosal tolerance of formulations intended for repeated 
administration. The Slug Mucosal Irritation test can be used to perform concentration 
response experiments of excipients or drugs. Because substances can be tested on several 
days, the test can identify slow-acting irritants (i.e. irritants with a delayed response). Taking 
into account that the Slug Mucosal Irritation test can even predict mucosal burning and 
stinging and levels of mild irritation, the test can be a very helpful tool in prioritising 
formulation compounds or concentrations of compounds early in the drug development phase 
before pre-clinical studies in vertebrates and clinical studies. The test procedures can be 
further modified on demand of the customer that appeals to the Slug Mucosal Irritation test. 
However, it has to be noted that the relevance and reliability of the optimised test procedures 
have to be further evaluated with additional formulations with known in vivo mucosal 
tolerance data. Establishment of a data bank containing information about formulations and 
their mucosal irritating and damaging properties would benefit the validation of alternative 
mucosal tolerance tests.  
It can be concluded that the Slug Mucosal Irritation test seems to be a promising 
method for the evaluation of the eye irritating properties of chemicals and for mucosal 
tolerance testing of solid, semi-solid and liquid formulations.  
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SUMMARY 
 
 
 
 
 
 
 
Because irritation and damage of the mucosa can break the protective barrier against 
micro-organisms and noxious substances, it is important to evaluate the mucosal irritation 
potential of chemicals and pharmaceutical formulations which can come into contact with the 
mucosa. Regulatory authorities generally require that the eye irritation potential of chemicals 
and the mucosal tolerance of pharmaceutical formulations are assessed in vertebrates. 
However, the use of vertebrates for safety studies is criticised. Consequently, there is a great 
interest in developing alternative methods such as in vitro methods and the use of ‘lower’ 
organisms as test organisms. Before an alternative method is accepted by researchers and 
regulators, the relevance and the reliability of the test have to be investigated using reference 
standards (Chapter 1 and Chapter 2).  
Within this scope, an alternative mucosal irritation test using slugs (i.e. Arion 
lusitanicus) was developed. The slug was selected as test organism, because the mucosal 
tissue of interest is located at the outside of the slug and because the slug mucosa 
histologically resembles the human mucosa. The mucus production of the slugs was chosen as 
end point to evaluate the irritation potential of substances; the release of proteins and enzymes 
from the slug body wall was used as measure of tissue damage. This research aimed at the 
optimisation and validation of the procedure and prediction model of the Slug Mucosal 
Irritation test for the evaluation of the eye irritation and damage potential of chemicals after 
single exposure. Another objective was the optimisation of the five-day procedure for local 
tolerance testing of solid, semi-solid and liquid formulations intended for repeated 
administration (Chapter 1 and Chapter 2).  
In Chapter 3, reference chemicals (with known rabbit eye irritation data) were used to 
optimise and validate the Slug Mucosal Irritation test procedure and prediction model for the 
evaluation of eye irritation and damage. The results of this study demonstrate that by 
increasing the test concentration of the second contact period to 3.5%, the Slug Mucosal 
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Irritation test procedure can be reduced to one day. A classification prediction model was 
developed that classifies the chemicals first based on the amount of mucus produced during a 
60 minute contact period with a 1% dilution of the chemical. Chemicals that do not affect this 
end point are classified based on the tissue damage induced by the first treatment and by a 
second treatment with a 3.5% dilution of the chemical. Repeated testing of 28 chemicals on 
five separate occasions revealed good intra-laboratory reproducibility. Only for four test 
substances, there was a switch between non-irritant and R36, whereas there was no switch 
between non-irritant and R41. When the 28 chemicals were divided into non-irritants or 
irritants, a sensitivity and specificity of 94% and 75% were respectively obtained. 
Furthermore, 71% of the 28 chemicals were correctly predicted into the three EU eye 
irritation categories. Evaluation of the data of the 28 chemicals and 12 additional chemicals 
revealed that chemicals with anaesthetizing properties were generally classified differently by 
the Slug Mucosal Irritation test compared to the rabbit eye irritation test. Lauric acid (a 
chemical that causes mechanical injury), sodium lauryl sulphate, and Triton X-100® were also 
classified differently. For most of these differently classified chemicals, however, the results 
obtained with the Slug Mucosal Irritation test correspond with available in vivo data or data of 
other alternative eye irritation tests. 
In Chapter 4, the effects of the slug population and species on the test end points and 
on the eye irritation classification were investigated. Comparison of the results of one Belgian 
and two Swiss A. lusitanicus populations indicates that the geographic and ecological origins 
of the tested slug populations influence neither the mucus production, nor the score for tissue 
damage. Slug species-specific effects on the test end points were investigated by comparing 
the data of Belgian A. lusitanicus with similar data of Belgian L. flavus and L. maximus.  L. 
flavus and L. maximus produced more mucus than A. lusitanicus, so that the mucus production 
cut-off values had to be increased. Therefore, the results indicate that the test procedure and 
the prediction model have to be optimised and validated, if other slug species are used instead 
of A. lusitanicus.  
In Chapter 5, the local tolerance of bioadhesive powder formulations intended for 
repeated buccal administration (containing Amioca® starch and linear polyacrylic acid or 
Carbopol® 974P) was evaluated. For this purpose, the five-day procedure of the Slug Mucosal 
Irritation test – currently utilised for local tolerance testing of nasal bioadhesive powders at 
the start of this research work – was used. A classification prediction model was developed 
which classifies the formulations into four irritation categories based on the total mucus 
production and into four tissue damage categories based on the protein and enzyme release. 
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The test enabled to investigate the concentration effect of ingredients of buccal powder 
formulations on the mucosal tissue. The mucosal irritation and damage potential of the cross-
linked polyacrylic acid (Carbopol® 974P) was more pronounced that of the linear polyacrylic 
acid. Furthermore, the irritation and tissue damage potential increased with increasing 
polyacrylic acid content. The results are in good agreement with available (pre-) clinical data 
on the buccal tolerance. These concentration response experiments can be a very helpful tool 
in prioritising concentrations of formulation compounds in the drug development phase.  
Chapter 6 describes the optimisation of the five-day procedure of the Slug Mucosal 
Irritation test for the evaluation of the local tolerance of bioadhesive powders intended for 
repeated ocular administration and their ingredients. The results indicate that a repeated 
treatment with 20 mg powder on five successive days – similar to the procedure used in 
Chapter 5 – enables the best discrimination between the mucus production, protein and 
enzyme release data of the negative and positive control slugs. DDWM and DDWM/SLS 
80/20 were selected as negative and positive control, respectively. A repeated treatment with 
the ingredients DDWM, sodium stearyl fumarate or Amioca® resulted in no irritation of the 
slug mucosa. Ciprofloxacin HCl and gentamycin sulphate were classified as mildly irritating 
compounds. Vancomycin HCl induced severe irritation of the slug mucosa. Treatment with 
each of the previous compounds resulted in minimal damage of the mucosa. Carbopol® 974P 
induced severe irritation and moderate damage of the slug mucosa. The powders containing 
DDWM, 5% Carbopol® 974P, 1% sodium stearyl fumarate, and up to 10% ciprofloxacin HCl 
were classified as non-irritating formulations, whereas the powders containing Amioca®, 1% 
sodium stearyl fumarate, 5% gentamycin sulphate, 5% vancomycin HCl, and 4.45% or 
13.35% Carbopol® 974P were classified as mildly irritating powders. For the tested ocular 
powders and their ingredients, the local tolerance data obtained with the Slug Mucosal 
Irritation test are in good agreement with existing in vivo data on the ocular tolerance.  
In Chapter 7, the five-day procedure of the Slug Mucosal Irritation test was optimised 
for the evaluation of the local tolerance of suppositories. The results indicate that a repeated 
treatment with 50 mg grinded suppository enables good discrimination between the mucus 
production, protein and enzyme release data of the negative and positive control slugs. 
Novata® B and Novata® B/SLS 90/10 were selected as negative and positive control, 
respectively. The prediction model developed for bioadhesive powders was used to classify 
the suppositories. A repeated treatment of the slugs with Novata® B, Suppocire® AM or 
Colitofalk® suppositories – each containing a fatty suppository base – resulted in no irritation 
and minimal damage of the slug mucosa. Pentasa® suppositories – containing PEG as base – 
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and PEG 1500/PEG 4000 3/7 were respectively classified as mildly and severely irritating 
formulations. Neither Pentasa® nor PEG 1500/PEG 4000 3/7 resulted in damage of the slug 
mucosa. For the tested suppositories, the local tolerance data obtained with the Slug Mucosal 
Irritation test are in line with (pre-) clinical rectal tolerance data.  
Chapter 8 deals with the optimisation of the five-day procedure of the Slug Mucosal 
Irritation test for the evaluation of the local tolerance of semi-solid vaginal formulations. 
Based on the results, 100 mg was selected as test amount to evaluate the mucosal tolerance of 
semi-solids. 5% HEC gel and Conceptrol® were selected as negative and positive control, 
respectively. A classification prediction model was developed for the determination of the 
irritation category of semi-solid formulations. A repeated treatment of the slugs with 5% HEC 
gel, Monistat® 7 or gels containing up to 10 mM dapivirine induced no mucosal irritation. 
Replens® and K-Y® jelly were respectively classified as mildly and moderately irritating semi-
solids. None of the previous formulations induced damage of the mucosa. The irritation 
potential of the semi-solid formulations containing N-9 as only active compound (Gynol II®, 
Gynol II® Extra Strength, Advantage S®, Conceptrol®, and Delfen®) increased with increasing 
concentration of N-9. The latter formulations induced mild, moderate or severe damage of the 
slug mucosa. Protectaid® was classified as a severely irritating formulation that causes mild 
mucosal damage. For all the tested semi-solids with the exception of Protectaid®, the local 
tolerance data obtained with the Slug Mucosal Irritation test are in good agreement with 
existing in vivo data concerning the vaginal tolerance. The overestimation of the irritating and 
damaging properties of Protectaid® by the Slug Mucosal Irritation test may be explained by 
the fact that we tested only the gel that is impregnated in the Protectaid® sponge whereas 
application of the Protectaid® sponge by women leads to less exposure to gel. 
In Chapter 9, the five-day procedure of the Slug Mucosal Irritation test was evaluated 
for the evaluation of the local tolerance of liquid nasal formulations. A classification 
prediction model was developed for the determination of the irritation category of liquid 
formulations. A repeated treatment of the slugs with Naaprep® or Luffeel® induced no 
mucosal irritation. Flixonase Aqua was classified as a mildly irritating formulation, whereas 
Nasonex®, Nesivine®, and Allergodil® were classified as moderately irritating formulations. 
None of the previous formulations induced damage of the slug mucosa. Syntaris® induced 
severe irritation and mild damage of the slug mucosa. For the tested liquid nasal formulations, 
local tolerance data obtained with the Slug Mucosal Irritation test are in good agreement with 
(pre-) clinical nasal tolerance data. 
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SAMENVATTING 
 
 
 
 
 
 
 
De mucosa vormt een beschermende barrière tegen micro-organismen en schadelijke 
stoffen. Bijgevolg is het belangrijk om voor chemische producten en farmaceutische 
formulaties die met de mucosa in contact komen na te gaan of ze mucosale irritatie en 
beschadiging veroorzaken. De regelgevende instanties vereisen over het algemeen dat de 
lokale tolerantie van producten in vertebraten wordt beoordeeld. Het gebruik van vertebraten 
voor veiligheidstests wordt echter sterk in vraag gesteld. Bijgevolg is er een grote 
belangstelling voor de ontwikkeling van alternatieve methodes zoals in vitromethodes en voor 
het gebruik van lagere organismen als testorganismen. Alvorens een alternatieve methode 
door onderzoekers en regelgevers wordt aanvaard, moeten de relevantie en de 
betrouwbaarheid van de test onderzocht worden met behulp van referentiestoffen (Hoofdstuk 
1 en Hoofdstuk 2).  
In dit raam werd een alternatieve mucosale irritatietest ontwikkeld die gebruik maakt 
van naaktslakken (namelijk Arion lusitanicus). De naaktslak werd gekozen als testorganisme, 
omdat de mucosa zich aan de buitenzijde van de slak bevindt en omdat de mucosa van de slak 
histologisch lijkt op de humane mucosa. De mucusproductie van de slakken werd geselecteerd 
als eindpunt om de potentieel irriterende effecten van een substantie te evalueren; de 
vrijstelling van proteïnen en enzymen uit de lichaamswand van de slakken werd gekozen om 
de weefselbeschadiging te beoordelen. Dit onderzoek beoogde de optimalisatie en validatie 
van de testprocedure en het predictiemodel van de mucosale irritatietest voor de evaluatie van 
de oogirritatie en -beschadiging die kunnen veroorzaakt worden door een éénmalige 
blootstelling aan chemische producten. Een ander objectief was de optimalisatie van de vijf 
dagen procedure voor de evaluatie van de lokale tolerantie van vaste, halfvaste en vloeibare 
formulaties bestemd voor herhaalde toediening (Hoofdstuk 1 en Hoofdstuk 2).  
In Hoofdstuk 3 werden referentiechemicaliën (waarvan gegevens over oogirritatie bij 
konijnen beschikbaar waren) gebruikt om de mucosale irritatie testprocedure te optimaliseren 
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en valideren voor de evaluatie van oogirritatie en -beschadiging. De resultaten van deze studie 
tonen dat de testprocedure kan worden verkort tot één dag door de testconcentratie van de 
tweede contactperiode te verhogen tot 3.5%. Er werd een predictiemodel ontwikkeld dat de 
chemicaliën eerst klasseert op basis van de hoeveelheid mucus die geproduceerd wordt tijdens 
een 60 minuten durende behandeling met een 1% verdunning van het chemische product. De 
chemicaliën die dit eindpunt niet beïnvloeden worden geklasseerd op basis van de 
weefselbeschadiging die wordt veroorzaakt door de eerste behandeling en door een tweede 
behandeling met een 3.5% verdunning van het product. Herhaald testen van 28 chemicaliën in 
vijf afzonderlijke experimenten toonde een goede intralaboratorium reproduceerbaarheid. 
Slechts vier chemicaliën werden zowel niet-irriterend als R36 geklasseerd in de herhaalde 
experimenten, terwijl geen enkele chemische stof zowel niet-irriterend als R41 geklasseerd 
werd. Wanneer de 28 chemicaliën werden ingedeeld in niet-irriterende of irriterende stoffen, 
werden een gevoeligheid en specificiteit van respectievelijk 94% en 75% bekomen. 
Bovendien werden 71% van de 28 chemische producten correct voorspeld in de drie EU 
oogirritatiecategorieën. Evaluatie van de data van de 28 chemicaliën en 12 bijkomende 
chemicaliën leerde dat chemische producten met verdovende eigenschappen over het 
algemeen verschillend geklasseerd worden met de mucosale irritatietest dan met de 
oogirritatietest bij konijnen. Laurylzuur (een chemische stof die mechanische beschadiging 
veroorzaakt), natriumlaurylsulfaat en Triton X-100® werden ook verschillend geklasseerd. 
Voor de meeste van de verschillend geklasseerde chemicaliën zijn de resultaten bekomen met 
de mucosale irritatietest echter in overeenstemming met beschikbare in-vivogegevens of 
resultaten bekomen met andere alternatieve oogirritatietests. 
In Hoofdstuk 4 werden de effecten van slakkenpopulatie en -species op de eindpunten 
van de test en op de oogirritatieclassificatie nagegaan. Vergelijking van de resultaten van één 
Belgische en twee Zwitserse A. lusitanicus populaties leert dat de geografische en ecologische 
oorsprong van de geteste populaties noch de mucusproductie, noch de score voor 
weefselbeschadiging beïnvloedt. De species specifieke effecten op de testeindpunten werden 
onderzocht door de gegevens van Belgische A. lusitanicus slakken te vergelijken met 
gelijkaardige gegevens van Belgische L. flavus en L. maximus slakken. L. flavus en L. 
maximus produceerden meer mucus dan A. lusitanicus, zodat de grenswaarden van de 
mucusproductie moesten worden verhoogd. De resultaten tonen bijgevolg aan dat de 
testprocedure en het predictiemodel dienen geoptimaliseerd en gevalideerd te worden als 
andere slakkenspecies gebruikt worden in plaats van A. lusitanicus. 
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In Hoofdstuk 5 werd de lokale tolerantie geëvalueerd van bioadhesieve poeders 
bestemd voor herhaalde buccale toediening (die Amioca® zetmeel en lineair polyacrylzuur of 
Carbopol® 974P bevatten). Hiervoor werd de vijf dagen procedure van de mucosale 
irritatietest – die bij het begin van dit onderzoek aangewend werd voor de evaluatie van de 
lokale tolerantie van nasale bioadhesieve poeders – gebruikt. Er werd een predictiemodel 
ontwikkeld dat de formulaties klasseert in vier irritatiecategorieën op basis van de totale 
mucusproductie en in vier weefselbeschadigingcategorieën op basis van de vrijstelling van 
proteïnen en enzymen. De test liet toe om het concentratie-effect van ingrediënten van 
buccale poederformulaties te evalueren. Het vernet polyacrylzuur (Carbopol® 974P) 
veroorzaakte meer mucosale irritatie en beschadiging dan het lineaire polyacrylzuur. 
Bovendien nam het irriterend en beschadigend vermogen toe met een stijgende concentratie 
aan polyacrylzuur. De resultaten zijn in overeenstemming met beschikbare (pre)klinische data 
over de buccale tolerantie. Deze concentratie-respons experimenten kunnen een zeer nuttig 
hulpmiddel zijn bij de selectie van concentraties van componenten die bestemd zijn voor de 
ontwikkeling van geneesmiddelen. 
Hoofdstuk 6 beschrijft de optimalisatie van de vijf dagen procedure van de mucosale 
irritatietest voor de evaluatie van de lokale tolerantie van bioadhesieve poeders bestemd voor 
herhaalde oculaire toediening en hun ingrediënten. De resultaten toonden aan dat een 
herhaalde behandeling met 20 mg poeder op vijf opeenvolgende dagen – gelijkaardig aan de 
procedure gebruikt in Hoofdstuk 5 – best discrimineert tussen de gegevens over de 
mucusproductie en de proteïnen- en enzymen-vrijstelling van de negatieve en positieve 
controleslakken. DDWM en DDWM/SLS 80/20 werden respectievelijk als negatieve en 
positieve controle gekozen. Een herhaalde behandeling met de ingrediënten DDWM, 
natriumstearylfumaraat of Amioca® resulteerde niet in irritatie van de mucosa van de slakken. 
Ciprofloxacine HCl en gentamycinesulfaat werden als mild irriterende componenten 
geklasseerd. Vancomycine HCl induceerde sterke irritatie van de mucosa. Behandeling met 
elk van de voorgaande componenten resulteerde in minimale beschadiging van de mucosa. De 
poeders die DDWM, 5% Carbopol® 974P, 1% natriumstearylfumaraat en tot 10% 
ciprofloxacine HCl bevatten werden geklasseerd als niet-irriterende formulaties. De poeders 
die Amioca®, 1% natriumstearylfumaraat, 5% gentamycinesulfaat, 5% vancomycine HCl en 
4.45% of 13.35% Carbopol® 974P bevatten werden geklasseerd als mild irriterende poeders. 
De lokale tolerantiedata van de geteste poeders en hun ingrediënten bekomen met de 
mucosale irritatietest zijn in goede overeenstemming met bestaande in-vivodata over de 
oculaire tolerantie. 
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In Hoofdstuk 7 werd de vijf dagen procedure van de mucosale irritatietest 
geoptimaliseerd voor de evaluatie van de lokale tolerantie van suppositoria. De resultaten 
tonen aan dat een herhaalde behandeling met 50 mg fijngemalen suppositorium goed 
discrimineert tussen de gegevens over de mucusproductie en de proteïnen- en enzymen-
vrijgave van de negatieve en positieve controleslakken. Novata® B en Novata® B/SLS 90/10 
werden respectievelijk als negatieve en positieve controle gekozen. Het predictiemodel 
ontwikkeld voor bioadhesieve poeders werd gebruikt om de suppositoria te klasseren. Een 
herhaalde behandeling van de slakken met Novata® B, Suppocire® AM of Colitofalk® 
suppositoria – die elk een vette suppobasis bevatten – resulteerde niet in irritatie of 
beschadiging van de mucosa van de slakken. Pentasa® suppositoria – met PEG als basis – en 
PEG 1500/PEG 4000 3/7 werden respectievelijk als mild en sterk irriterende formulaties 
geklasseerd. Noch Pentasa®, noch PEG 1500/PEG 4000 3/7 resulteerde in beschadiging van 
de mucosa. De lokale tolerantiedata van de geteste suppositoria bekomen met de mucosale 
irritatietest zijn in goede overeenstemming met beschikbare (pre)klinische data over de rectale 
tolerantie. 
Hoofdstuk 8 behandelt de optimalisatie van de vijf dagen procedure van de mucosale 
irritatietest voor de evaluatie van de lokale tolerantie van halfvaste vaginale formulaties. Op 
basis van de resultaten werd 100 mg geselecteerd als testhoeveelheid om de mucosale 
tolerantie van halfvaste formulaties te beoordelen. 5% HEC gel en Conceptrol® werden 
respectievelijk als negatieve en positieve controle gekozen. Er werd een predictiemodel 
opgesteld dat de irritatiecategorie van halfvaste formulaties voorspelt. Een herhaalde 
behandeling van de slakken met 5% HEC gel, Monistat® 7 of gelen die tot 10 mM dapivirine 
bevatten induceerde geen mucosale irritatie. Replens® en K-Y® jelly werden respectievelijk 
als mild en matig irriterende formulaties geklasseerd. Geen van voorgaande formulaties 
induceerde mucosale beschadiging. Het irriterend vermogen van de halfvaste formulaties die 
N-9 als enige actief bestanddeel bevatten (Gynol II®, Gynol II® Extra Strength, Advantage S®, 
Conceptrol® en Delfen®) nam toe met toenemende concentratie aan N-9. Deze formulaties 
induceerden milde, matige of sterke beschadiging van de mucosa van de slakken. Protectaid® 
werd geklasseerd als een sterk irriterende formulatie die milde mucosale beschadiging 
veroorzaakt. Voor alle geteste halfvaste formulaties met uitzondering van Protectaid® zijn de 
data bekomen met de mucosale irritatietest in goede overeenstemming met bestaande in-
vivodata over de vaginale tolerantie. De overschatting van de irriterende en beschadigende 
eigenschappen van Protectaid® door de mucosale irritatietest kan verklaard worden door het 
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feit dat we enkel de gel testten die aanwezig is in de Protectaid® spons. Gebruik van de 
Protectaid® spons door vrouwen resulteert echter in een beperktere blootstelling aan de gel. 
In Hoofdstuk 9 werd nagegaan of de vijf dagen procedure van de mucosale irritatietest 
kan gebruikt worden voor de evaluatie van de lokale tolerantie van vloeibare nasale 
formulaties. Er werd een predictiemodel ontwikkeld dat de irritatiecategorie van vloeibare 
formulaties voorspelt. Een herhaalde behandeling van de slakken met Naaprep® of Luffeel® 
induceerde geen mucosale irritatie. Flixonase Aqua werd geklasseerd als een mild 
irriterende formulatie, terwijl Nasonex®, Nesivine® en Allergodil® geklasseerd werden als 
matig irriterende formulaties. Geen van voorgaande formulaties induceerde beschadiging van 
de mucosa van de slakken. Syntaris® induceerde sterke irritatie en milde beschadiging van de 
mucosa. De lokale tolerantiedata van de geteste vloeibare nasale formulaties bekomen met de 
mucosale irritatietest zijn in goede overeenstemming met (pre)klinische data over de nasale 
tolerantie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________________
Samenvatting 196 
 
 
 
 
 
 
 
 
 
  
___________________________________________________________________________
Résumé 197 
RÉSUMÉ 
 
 
 
 
 
 
 
Il est important d'évaluer le potentiel irritatif des produits chimiques et des 
formulations pharmaceutiques qui peuvent entrer en contact avec la muqueuse, parce que 
l'irritation et les dégâts à la muqueuse peuvent détruire la barrière protectrice contre les 
substances nocives et les micro-organismes. Les autorités réglementaires exigent 
généralement que l'irritation oculaire des produits chimiques et la tolérance muqueuse des 
formes pharmaceutiques soient évaluées en utilisant des vertébrés. Cependant, l'utilisation des 
vertébrés pour des études de toxicologie est fortement critiquée. En conséquence, le 
développement de méthodes alternatives telles que les méthodes in vitro et l’utilisation des 
invertébrés suscitent un grand intérêt. Avant qu'une méthode alternative ne soit acceptée par 
des chercheurs et des législateurs, la pertinence et la fiabilité de l'essai doivent être étudiées en 
utilisant des substances de référence (Chapitre 1 et Chapitre 2).  
Dans ce cadre, un test alternatif pour l’évaluation du potentiel irritatif a été développé 
en utilisant des limaces (notamment Arion lusitanicus). La limace a été choisie, parce que le 
tissu muqueux est situé à l'extérieur des limaces et que la muqueuse des limaces ressemble 
histologiquement à la muqueuse humaine. La production de mucus des limaces a été choisie 
comme paramètre pour évaluer le potentiel irritatif des substances; la libération de protéines et 
d’enzymes de la muqueuse des limaces a été sélectionnée pour évaluer les dégâts au tissu. 
Cette thèse de doctorat a visé l'optimisation et la validation de la procédure et du modèle de 
prédiction du test d’irritation muqueuse pour l'évaluation de l'irritation oculaire et des dégâts 
oculaires qui peuvent être causés par une exposition unique aux produits chimiques. Un autre 
objectif de cette thèse était l'optimisation de la procédure de cinq jours pour l'évaluation de la 
tolérance locale des formulations solides, semi-solides et liquides destinées à l'administration 
répétée (Chapitre 1 et Chapitre 2).  
Dans le Chapitre 3, des produits chimiques de référence (dont les données sur 
l’irritation oculaire chez le lapin étaient disponibles) ont été employés pour optimiser et 
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valider la procédure et le modèle de prédiction du test d’irritation muqueuse pour l'évaluation 
de l'irritation oculaire et des dégâts oculaires. Les résultats de cette étude démontrent que la 
procédure du test d'irritation muqueuse peut être réduite à un jour en augmentant la 
concentration d’essai de la deuxième période d'exposition à 3.5%. On a développé un modèle 
de prédiction qui classe d’abord les agents chimiques selon la quantité de mucus produite 
pendant une période d'exposition de 60 minutes à une dilution de 1% du produit. Les produits 
chimiques qui n'affectent pas la production de mucus sont classés selon les dégâts au tissu 
induits par le premier traitement et par un deuxième traitement avec une dilution de 3.5% du 
produit. L'évaluation répétée de 28 agents chimiques à cinq périodes séparées a permis de 
démontrer la bonne reproductibilité intra-laboratoire. Seulement quatre substances ont été 
classées comme non irritantes et R36 aux expériences répétées, tandis qu'aucune substance 
n’a été classée à la fois comme non irritant et R41. Quand les 28 produits chimiques ont été 
classés en deux classes (non irritant ou irritant), une sensibilité et une spécificité de 94% et de 
75% ont été respectivement obtenues. En outre, 71% des 28 agents chimiques ont été 
correctement classés dans les trois catégories d'irritation oculaire d'UE. L'évaluation des 
données des 28 produits chimiques et de 12 produits chimiques additionnels a indiqué que les 
produits ayant des propriétés anesthésiques ont généralement été classés différemment par le 
test d’irritation muqueuse par comparaison au test d’irritation oculaire de Draize. L’acide 
laurique (causant des dégâts mécaniques), le lauryl sulfate de sodium et le Triton X-100® ont 
également été classés différemment. Cependant, les résultats obtenus à l’aide du test 
d’irritation muqueuse correspondent à ceux obtenus par d'autres essais in vivo or alternatifs 
pour la plupart des produits classés différemment. 
Dans le Chapitre 4, les effets des populations et des espèces de limaces sur les points 
limites du test et sur la classification de l'irritation oculaire ont été étudiés. La comparaison 
des résultats d'une population belge et de deux populations suisses d’A. lusitanicus indique 
que les origines géographiques et écologiques des populations de limaces n'influencent ni la 
production de mucus, ni le score des dégâts au tissu. Les effets des espèces de limaces sur les 
points limites du test ont été étudiés en comparant les données d’A. lusitanicus belge aux 
données semblables du L. flavus et du L. maximus belges.  L. flavus et L. maximus ont produit 
plus de mucus qu'A. lusitanicus, de sorte que les valeurs limites de la production de mucus ont 
dû être augmentées. Par conséquent, les résultats indiquent que la procédure et le modèle de 
prédiction doivent être optimisés et validés, si d'autres espèces de limaces sont employées au 
lieu d’A. lusitanicus.  
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Dans le Chapitre 5, la tolérance locale des poudres bioadhésives destinées à 
l'administration buccale répétée (contenant l’amidon Amioca® et l’acide polyacrylique 
linéaire ou le Carbopol® 974P) a été évaluée. A cet effet, la procédure de cinq jours du test 
d’irritation muqueuse – qui a été employée au début de cette étude pour l'évaluation de la 
tolérance locale des poudres bioadhésives nasales – a été utilisée. On a développé un modèle 
de prédiction qui classe les formulations en quatre catégories d'irritation sur la base de la 
production de mucus et en quatre catégories de dégâts au tissu sur la base de la libération de 
protéines et d'enzymes. L'essai a permis d'étudier l'effet de la concentration des ingrédients 
des poudres buccales sur le tissu muqueux. L’irritation muqueuse et les dégâts à la muqueuse 
causés par l’acide polyacrylique réticulé (Carbopol® 974P) étaient plus prononcés que ceux 
causés par l'acide polyacrylique linéaire. En outre, le potentiel irritatif des poudres augmentait 
quand le contenu en acide polyacrylique s’élevait. Les résultats concordent bien avec les 
données (pré-) cliniques disponibles sur la tolérance buccale. Ces expériences de 
concentration-réponse peuvent être un outil très utile pour sélectionner des concentrations de 
composants de formulation dans le développement des médicaments.  
Le Chapitre 6 décrit l'optimisation de la procédure de cinq jours du test d’irritation 
muqueuse pour l'évaluation de la tolérance locale des poudres bioadhésives destinées à 
l'administration oculaire répétée et leurs ingrédients. Les résultats indiquent qu'un traitement 
répété avec 20 mg de la poudre pendant cinq jours successifs – semblable à la procédure 
utilisée dans le Chapitre 5 – permet la meilleure discrimination entre les productions de 
mucus et entre les données sur la libération de protéines et d'enzymes des contrôles négatifs et 
positifs. Le DDWM et le DDWM/SLS 80/20 ont été respectivement choisis comme contrôle 
négatif et positif. Un traitement répété avec le DDWM, le stéarylfumarate de sodium et 
l’Amioca® n’a pas causé de l’irritation de la muqueuse des limaces. Le chlorhydrate de 
ciprofloxacine et le sulfate de gentamycine ont été classés comme des composants légèrement 
irritants. Le chlorhydrate de vancomycine a induit une irritation sévère de la muqueuse des 
limaces. Le traitement avec chacun des composants précédents a causé des dégâts minimes. 
Le Carbopol® 974P a induit une irritation sévère et des dégâts modérés à la muqueuse des 
limaces. Les poudres contenant du DDWM, 5% de Carbopol® 974P, 1% de stéarylfumarate de 
sodium et jusqu'à 10% de chlorhydrate de ciprofloxacine ont été classées comme des poudres 
non irritantes, tandis que les poudres contenant de l’Amioca®, 1% de stéarylfumarate de 
sodium, 5% de sulfate de gentamycine, 5% de chlorhydrate de vancomycine et 4.45% ou 
13.35% de Carbopol® 974P ont été classées comme des poudres légèrement irritantes. En ce 
qui concerne les poudres ophtalmiques et leurs ingrédients examinés, les données de tolérance 
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locale obtenues à l’aide du test d’irritation muqueuse correspondent bien aux données in vivo 
existantes concernant la tolérance oculaire. 
Le Chapitre 7 examine l'optimisation de la procédure de cinq jours du test d’irritation 
muqueuse pour l'évaluation de la tolérance locale des suppositoires. Les résultats indiquent 
qu'un traitement répété avec 50 mg de poudre de suppositoire permet la bonne discrimination 
entre les productions de mucus et entre les données sur la libération de protéines et d'enzymes 
des contrôles négatifs et positifs. Novata® B et Novata® B/SLS 90/10 ont été respectivement 
choisis comme contrôle négatif et positif. Le modèle de prédiction développé pour les poudres 
bioadhésives a été employé pour classer les suppositoires. Un traitement répété des limaces 
avec des suppositoires de Novata® B, de Suppocire® AM ou de Colitofalk® – chacun 
contenant une base lipophile de suppositoire – n’a pas causé de l’irritation ou des dégâts à la 
muqueuse des limaces. Les suppositoires de Pentasa® – contenant PEG comme base – et PEG 
1500/PEG 4000 3/7 ont été respectivement classés comme des formulations légèrement et 
sévèrement irritantes. Ni Pentasa® ni PEG 1500/PEG 4000 3/7 n’ont causé des dégâts à la 
muqueuse des limaces. En ce qui concerne les suppositoires examinés, les données de 
tolérance locale obtenues à l’aide du test d’irritation muqueuse concordent bien avec les 
données (pré-) cliniques disponibles sur la tolérance rectale. 
Le Chapitre 8 décrit l'optimisation de la procédure de cinq jours du test d’irritation 
muqueuse pour l'évaluation de la tolérance locale des formulations semi-solides vaginales. 
Sur la base des résultats, 100 mg a été choisi comme quantité d'essai pour évaluer la tolérance 
muqueuse des formulations semi-solides. 5% de gel HEC et Conceptrol® ont été 
respectivement choisis comme contrôle négatif et positif. Un modèle de prédiction a été 
développé pour déterminer la catégorie d'irritation des formulations semi-solides. Un 
traitement répété des limaces avec 5% de gel HEC, Monistat® 7 ou des gels contenant jusqu'à 
10 mM de dapivirine n'a induit aucune irritation muqueuse. Replens® et K-Y® jelly ont été 
respectivement classés comme des formulations légèrement et modérément irritantes. Aucune 
des formulations précédentes n'a induit des dégâts à la muqueuse. Le potentiel irritatif des 
formulations semi-solides contenant seulement N-9 comme composant actif (Gynol II®, 
Gynol II® Extra Strength, Advantage S®, Conceptrol® et Delfen®) augmentait quand la 
concentration de N-9 s’élevait. Les dernières formulations ont induit des dégâts légers, 
modérés ou sévères à la muqueuse des limaces. Protectaid® a été classé comme formulation 
sévèrement irritante qui endommage légèrement la muqueuse. En ce qui concerne toutes les 
formulations semi-solides examinées excepté Protectaid®, les données de tolérance locale 
obtenues à l’aide du test d’irritation muqueuse correspondent bien aux données in vivo 
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existantes concernant la tolérance vaginale. La surestimation des caractéristiques d’irritation 
et de dégâts de Protectaid® par le test d'irritation muqueuse peut être expliquée par le fait que 
nous avons examiné seulement le gel qui est imprégné dans l'éponge de Protectaid®, tandis 
que l'application de l'éponge de Protectaid® par des femmes entraîne une moindre exposition 
au gel. 
Dans le Chapitre 9, la procédure de cinq jours du test d’irritation muqueuse a été 
évaluée pour l'évaluation de la tolérance locale des formulations nasales liquides. Un modèle 
de prédiction a été développé pour déterminer la catégorie d'irritation des formulations 
liquides. Un traitement répété des limaces avec Naaprep® ou Luffeel® n'a pas induit de 
l’irritation muqueuse. Flixonase Aqua a été classé comme une formulation légèrement 
irritante, tandis que Nasonex®, Nesivine® et Allergodil® ont été classés comme des 
formulations modérément irritantes. Aucune des formulations précédentes n'a induit des 
dégâts à la muqueuse des limaces. Syntaris® a induit de l’irritation sévère et de légers dégâts à 
la muqueuse. En ce qui concerne les formulations liquides nasales examinées, les données de 
tolérance locale obtenues à l’aide du test d’irritation muqueuse concordent bien avec les 
données pré-cliniques et cliniques disponibles sur la tolérance nasale. 
